Recognition of Tumor-Specific Proteins in Human Cancer by Berendes, P.B. (Paul)
RECOGNITION OF TUMOR-SPECIFIC PROTEINS 
IN HUMAN CANCER 
ISBN 90-73436-36-2 
RECOGNITION OF TUMOR-SPECIFIC PROTEINS 
IN HUMAN CANCER 
Herkenning van tumor-specifieke eiwitten bij kanker 
PROEFSCHRIFT 
tel' verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam op gezag van de 
rector magnificus 
prof. dr P.W.C. Akkermans M.A. 
en vol gens besluit van het college voor promoties. 
De openbare verdediging zal plaatsvinden op 
woensdag 4 juni 1997 om llAS uur 
door 
Paulus Benjamin Berendes 
geboren te 's-Gravenzande 
PROMOTIECOMMISSIE 
Promotor: Prof. dr W. van Ewijk 
Overige led en: Prof. dr J.J .M. van Dongen 
Prof. dr F.G. Grosveld 
Prof. dr B. Lowenberg 
IMMUNOLOGY 
OTTERDA~! 
Dit proefsehrift is tot stand gekomen 
binnen de afdeling Immunologie van de 
Erasmus Universiteit Rotterdam. 
Omslag: fluorescentieopnamen van twee getransfecteerde COS eellen. De COS 
eel aan de bovenkant werd getransfecteerd met eDNA eoderend voor 
E2A-PBX I eiwitten. de onderste COS eel werd getransfeeteerd met 
eDNA eoderend voor ela2P 190BCR.ABL eiwitten. De COS eellen werden 
aangekleurd met respeetievelijkER-G04 ofER-FPl antiliehamen (voor 
een gedetailleerde beschrijving, zie hoofstukken 6 en 7). 
Illustraties: Tar van Os 
Drukwerk: Ridderprint te Ridderkerk 
Tllis is what we know about leukenlia: 
during normal blood cell proliferation 
the cells differentiate into specific 
types. In a pathological situation the 
differentiation into specific cells is 
blocked. Tllis disturbance of normal 
differentiation - so called leukenlia -
is a disease SlIi gelleris. We know the 
sequela of this disease, but we don't 
know its origin, 
Virchow 1849 
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General Introduction 
Cancer: 
At present, approximately 20% of people Iivillg ill the developed countries of 
the world, will die of callCel: 
Cancer is a disease of all ages and even though cancer is not a common disease in 
younger people, cancer is recognized as one of the most imp0l1ant causes of death at 
any age. In fact, when considering the main death causes in people younger than thirty 
years, cancer is second only to accidents. Beyond the age of thirty years, the number 
of deaths from cancer increases upon aging, gradually at first, rising simply later on. 
Apm1 from cancer causing death, the disease is fem'ed because patients who suffer 
from cancer are often condemned to a long and painful terminal illness. 
Based on their frequency of occurrence, cancers are traditionally categorized as either 
epithelial cancers (approximately 85% of all human cancers) or non-epithelial cancers 
(approximately 15% of all human cancers). Cancers arising from epithelial cells (i.e. 
cells lining the body cavities and skin) are called cm'Cinomas (Latin: km'kinos - crab or 
lobster; oma - swelling), while those arising from non-epithelial cells are further 
subdivided according to the tissue and cell type from which they originate. Thus, 
sarcomas are derived from connective tissue or muscle cells (Greek: sarx - meat), 
while leukemias are derived from hematopoietic cells (Greek: leucos - white; haima-
blood). Other non-epithelial cancers include the ones deJived fi'Om cells ofthe nervous 
system and germinal or embryonal cells. 
Cancer is often traced to a primm')' site in the human body where cancer cells have 
stmted to grow initially. Since most individual cancer cells in a primal')' tumor fre-
quently display vet')' similm' morphological characteristics, cancer is thought to origi-
nate from one single, autonomously growing cell that withdrew from environmental 
growth regulating signals (i.e. clonal growth). The transition from a healthy cell to a 
malignant cancerous cell is caused by a 'multi-step' process, that often starts with a 
certain change in the cell's genome (i.e. the entire genetic information needed for a 
human body to survive). While a single genomic change is usually not enough to 
cause cancer, the genomic change may be irreversible and consequently transmitted to 
a cell's progeny. From this point on, cells encounter other genomic changes, of which 
a cet1ain combination eventually causes a cell to proliferate autonomously. 
While autonomous proliferation is one characteristic of cancer cells, it is not the sole 
reason that cancer is life-threatening. In fact, cet1ain autonomously growing tumors, 
the so-called 'benign tumors', are often relatively harmless as they remain localized to 
a particulm' place in the human body. In contrast, malignant tumors, known collec-
tively as cancer, are feared, as their malignant cells invade surrounding tissues, bur-
row tln'ough local blood and lymphatic vessels and spread to other pat1S of the body 
where they give rise to secondary tumors, or metastases. 
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If left untreated, a patient with cancer eventually dies when vital tissues or organs are 
involved (e.g. lung, liver or brain). Although striking reductions in death from cancers 
have been achieved over the past few years, approximately 50% of patients with can-
cer still die. Depending on the origin and spread of a cancer, therapeutic outcomes 
differ enormously. While most patients with skin cancer can be cured completely, 
almost all patients suffering from anaplastic thyroid carcinoma, a fortunately rare type 
of cancer, die within five years from diagnosis. 
The term 'cancer' comprises a heterogeneous group, in which each type has its own 
characteristics when considering its malignant potential and its response to therapy. It 
is because of this variability that a simple, universal treatment, effective for all can-
cers, is illusive. The kind of therapy chosen depends on characteristics of the cancer 
type and is usually based on three modalities: 
1. Surgical treatment is, despite recent progress in other fields of cancer treatment, 
still the primmy choice in cancer treatment for most solid tumors. Most people 
with cancer m'e cured through the surgical removal of a tumor. Yet, an important 
limitation of surgery is that it is often difficult to remove the microscopic inva-
sions of malignant cells in surrounding tissues. 
2. Radiation therapy is preferred over surgery in many instances. Cancer cells are 
often more vulnerable to radiation than normal cells. The genetic damage, in-
flicted through radiation, causes cancer cells to die, including the ones that have 
microscopically spread. Yet, like surgelY, radiation therapy is not enough to cure a 
patient with cancer that has ah'eady metastasized throughout the body. 
3. Chemotherapy provides a means to destroy metastasized tumors. Tumors, that 
cannot be removed by using surgelY or radiotherapy (e.g. leukemias) are treated 
with chemotherapeutic drugs as well. It has been verified that, when different 
chemotherapeutic drugs m'e combined into one therapeutic protocol, they are of-
ten more effective in destroying cancer cells, although not all cancers respond 
equally well. Yet, chemotherapeutic drugs tend to destroy all proliferating cells: 
cancer cells, but unfOltunately also normal healthy dividing cells. 
The effectiveness of cun'ent treatment protocols is empirically determined. It has been 
demonstrated that, depending on the origin and spread of the cancer and the physical 
condition of a patient, the three basic cancer treatments prove more effective when 
they are joined in one protocol. Although current treatment protocols have improved 
the chance of survival from most types of cancer, they are in a way still dissatisfactory. 
It is realized that current cancer treatment often gives rise to side-effects that compro-
mise the benefits of treatment enormously. 
Despite recent progress in our understanding of the developmental issues of cancer, 
tailor made therapies, that allow the specific eradication of celtain cancer cells with-
out concurrently affecting healthy cells, are still not available. One of the major limi-
tations in reaching this goal is basically due to inaccurate diagnosis. If one cannot 
identify a cancer correctly and distinguish it from other cancer types, one cmmot dis-
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cover its causes, predict its outcome, select (or develop) the most appropriate treat-
ment for a given patient, and make trials on a population of patients to judge whether 
a proposed treatment is effective. 
Scope of the thesis 
Cancer is a heterogeneous disease regarding both its biology as well as its prognosis. 
Years of cancer research have paved the way for understanding the essential processes 
involved in the malignant change of previously healthy, normal cells (i.e. carcinogen-
esis). It was only recently that researchers clearly demonstrated that most cancers 
have a genetic basis. This new insight was paralleled by the development of new 
(diagnostic) techniques. These techniques are not only beneficial for a correct tumor-
diagnosis but they may also contribute to the development of new therapeutic proto-
cols. 
Tlus thesis is designed as a guide to understanding our experimental work that aimed 
at the development of a new kind of tumor-specific, immunological diagnosis. 
Chapter 2 covers the theoretical basis of cancer, starting with the description of the 
normal cellular processes involved in cell growth and division, concluding with the 
chromosomal, the genetic and the protein basis of cancer in general. 
Chapter 3 represents an overview of the genetic basis of leukemia. When considering 
the CUl1'ent status of our understanding of the processes involved in carcinogenesis, it 
can be stated that at present, the greatest achievements have been realized in leuke-
nua. Recent discoveries indicate that leukemia is a heterogeneous disease. Several 
examples of its heterogeneity and their implications considering diagnosis, treatment 
and prognosis of the leukenuc disease are discussed. Special emphasis will be placed 
on two of the most important aberrant genes involved in acute lymphoblastic leuke-
nua: BCR-ABL and E2A-PBXl. 
Chapters 4, 5, 6, 7 alld 8 describe our experimental work. The presence of consistent 
chromosomal and molecular aberrations in leukemic cells provides the opp0i1tmity to 
screen patients at diagnosis for the presence of these abnormalities. Our experimental 
work rep0i1s on the immullologic identification of two of these abnormalities: the 
tumor-specific BCR-ABL and E2A-PBXI proteins. We focus on both the generation 
as well as the application of both polyclonal and monoclonal antibodies directed against 
both types of tumor-specific proteins. 
In the general discussion in Chapter 9 we discuss several aspects that concern the 
immunologic recoglution of cancer cells. When considering an antibody based tumor 
diagnosis, it is essential to understand the background of the reagents used in diagnos-
tic, immunological assays. We focus on antibodies specifically recogluzing cancer 
cells and we present new ideas on how to develop new innnunological reagents that 
are useful for tumor diagnostic purposes. 
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The theoretical basis of cancer 
Fundamental to the origin of cancer is loss of responsiveness to normal growth 
controls. Cancer cells divide continuously, apparently unaware of the various regu-
latory mechanisms that control normal cell growth. To place the abnormal neoplastic 
cellular proliferations in perspective of the normal, non-neoplastic controlled pro-
liferations are considered first. 
Normal cell prolifel'ation 
Cell proliferation is an ongoing process in the healthy human body. Cells are initi-
ated to grow and divide primarily to compensate for ongoing cell loss (e.g. skin, gut 
and blood). To maintain the steady state of the adult human body (i.e. homeostasis), 
overgrowth must be prevented. Therefore, cell proliferation is, on its turn, also down-
regulated (I). 
The complex processes of cell proliferation are controlled by ingenious networks of 
growth regulatory pathways (2, 3). Growth control is realized by regulatory proc-
esses known as normal growth regulation and normal cell cycle regulation. Although 
both processes are intrinsically related, they are discussed separately below. 
Normal growth regulation 
Growth regulation is controlled by several molecules associated with growth stimu-
latory and growth inhibitOlY relay systems. These relay systems are activated by 
incoming growth regulating signals, either produced by cells located in close prox-
imity to the target cell (i.e. cytokines) or by cells located at distant sites from the 
target cell (i.e. hormones). Unless growth inllibitOlY signals have been provided 
concurrently, growth stimulatory signals trigger a cell to prepare itself for cell divi-
sion. 
It has been demonstrated that most growth stimulatory molecules activate a cell to 
differentiate (i.e. the transition from a primitive to a more sophisticated status). 
Although in some cases the fully differentiated cell simply divides to produce daugh-
ter cells of the same type (e.g. endothelial cells and hepatocytes), most cells, espe-
cially those with a rapid turnover (e.g. epithelial cells and blood cells), develop 
tln'ough differentiating from primitive dividing 'stem' cells (4). The more differen-
tiated a cell becomes, the less likely it is for such a cell to proliferate. 
As long as such differentiated cells serve a particular purpose in the human body 
they are tolerated. However, when such cells impede other developmental proc-
esses (e.g. embryonal development), are irreversibly damaged (e.g. radiation), or 
become potentially harmful to the human body (e.g. cells from the immune system), 
they are sacrificed by a process known as apoptosis (5, 6). Similar to the stimulatOlY 
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and inhibitory processes that govern cell proliferation, apoptosis is controlled by a 
delicate balance between both positively and negatively regulating factors. Thus, a 
cell's intracellular death program will be activated by the appearance of activating 
signals or disappearance of inhibiting signals (6). 
Normal cell cycle regulatioll 
Cell growth usually precedes cell division. During cell growth a cell duplicates its 
contents (e.g. its organelles and DNA) and prepares itself to divide. While the divi-
sion of most of the cellular contents among daughter cells does not have to occur 
precisely on a 1: 1 basis, chromosomes are, after duplication, equally distributed. 
The events involved in cell proliferation occur in four defined successive stages, 
termed G" S, G, and M. 
In the G, (gap 1) phase, the cell increases in size and prepares to duplicate its DNA. 
Tlus DNA duplication occurs in the next stage, termed S (for synthesis). Then, after 
the DNA is copied, a second gap period (G,) follows, in which the cell prepares 
itself for M (nutosis). During mitosis the enlarged cell divides in half to produce its 
two daughter cells, each of them endowed with a complete set of c1n·omosomes. On 
their turn, these daughter cells start a new cell cycle by entering G" or they may 
withdraw into a quiescent state, termed Go(1). 
Although each respective time period, needed for a cell to complete a particular 
phase of the cell cycle, varies to some extent, by far the greatest variation occurs in 
the duration of G,. In the G, phase of the cell cycle, both growth stimulatory as well 
as growth inhibitory signals determine whether a cell progresses through the cell 
cycle or whether a cell remains quiescent. It appears that most cells have a cdtical 
time point in the G, phase, termed: the restriction point. Once beyond this point, 
growth factors are of no further influence and DNA synthesis usually starts one to 
three hours later (i.e. the G, to S transition). During the next steps, the cell checks 
the integrity of its DNA and monitors whether the different steps in the cell cycle 
are completed successfully. The cell may be provoked to commit suicide when essen-
tial intra-cellular checkpoints within the cycle are not reached in time. Otherwise, the 
cell completes the subsequent steps of the cycle according to a rigid timetable (7). 
Thus, while eXIra-cellular signals are required to enter the cell cycle (i.e. G,), illlra-
cel/ular signals determine whether the cycle can be completed (i.e. succeeding 
through S, G, and M). 
The basics of carcinogenesis 
The chromosomal basis of cal/cer 
Genes cany the genetic information wluch is needed for a human body to survive. 
Genes are located on enormously long DNA molecules, ofwluch each of them forms 
the basic structure of one chromosome. Virtually all human cells carry 23 pairs of 
chromosomes: half a pair inherited from the mother, the other half from the father. 
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As microscopic techniques improved in the early 1970s, both numerical chromosomal 
changes (e.g. more than 23 pairs of chromosomes) as well as stlUctural chromosomal 
changes (e.g. a reciprocal exchange of chromosome fragments between non-homolo-
gous chromosomes) were revealed in human cancer. A causal relationship of chromo-
somal changes with neoplasm was suggested when specific chromosomal aberrations 
were identified in characteristic tumor types. Yet, until the 1980s, investigators lacked 
the tools to determine whether cln'omosomal aberrations were among the causes of 
cancer or, were a by-product of cancer development (8). 
Tile gelletic basis of callcer 
The causal relationship between chromosomal aben'ations and cancer became clear in 
the early 1980s through the discovery that foreign DNA introduced into cells (e.g. by 
a tumor virus) changes these cells into a malignant state (9). This experimental break-
through paved the way for the discovery of two new human gene classes that have 
become known as: proto-oncogenes and tumor-suppressor genes (2, 3). These genes 
are localized at different places in human chromosomes and are involved in the offset 
of cancer. However, as long as these genes are not damaged, they play central roles in 
normal regulatory processes of cell growth and division. In such regulatory processes, 
cell growth is stimulated by the products of proto-oncogenes and inhibited by the 
products of tumor-suppressor genes (2, 3). 
A proto-oncogene may change into a cancerous oncogene when it is mutated as a 
result of either carcinogens (e.g. tar from cigarette smoke, causing lung cancer), radia-
tion (e.g. ultraviolet rays in sunlight, causing skin cancer) or tumor vimses (e.g. papil-
loma vitus, causing cervical tumors). Gene mutations cause the (proto-)oncogene to 
encode a growth stimulatOlY factor that is either abundantly expressed or simply overly 
active. However, one altered (proto-)oncogene does not necessarily lead to cancer 
(10). As has been discussed before, cells tum cancerous through the accumulation of 
various oncogenic events (i.e. the multi-step theory). In order to prevent cancer devel-
opment, a cell is provided with complex fail-safe systems that take care of any distur-
bance in the regulatory processes of normal cell growth. When a number of these 
fail-safe systems are damaged, a cell may eventually turn cancerous (II). 
One of the most obvious ways for a cell to prevent the initiation of cancer is to restore 
the DNA damage inflicted by cancer causing agents. Therefore, a cell is provided 
with so-called 'gene repairing' systems: these systems recognize and repair damaged 
DNA at various stages of the cell cycle (12). Moreover, even if these gene repairing 
systems fail, the oncogene's growth promoting stimuli are still not necessarily brought 
into effect. As long as their growth stimulatOlY effects are reduced by the growth 
inhibitory products of tumor suppressor genes, a cell is protected from autonomous 
growth. When tumor suppressor genes are damaged in such a way that they are not 
able to counteract the growth-stitnulatOlY signals of (proto-) oncogenes, endogenously 
produced growth stimulatory factors are given a free hand and eventually cause a cell 
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to become cancerous. In contrast to oncogenes, where the presence of only one mu-
tated allele is sufficient to contribute to cancerous growth, gene mutations must have 
been aft1icted by cancer causing agents on both alleles of a tumor suppressor gene. 
Only if none of both tumor suppressor genes produce active growth inhibitOlY signals, 
cell growth and proliferation result from ongoing growth stimulatory signaling. 
From the aforementioned successive stages it is clear that gene mutations are the basis 
on which a cell changes into a cancel' cell. Although these gene mutations do not 
necessarily have to occur in this proposed order, they contlibute to a cancerous behavior 
as each of them causes either: 1) ectopic expression of a gene product, 2) an altered 
function of an altered gene product or, 3) the inactivation of a gene product (2, 3). 
The proteil/ basis of cal/cer 
Genes encode for proteins through processes known as transcription and translation. 
It is not difficult to imagine that gene mutations can cause severe changes in protein 
stLUcture. Because proteins are involved in various vital cellular processes (e.g. cell 
proliferation, cell differentiation and cell metabolism), they are generally considered 
as the tLUe working elements in a cell. 
How proteins are involved in cancer is best exemplified t1u'Ollgh tracing the pathway 
that is followed by incoming growth regulatory signals, once they have reached the 
cell's surface. The signaling relay system is therefore characterized by successive 
stages, occUlTing at three different levels of a cell: 1) the cellular membrane, 2) the 
cytoplasm and 3) the nucleus. 
The cellular membrane, or plasma membrane, defines the cell's boundaries and main-
tains essential differences between its contents and the environment. This membrane 
encloses the cell's interior, which comprises the cytoplasm and the nucleus. The cyto-
plasm on its turn is compartmentalized into various cell organelles, 'floating' in a 
conml0n space, termed the cytosol. The cell nucleus is regarded as the most signifi-
cant cellular sttUcture as it contains nearly all of the cellular DNA molecules; provid-
ing the coding sequences of the various components needed for a cell to interact with 
the environment. 
When (proto-)oncogenes force a cell to produce gl'Owth factors, they drive the prolif-
eration of nearby cells or, in cancer cells, when these signals turn back, they drive 
proliferation of the cell that just produced them (i.e. autocrine growth stimulation 
model). These growth factors are captured by specific membrane proteins, or mem-
brane receptors. As many membrane receptors extend across the membrane's lipid 
bilayer, they form communication bridges between the environment and the interior 
of a cell. When signals from the outside are captured by membrane receptors, these 
signals are switched to the intedor of the cell by changing the chemical state of the 
intra-cellular part of the membrane receptor protein. At the inner side of the plasma 
membrane other signal transducing proteins are successively activated. Thus, by acti-
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vating membrane receptor molecules a cascade of intra-cellular signaling is started, 
which usually ends in the nucleus. 
A cancer cell may replace its signal transducing proteins by abelTantly activated pro-
teins at each point in this signaling relay system. Such aberrantly activated membrane 
receptor proteins, cytoplasmic proteins or abelTantly activated nuclear proteins cause 
down-stream activation of the growth promoting relay system. As each of these aber-
rantly activated proteins result in abnormal growth stimulating stimuli, it is clear that 
the cancerous effects of the protein products of oncogenes is exelted at vm"ious cellu-
1m' levels. 
As mentioned em'lier, cells must do more than overstimulate their growth promoting 
machinery to become truly malignant. Any tendency towards autonomous prolifera-
tion is tempered by growth inhibitOiY signals. Growth inhibitory signals are encoded 
by tumor suppressor genes and these genes provide a second fail-safe system that 
prevents cancerous behavior. However, growth inhibitory signals are delivered and 
relayed in a similar fashion as described for growth stimulatory signals. Any disrup-
tion of the growth inhibitory signaling cascade disables a cell to counteract growth 
stimulatOiY signals which results in loss of control on proliferation. 
Other genetic alterations, increasingly implicated in cancer, are the ones that lead to 
an inappropriate expression of transcription factors. Transcription factors m'e nuclear 
proteins that recognize and bind specific regulatOiY DNA sequences. As a conse-
quence, they stimulate or repress the mRNA transcription of their tm'get genes. 
The transcdption factors that act on most mammalian genes can be divided in two 
types (13). The first category consists of general transcription factors that form part of 
a multi-protein complex (i.e. the RNA polymerase II initiation complex). This multi-
protein complex recognizes specific DNA sequences inmlediately adjacent to a tran-
scdptional stmt site. Binding of this mUlti-protein complex usually results in the active 
transcdption of the involved gene. The rate of gene transcription is greatly influenced 
by the stability of the initiation complex and the frequency with which initiation com-
plexes are formed. These variables are regulated by members of the second categOiY 
of transcription factors: the specific transcription factors. 
In contrast to general transcription factors, specific transcription factors recognize 
and bind specific DNA motifs, present in some genes but not in others. They regulate, 
through so-called transactivation domains, the RNA polymerase II activity by direct 
or indirect interaction with the initiation complex. Specific transcription factors are 
categorized in several families, based on homology of DNA-binding domains be-
tween various specitic transcription factors (13). 
Transcription factors are developmentally regulated (i.e. they are !tImed on or off at 
specific differentiational stages) and m'e usually involved in cell differentiation. These 
transcription factors may directly or indirectly influence the transcdptional rate of 
(proto-)oncogenes, tumor-suppressor genes or other genes involved in cell prolifera-
tion. 
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The 'master-gelle' model: 
The complexity of protein processes involved in carcinogenesis is best simplified by 
the 'master-gene' model, originally described by Rabbitts (14). According to the original 
model, master-genes are developmentally regulated and influence, although they do 
not necessarily encode transcription factors, the expression of one or several 'responder-
genes' (14). The products of master-genes can act positively and up-regulate the ex-
pression of responder-genes or, they can act lIegatively by down-regulating the 
expression of responder-genes (14). 
The master-gene model is important to understand the malignant transfonnation of 
previously normal, healthy cells. In cancer cells, abenantly activated master-genes do 
not only upset a cell's transcriptional status, but they may also break the lineage 
specificity of transcription by activating responder-genes from different cellular ori-
gins. It is imaginable that, when master-genes and/or responder-genes are abenantly 
expressed or activated, they cause the cell to respond to or neglect stimuli that are 
important for cell proliferation and differentiation control. 
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Cancer: one disease ? 
The traditional classification of cancer, which is based on morphological features, is 
inadequate. A close examination of the conventional categories reveals that most 
cancers consist of heterogeneous collections of disorders, each characterized by its 
own array of genetic lesions. Owing primarily to technical considerations, our 
knowledge of pathogenetic processes is most extensive in hematologic malignancies. 
Recent findings in a number of these hematologic malignancies not only exemplify 
the complexity and variability of human cancer, but also provide new tools that allow 
a precise diagnosis. 
Leukemia 
The formation of different types of blood cells (i.e. hematopoiesis) is essential for the 
development and survival of a healthy individual. New blood cells belonging to dif-
ferent cell lineages are fOlmed from stem cells to replace cells that have completed 
their life span. These processes statt early during emblyogenesis atld proceed throughout 
human life. Abnormalities in this normal developmental program for blood cell forma-
tion result in hematological diseases including leukemia (I). 
Leukemic cells colonize the mat'l'OW of many of the bones. Like normal leukocytes, 
such neoplastic cells escape into the blood where they may be present inlat'ge numbers 
(hence 'leukemia'). Leukemic cells inhibit normal hemopoiesis, partly by replacing 
the bone manow tissue, but also by secreting substances (e.g. cytokines) that inhibit 
the proliferation of (healthy) hematopoietic stem cells. As a consequence, death usually 
results from anemia, hemonhage, or infection, resulting from a deficiency of red cells, 
platelets, or normal leukocytes, respectively (2). 
Compat'able to most malignant tumors, leukemias differ in the degree of differentia-
tion of the tumor cells and, in general, their rate of neoplastic proliferation varies 
inversely with their degree of differentiation. According to clinical presentation, the 
leukemias are divided in acute leukemias which, if untreated, usually cause death in 
weeks or months and chronic leukemias which, if untreated, cause death in months or 
years (2, 3). 
The acute leukemias are usually charactetized by extensive cellular proliferation of 
abnormally differentiated, immature white blood cells in bone mat'l'Ow. This kind of 
leukemia comprises a heterogeneous group of conditions that differ in both biology as 
well as prognosis. Depending on the celllineage(s) involved in the leukemic process, 
acute leukemias are classified as acute lymphoblastic leukemias (ALL) and as acute 
non-lymphoblastic leukemias (ANLL) (2, 3). Acute leukemias are usually divided 
into those occt1l1'ing in childhood (<15 years), with ALL as the most predominant 
type (80%) and those occurring in adults (> 15 years), of which ± 85% at'e ANLLs 
(3,4). 
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Chronic leukemias are characterized as hematological malignancies in which the 
uncontrolled proliferating leukemic cells are capable offull maturation. Two subtypes 
of clu'Onic leukemia are distinguished: chronic lymphocytic leukemia (CLL) and chronic 
myeloid leukemia (CML). The median age of patients with CLL is 65 years (5). 
Depending on complicating features such as anemia and thrombocytopenia, median 
survival rates between these patients vary from 24 months to 10 years (5). While CLL 
is rare below 40 years of age, CML may occur at any age, although the disease is 
commonest in adults (median age of CML patients is 50 years) (6). The course of 
CML is bi-phasic: initially statting as a chronic phase that lasts for 1-4 years, the 
disease changes into a second phase termed 'the blast crisis'. Blast crisis is chat'acterized 
by the appearance of an unusually high number of immature lymphoid or myeloid 
blast cells in the peripheral blood. Usually, patients in blast crisis respond poorly to 
therapy (6, 7). 
With the exception of CML, both ALL, AML, and CLL demonstrate a considerable 
heterogeneity in biology and prognosis. One of the first attempts to assess the prognosis 
and select the therapy more properly was made by a group of French, American, and 
British hematologists. This group developed a classification system (i.e. FAB 
classification) that was based on conventional morphological and cytochemical analysis 
of peripheral blood and bone marrow smears from patients with acute leukemia (8). 
Nowadays, according to redefined FAB criteria, the far majority (> 99%) of acute 
leukemias consists of three groups of acute lymphoblastic leukemias (i.e. L1 to L3) 
and eight groups of acute myeloid leukemias (i.e. MO to M7), while only a small 
fraction «1 %) represents acute undifferentiated leukemias (AUL) (9-11). The FAB 
group also proposed morphologic criteria to classify CLL. Based on the propOition of 
atypical lymphocytes in blood, CLL is subdivided in: typical CLL, CLL-prolymphocytic 
leukemia and atypical CLL (5, 12). However, contrmy to the FAB classification of 
acute leukemias, a FAB classification for CLL is still of much controversy (5, 13). 
The need to further subdivide ALL, AML and CLL is exemplified by worse treatment 
outcomes within subgroups. It is realized that a stratification that is primarily based on 
morphological features only partly reflects the biology of the malignancy and is, as 
such, limited to predict the prognosis of a leukemia patient. 
Cytogenetics and leukemia 
In 1960 Nowell and Hungetford detected a small marker chromosome, the so-called 
Philadelphia (Ph) chromosome, which was consistently found in CML (14). In 1973, 
Rowly (15) demonstrated that the Ph clu'omosome is identical to the 22q- chromo-
some and results from the reciprocal exchange of chromosomal fragments between 
chromosomes 9 and 22: t(9;22)(q34;qU). These findings initiated the field of cancer 
cytogenetics and it was realized that certain chromosomal aberrations were strongly 
associated with characteristic clinical features, response to treatment, and survival. 
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Nowadays, numerous chromosomal abelTations are detected by conventional cytoge-
netic techniques. In these techniques, cells are m1'ested at metaphase (i.e. one of the 
six phases in which the M phase is divided) and their chromosomes are stained with 
dyes, such as Gicmsa or fluorescent dyes (e.g. atebrine and acridine orange). Typical 
chromosome bands are visualized; e.g. Giemsa staining distinguishes DNA rich in 
A-T nucleotide pairs (so-called Giemsa - or G-bands) from DNA rich in G-C nucle-
otide pairs (so-called reverse - or R-bands). Since clu'omosome bands m'e localized at 
specific places within chromosomes, it is possible to categorize each cln'omosome or 
pmt of the chromosome. Accordingly, abelTant cln'omosomes can be analyzed and 
classified (16). 
Chromosomal aberrations are either numerical, meaning loss or gain of entire cln'o-
mosomes (i.e. -7 or +S), or structural (e.g. translocations, deletions and inversions). 
There are two general types of structural aberrations: I) balanced, primarily recipro-
cal translocations or inversions without visible gain or loss of chromosomal material 
and, 2) unbalanced aberrations, with gain or loss of parts of chromosomes. Further-
more, when referring to chromosome aberrations, a distinction is made between pli-
mmy and secondaty changes. Primmy cln'omosome changes in leukemia are usually 
structural. Secondmy (or subsequent) changes are often numerical and appear to cor-
relate with tumor progression (17). 
In childhood ALL, the group of patients with high hyperdiploidy (i.e. more than 50 
chromosomes) proves to have the most durable responses to treatment, meaning that 
these patients have the least chance, when compared with children suffering from 
other types of childhood ALL, of reappearing leukemic blasts ensuing complete re-
mission (1S). While the hyperdiploid group accounts for about 25% of childhood 
cases, the largest group is formed by the group of patients with a pseudo diploid 
karyotype (± 40%). This group is characterized by a chromosome number of 46 per 
cell with structural abnormalities, most often translocations (18, 19). 
The t(9;22) and the t( 4; 11) have both been shown to identify groups of patients with a 
patticulat' poor therapeutic outcome (20, 21). The most frequently observed stmctural 
abnormality upon conventional cytogenetic analysis of childhood ALL cases is the 
t(I;19), which identifies a group of patients with several adverse prognostic features 
(e.g. high white blood cell count and lack of hyperploidy) (18,19). However, as will 
be discussed later on, one must realize that conventional cytogenetic analysis is lim-
ited by technical difficulties and does not detect all chromosomal abnormalities (e.g. 
the t(12;21)(pI2;q22) in childhood ALL) (22). 
While remarkable improvements in the cure rate of children with ALL have occUl1'ed 
over the past 30 years, the results in treatment of adults with ALL remain poor, despite 
adoption of strategies used successfully in children (23). However, as was also ob-
served in childhood ALL, when leukemia cells have a hyperdiploid katyotype, adult 
ALL patients usually have a more favorable prognosis than patients suffering from 
ALL with different karyotypes. Presence of t(9;22) hallmarks a large group of ALL 
patients (± 30% of adult ALL) with an unusual poor prognosis (23). 
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Numerical chromosomal changes in AML, in particular +8 or -7 are typical examples 
of secondary changes and are the major components that characterize a type of leuke-
mia with a velY poor prognosis. Approximately one third of AML cases is associated 
with specific translocations. The t(8;21), t(l5;17) and t(9;22) are the most frequently 
observed cytogenetic abnormalities in AML. While patients with t(8;21) or t(l5;17) 
are generally regarded as having a favorable prognosis, AML patients with the t(9;22) 
are associated with poor prognosis and short survival (24). 
About 50% of patients with CLL has karyotypic abnormalities, par1icularly trisomy 
12, del(13)(qI2-14) and 14q+. Trisomy 12, which accounts for ± 35% of all CLL 
cases, is the best known karyotypic abnormality in CLL that is associated with a poor 
prognosis. Although other cytogenetic aberrations, such as t(ll; 14)(q 13;q32), 
t(l4;19)(q32;qI3) have been reported, their impact on the prognosis of CLL is still 
unclear'. However, as is also observed in other leukemias, the more cytogenetic abelTa-
tions ar'e detected in CLL, the greater the likelihood of a short survival (13, 16). 
Both ALL, AML, and CLL, are heterogeneous regarding their diversity of c1u'omo-
somal abelTations. In contrast, the leukemic cells of more than 90% of CML patients 
are characterized by a typical c1u'omosomal abelTation: the t(9;22)( q34;q 11) or, the 
Philadelphia translocation. Additionally, 5% of CML patients can be identified by a 
variant Ph translocation, seemingly not affecting c1ll'omosome 22. In these variant 
cases, part of the Philadelphia c1ll'omosome appear's to have moved to other chromo-
somes (6). In CML blast crisis, additional chromosomal abnormalities, such as +8, 
i(l7q) and +22q-, are often detected. 
Although 5% of CML patients lack characteristic or variant Philadelphia chromo-
somes, it is common practice to consider the presence of a Philadelphia chromosome 
as a hallmark for CML diagnosis (7). 
In summary, certain (characteristic) chromosomal aberrations are strongly related with 
typical clinical features, response to treatment and survival and it appears that a number 
of these c1n'omosomal abelTations is causally related to the malignant properties of the 
leukemic (sub-)type. By using cytogenetic analysis, it is possible to further classify 
the major subtypes of leukemia, especially ALL and AML, according to their c11ar'ac-
teristic chromosomal aberrations. 
Molecular genetics and leukemia 
The resolution of conventional cytogenetic techniques is not more than a single chro-
mosome band. When one realizes that even the thinnest c1n'omosomal band that is 
visible through the microscope, comprises an enormous amount of DNA, it is obvious 
that chromosomes of leukemia cells may appear normal upon microscopic evaluation 
even though (submicroscopic) aberrations are present (16). Furthermore, metaphase 
analysis using banding techniques depends on the number of metaphases, and hence, 
also on the proliferative rate of leukemic cells (25). 
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New molecular techniques prove independent of the cell cycle and they provide a 
means to discover even the smallest genetic change imaginable. Typical examples of 
genetic changes that can be identified upon molecular analysis are given below: 
I. Point Illutations: one of the four bases (i.e. A, T, C, and 0) in the DNA molecule 
is replaced by any of the other three bases. Point mutations may either activate 
(proto-) oncogenes (e.g. the RAS oncogene in AML) (26) or they may inactivate 
tumor-suppressor genes (e.g. the P53 tumor-suppressor gene in CML) (27). 
II. Gene rearrangements: part of the gene is lost and replaced by another part of the 
DNA molecule. This pmt is either derived from the same gene (see: 'imllull1oglobu-
lin or T-cell receptor gene rearrangements') or from another gene. When this 
replacement involves a gene that is different from the original gene, the substitut-
ing gene is either derived from the same chromosome (see: 'deletions') or from 
another cln'omosome (see: 'translocations'). 
a. Immunoglobulin or T-cell receptor gene rearrangements: 
Immuuoglobulin (IG) and T-cell receptor (TCR) gene rearrangements are normal 
physiological processes that are required to generate the enormous diversity of 
the autigen receptor molecules which typify the lymphoid cell population (28). 
Innnunogiobulin (Ig) molecules, characteristic antigen receptors located on the 
smface of the B-Iymphoid cell population, m'e composed of two heavy chain mol-
ecules, encoded by the IGH gene located on chromosome 14, and two light chain 
molecules. These light chains are either encoded by the IGK gene located on cln'o-
mosome 2, or by the IGA gene located on c1n'omosome 22 (28). T-cell receptor 
(TcR) molecules m'e, as the name implies, chm'acteristic for the T-Iymphoid cell 
population. In mature T -cells, two different types of TcR molecules have been 
identified: TcRo:P and TcRro. The TcRo:P molecule is composed of two different 
glycoproteins, encoded by two genes TCRa and TCRf3, located on chromosomes 
14 and 7, respectively. The TcRro molecule consists of two glycoproteins en-
coded by the TCRy gene located on chromosome 7 and, the TCRo gene located 
within the TCRagene on chromosome 14 (28). 
These antigen-receptor genes comprise several discontinuous germline segments 
(i.e. V-variable, D-diversity, I-joining and C-constant regions). The V-, D-, and I-
segments are successively remmnged during differentiation from stem cell to mature 
lymphoid B- or T-cell, creating a diversity of antigen receptor genes Im'ge enough 
to provide (in principle) each lymphocyte in the human body with its own specific 
antigen receptor. Because such IG and TCR gene rearrangements are unique for 
the individual cell and its progeny, they are particularly useful in leukemia diag-
nosis. Leukemia is a clonal disease that is, especially in ALL and CLL patients, 
featured by abundant presence of a characteristic IG- and I or TCR gene rear-
rangement at diagnosis (25). 
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Thus, although antigen-receptor gene remTangements m·e by no means causative 
for the malignant transformation, such gene rearrangements provide excellent 
markers for clonality that can be extremely useful in both leukemia diagnosis as 
well as monitoring residual tumor-cells during and after treatment (25, 29, 30). 
b. Deletions: 
The complete gene or part of the gene is removed from the genome. Probably the 
best example of a slIb-microscopic deletion in leukemia is the so-called 'TALl 
deletion'. This deletion, del(l)(p32), is found in approximately 15-20% of patients 
with T-cell ALL. The del( I )(p32) is characterized by the juxtaposition of all coding 
exons of the TALI gene to the first nine non-coding exons of the SIL gene (31). 
Tllis gene remTangement results in deletion of the coding sequences of SIL, a gene 
that is, in contrast to the TALI gene, nOl1llally expressed in T-cells. As a result of 
the deletion, the TALl gene is transcriptionally controlled by the SIL promotor 
and, as a consequence, aberrantly transcribed into TALI mRNA. Aben-antly 
expressed transcription factor encoding genes, such as TALl in T-cells, me supposed 
to contribute, either directly or indirectly, to malignant transformation (32, 33). 
Table 1. TRANSLOCATlONS AND LEUKEMIA 
Typical IG and TCR gene rearrangements associated with leukemia:l 
lI-anslocation genes involved disease 
t(2;S)(pI2;q24) IGK;MYC B-ALL 
t(S;22)(q24;q II) MYC; IGL B-ALL 
t(S;14)(q24;q32) MYC;IGH B-ALL 
t(ll; 14)(q 13;q32) BCLI; IGH CLL' 
t(l4; I S)(q32;q2 I) IGH; BCL2 CLL' 
t(l4; 19)(q32;q 13) IGH; BCLJ CLL 
t(S; 14)(q24;q II) MYC; TCRao T-ALL 
t(I;7)(p32;q35) TALI; TCRfJ T-ALL 
t(l;7)(p34;q35) LCK;TCRfJ T-ALL 
t(7;9)(q35;q34) TCRfJ; TANI T-ALL 
t(7;9)(q35;q32) TCRfJ; TAU T-ALL 
t(7;1O)(q35;q24) TCRfJ; HOX4 T-ALL 
t(7;II)(q35;p13) TCRfJ; RBTN2 T-ALL 
t(7;19)(q35;p13) TCRfJ; LYLI T-ALL 
t(l;14)(p32;qll) TALI; TCRo T-ALL 
t(lO; 14)(q24;qll) HOXII; TCRo T-ALL 
t(ll; 14)(p13;qll) RBTN2;TCRo T-ALL 
t(ll; 14)(p 15;q II) RBTNI; TCRo T-ALL 
asee references: 16, 17, 18, 19 and references therein 
bbolh translocations are more conullonly detected in lymphomas (see reference 34) 
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c. Translocations: 
TI,e discovelY of the IG and TCR genes provided new tools that allowed the 
identification of new genes involved in leukemia (34). The availability of molecu-
lar probes that fitted the antigen receptor genes, facilitated the discovery of adja-
cently located genes. When IG or TCR genes are involved in cln'omosomal 
translocations in lymphoblastic leukemia, they are often juxtaposed to genes that 
encode transcription factors (Table 1) (34, 35). Moreover, especially in T-ALL, 
these transcription factors are frequently ectopically expressed; meaning that these 
transcription factors are normally not expressed in T-cells or, if expressed, at least 
at far lower levels (35). The transcriptional control elements of the antigen recep-
tor gene (i.e. IG or TCR) are thought to regulate the (inappropriate) expression of 
the juxtaposed (onco-)gene (36). As noted above (see 'TALl deletion'), it is as-
sumed that aberrantly expressed oncogenes are causative, either directly or indi-
rectly, for the malignant transformation of normal cells (35, 36). 
Yet, various molecular genetic studies have indicated that IG or TCR genes are not 
involved in the majority of chromosomal translocations in hematopoietic malig-
nancies found to date (Table 2). New genes have been identified and a number of 
them suggest a fundamentally different mechanism of oncogenic conversion, of 
which the BCR-ABL and the E2A-PBXI genes are prototypes (37). 
Table 2. TRANSLOCATIONS AND LEUKEMIA 
Most frequently observed chromosomal translocations within leukemic suh-groupsa 
Childhood ALL frequency fusion-genes 
t(l2;21 )(p 12;q22) 25-30% TEL-AMLlb 
t(l; 19)(q23;p 13) 5-6% E2A-PBXI 
t(9;22)(q34;qll) 3-5% BCR-ABL 
Adult ALL 
t(9;22)(q34;qll) 30% BCR-ABL 
AML 
t(8;21)(q22;q22) 5-8% ETO-AMLl 
t( 15; 17)(q22;q 12-q21) 4-7% PML-RARa 
t(9;22)(q34;qll) 1-3% BCR-ABL 
CLL 
t(ll; 14)(q 13;q32) <5% no fusion-gene 
CML 
t(9;22)(q34;q II) >95% BCR-ABL 
a see references: 16, 17, 18. 19, 22 and references therein. 
b the t(12;21)(p 12;q22) is more reliably detected by FISH than by conventional cytogenetic analysis 
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BCR·ABL genes 
The c-ABL proto-oncogene was first identified in the mannualian genome (38) by its 
homology to the oncogene of the Abelson murine leukemia virus (A-MuLV) (39). In 
the early 1980s, the c-ABL gene was implicated in human cancer for the f1l'St time, 
when it was shown that tlus proto-oncogene was translocated to chromosome 22q-
(the Philadelplua cln'OIuosome) in t(9;22)(q34;q 11) positive CML (Figure 1) (40, 41). 
It was demonstrated that the c-ABL gene loses part of its coding sequence as a result of 
the t(9;22)(q34;qU) and becomes truncated. In the majority ofCML patients, break-
points in the c-ABL gene were found, scattered over a distance of approximately 200 
kb, nearly always 5' of exon 2 (termed a2) (41). From tlus point on, in quick succes-
siou, the gene (tenlled BCR - from breakpoint cluster region) and its breakpoints on 
chromosome 22 were identified (42-45). In contrast to the ABL gene, breakpoints in 
BCR are clustered within two regions, defmed as: the major breakpoint region (M-
BCR) and the miuor breakpoint region (m-BCR) (Figure 2). 
The M-BCR spans five exons, termed b1-b5; conesponding to exons 12-16 of the 
BCR gene. In CML, ahuost all breakpoints occur within the M-BCR, either between 
exon b2 and b3 (50% of Ph+ CML) or between exon b3 and b4 (50% of Ph+ CML). 
Breakpoints outside the M-BCR are extremely rare in CML (46-48). 
In ALL, the majority of BCR breakpoints is found within the m-BCR region, localized 
between the first (e1) and the second (e2) exon of the BCR gene (49). Within the 
population of ALL patients carrying a BCR-ABL gene translocation, 85% of all chil-
dren and almost 70% of all adults show m-BCR breakpoints (50). The remahung 
group of patients has CML-like breakpoints hI the M-BCR, with equal chance of a b2! 
b3 or a b31b4 breakpoint (50-52). 
The reciprocal exchauge between the telomeric ends of chromosome 9 and 22 in 
t(9;22)(q34;q II) positive leukenuas, results in a shOitened 22q- chromosome contain-
ing the BCR-ABL gene and a 9q+ derivative harboring the reciprocal ABL-BCR gene 
(Figure 1). Although reports on theABL-BCR fusion-gene are stilliinuted, it appears 
~ BCR ~ BCR-ABL 
ABL ABL-BCR 
9 22 t(9;22)(q34;qll) 
Figure 1. Schematic representation of the Philadelphia translocation, a reciprocal translocation 
between chromosome 9 and chromosome 22. As a result of the transocation a chimericABL-BCR gene 
has been generated on the 9q+ chromosome and a chimeric BCR-ABL gene has been generated on the 
22q- chromosome, the so-called 'Philadelplua chromosome' 
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that in approximately two thirds of CML patients the ABL-BCR fusion-gene is tran-
scribed into its corresponding ABL-BCR fusion transcript (53). Despite of the in-
frame fusion of the two open reading frames of both truncated genes, ABL-BCR 
fusion-proteins have not been detected (53). 
The BCR-ABL fusion-gene on the other hand, is transcribed into fusion mRNA and 
subsequently translated. While the 7 kb ela2 BCR-ABL fusion mRNA gives rise to a 
190 kDa fusion-protein designated e,a,PI9(JBcR-ABL, 8.5 kb BCR-ABL fusion mRNAs 
comprising b2a2 or the b3a2 BCR-ABL junctions are translated into 210 kDa fusion 
proteins, termed b,a,P21OBCR-ABL or b,a,P21(JBcR-ABL, respectively (54-57) (Figure 2). 
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Figure 2. Schematic representation of the normalABL and BCR genes and of the chimeric BCR-
ABL mRNAs and proteins. Black boxes and black bars representABL exons and ABL derived mRNA 
and protein sequences. Grey boxes and bars symbolize BCR exons and BCR derived mRNA and pro-
tein sequences, respectively. 
BCR-ABL mediated leukemogenesis: chimeric proteins, such as BCR-ABL proteins 
observed in t(9;22)(q34;q II) positive leukemias, combine different domains that are 
normally only present in one of both wild-type proteins. 
The wild-type c-ABL proto-oncogene encodes a 145 kDa protein; a non-receptor pro-
tein kinase with autokinase activity (Le. the capacity to phosphOlylate itself). The 
cytoplasmic c-ABL protein is as a non-receptor protein kinase, probably involved in 
intracellular signal transduction pathways. The c-ABL protein contains at least four 
functional domains: I) an N-terminal domain, encoded by two altel11ative exons termed 
Type 1a and Ib (54, 58), 2) a kinase regulatOlY domain, including two SRC-homology 
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regions (SH3 and SH2), 3) the tyrosine kinase domain (SHl) and, 4) a large C-termi-
nal region which is unique to the ABL family (59). The autokinase activity of the c-
ABL protein is tightly regulated, a feature that is mediated by the kinase regulatory 
domains SH2 and SH3. 
It has been demonstrated that all three types of BCR-ABL proteins have an enhanced 
tyrosine kinase activity in compadson with that of the normal c-ABL protein (56, 57, 
60). BCR sequences that are encoded by the first exon oftheBCR-ABL gene, inte.fere 
with the kinase regulatory domains through binding to the SH2 domain (61). The 
enhanced tyrosine kinase activity found in the chimedc BCR-ABL proteins is likely 
caused through shielding the SH3 domain by N-tenninal BCR sequences, through 
which the inhibitory effect of the SH3 domain on the tyrosine kinase domain is neu-
tralized (61, 62). 
However, the enhanced tyrosine kinase activity is probably not the sole reason that 
BCR-ABL proteins are oncogenic. N-terminal BCR sequences do not only bind to the 
SH2 domain found in BCR-ABL, but also bind to the SH2 domain of another SH2-
SH3 containing protein, termed GRB2. The GRB2 protein has been described to link 
tyrosine kinase activity to activation of the signaling pathway in which RAS proteins 
are involved (61, 63, 64). 
According to the master-gene model introduced by Rabbitts (65), it is estimated that 
BCR-ABL proteins are the products of a master-gene. In this model, the uncontrolled 
cellular proliferation of tumor-cells is explained by the disturbance of normal cell 
cycle regulating networks. When considering BCR-ABL proteins, it is possible that 
normal cell cycle regulation is directly affected by BCR-ABL master-genes or, indi-
rectly via responder genes such as RAS (66). Recently, interactions between c-ABL 
and the Retinoblastoma protein (pRB), the 'master brake' of the cell cycle clock, have 
been described (67, 68). 
Deciphering these master-responder gene networks contributes to our understanding 
of how the BCR-ABL proteins are involved in leukemogenesis processes.l1wt BCR-
ABL proteins are involved in the malignant transformation of hematopoietic cells was 
recently demonstrated ill vivo. Animal models for human Ph positive leukemia, whether 
generated tlu'ough retroviral (69-72) or transgenic technologies (73-75), demonstrate 
that 'BCR-ABL positive' animals develop leukemias resembling the leukemic dis-
ease observed in humans. The longer latency time of P21OBCR-ABL associated tumori-
genesis in trmlsgenic mice seems to reflect the intrinsic biochemical differences between 
P21OBCR-ABL on the one hand and P190BCR-ABL on the other (75). 
Prognostic alld therapeutic implications: the t(9;22) provides mm'kers that m'e appli-
cable for both tumor-specific diagnostic purposes as well as the specific detection of 
residual tumor-cells during and after treatment. Yet, conventional cytogenetic analy-
sis of leukemic cells is frequently hampered by a lack of sufficient metaphases as it 
largely depends on the proliferative rate of the leukemic cells. Moleculru' techniques, 
such as fluorescent in situ hybridization (FISH) (76, 77) or reverse transcriptase 
Cancer: one disease? 35 
polymerase chain reaction (RT-PCR), often detect BCR-ABL gene realTangements in 
cases in which no Philadelphia chromosome are detected by conventional cytogenetic 
teclnuques (78, 79). 
Patients suffering from a t(9;22)(q34;qll) positive leukemia have a poor prognosis. 
Especially in ALL, it is impOltant to distinguish Ph positive ALL from Ph negative 
ALL. Whether children or adults, patients with Ph positive leukenuas often relapse 
during or after their fmt round of therapy with chemotherapeutic dl1lgs (i.e. induction 
therapy) (20, 23, 80). To allow an early intervention with more aggressive and experi-
mental therapies (e.g. bone malTOW transplantation), it is not only impOltant to diag-
nose Ph positive leukenuas as accurately as possible, but it is also impOltant to diagnose 
these Ph positive leukenuas as quickly as possible (20, 23, 80). 
E2A-PBXl genes 
The transcriptional control of IG and TCR genes is dominated by specific nucleotide 
sequences, termed 'enhancers'. The IGH and IGK gene enhancers were the first to be 
identified and were found in the introns that separate the J and C regions. These 
enhancers are known as E-boxes, named after Anna Ephrussi, the first author on the 
hutial report (81). E-boxes bind multiple nuclear proteins, some of which are tissue 
specific while others are ubiquitously expressed (82). 
In 1989, Mllll"C reported on the isolation of two enhancer binding proteins El2 and 
E47 (83). These two proteins, together with theE2-5 protein, are dedved from a single 
gene termed E2A (84). Shortly after the E2A gene was discovered, it was found to be 
located witllin chromosome band 19p13: the breakpoint of the t(I;19)(q23;p13) ob-
served in childhood ALL (Figure 3) (85). 
Breakpoints in the E2A gene almost invariably occur within the 3.5 kb intron located 
between exons 13 and 14 (86). In both balanced t(1;19)(q34;qll) and unbalanced 
der(19)t(1 ;19) positive leukenuas the E2A gene is fused on c1n'omosome 19 to a pre-
viously unknown gene PBX1 located on chromosome 1 (87, 88). Although the ge-
nonuc orgatuzation of PBX1 has not been fully determined, it is assumed that the 
breakpoints occur in a single, lat'ge intron (> 50 kb) of the PBX1 gene (Figure 4) (86). 
The fusion-point detected in the E2A-PBXl transcript is remarkably consistent (89), 
although several groups detected a 27 additional nucleotide insert at the junction be-
tween E2A and PBX1 that seems to co-exist with the conventional E2A-PBXl tran-
scripts in 5-10% oft(1; 19) positive ALL (90, 91). These additional 27 nucleotides are 
identical in each case and appear to arise from a differentially spliced E2A or PBX1 
exon, but their exact derivation is unknown (90). The t( I; 19) is predominantly found 
hI pre-B-ALL, of which 25% carries this particular translocation (18). 
Unlike t(9;22)(q34;qll) positive leukenuas in wluch reciprocal chimeric ABL-BCR 
transcripts are detected together with the 'conventional' BCR-ABL nlRNAs, recipro-
cal PBXI-E2A transcripts are not observed in t(1;19)(q23;p13) positive leukemias. 
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Apart from loss of the PBX/-E2A gene on derivative cln'omosome 1 in unbalanced 
t(1 ;19) positive leukemias (i.e. more than 80% of all t(I;19) positive leukemias), tran-
scriptional regulation of PBX/-E2A would be mediated by the PBXl promotor (see 
Figure 3). This promotor is silent in pre-B and mature B-cells (88). 
The E2A-PBXlmRNA was calculated to give rise to protein products with a molecu-
lar mass of85 kDa (i.e. E2A-PBXla) and 77 kDa (i.e. E2A-PBXlb) (87, 88). Due to 
differential splicing in the PBXl patt of the E2A-PBXI primary transcript, different 
E2A-PBXl proteins at'esillluitalleously expressed by single t(1; 19) positive cells (Fig-
ure 4) (92). Tltis is in contrast to BCR-ABL proteins in Ph positive leukentias. Al-
though different BCR-ABL proteins have been described, they are usually /lot 
simultaneously expressed by a single t(9;22) positive cell (Figure 2). 
normal balanced unbalanced 
E2A-PBX1 E2A-PBX1 
PBX1 PBX1·E2A PBX1 
19 der (1) der (19) der(19) 
Figure 3. Schematic representation of the t(l;J9)(q23;p13) and its unbalanced vuriant. In the 
unbalanced form, the derivative chromosome I is probably lost by nondisjunction and is replaced by 
duplication of the normal chromosome I homoioquc. The unbalanced variant accounts for Illore than 
80% of all t( 1; 19)(q23;p 13) trans locations and does not harbor a reciprocal PBX1-E2A gene 
E2A-PBXl mediated leukemogenesis: chimeric E2A-PBXI proteins observed in 
t(I;19)(q23;p13) positive pre-B-ALL, combine two different transcription factor do-
mains that are normally only present in one of both wild-type proteins. 
E2A proteins belong to the so-called 'basic Helix-Loop-Helix' fantily of transcription 
factors (35). Specific DNA binding is mediated by the basic region located at the 
antino-tenninus of the Helix-Loop-Helix domain, the latter domain is involved in 
dimerization processes that mediate binding of E2A proteins to identical or related 
transcription factor proteins. It has been demonstrated that protein dimers, but not 
monomers, can bind DNA in a sequence specific matmer (93). RNA polymerase II 
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activity is regulated by direct or indirect interaction with the initiation complex through 
two transactivation domains (i.e, ADI and ADll) present on the E2A proteins (94), In 
the normal situation, E2A proteins are involved in the regulation of a diverse array of 
cellular processes including myogenic differentiation (95, 96), and transcription ofIG 
genes (96-98) and pancreatic genes (99), 
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77.2 kOa ADI ADIJ _1mlI11 
Figure 4. Schematic representation of the normal E2A and PBX] genes and of the chimeric 
E2A-PBXJ mRNA and proteins. Black boxes and bars represent E2A exons and E2A derived l11RNA 
and protein sequences. Grey boxes symbolize PBX] exons and PBX] derived l11RNA and protein 
sequences. Abbreviations: AD I and AD II, transcriptional activation domains 1 and 2; HOM, 
hOl11eodomain. 
In E2A-PBXl proteins, the basic Helix-Loop-Helix domain of E2A proteins is re-
placed by the homeobox DNA-binding and protein interaction domains of PBXl pro-
teins (87, 88), Contrary to the wild-type proteins, i.e, E2A and PBX1, the chimeric 
E2A-PBXl protein not only contains the two transactivation domains from E2A but 
also contains the homeobox DNA-binding and protein interaction domains from PBX1, 
Recent experiments have demonstrated that, in contrast to the wild-type proteins, the 
chimeric E2A-PBXl protein is capable to activate transcription of a reporter gene 
which contains the PBXl consensus binding site (100-102), 
The E2A-PBXl proteins perfectly fit the 'master-gene' model described by Rabbitts 
(65), The altered function of the chimeric E2A-PBXl 'master' protein is believed to 
cause activation of 'responder' genes that are normally not expressed, or expressed at 
far lower levels (103-105), These responder genes probably interact directly or indi-
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rectly with the cell cycle regulating network involved in cell proliferation. Recently, it 
has been demonstrated that E2A proteins have growth-inhibitory propelties at the GI-
S transition point when over-expressed in fibroblasts (106). 
The causative role of E2A-PBXl proteins in the malignant transformation of 
hematopoietic cells has been demonstrated ill vivo as well. From both 'simple' fibroblast 
transformation assays to the more elaborate animal models in which chimeric E2A-
PBXl genes are expressed, it was concluded that E2A-PBXl functions as a potent 
oncogene (92, 107, 108). Surprisingly, cells from E2A-PBXl transgenic mice suffer-
ing from T-cell lymphomas displayed a concomitant increase in cells undergoing pro-
grammed cell death or apoptosis, a feature that seems in paradox with the malignant 
character of the E2A-PBXI positive tumor-cell (108). 
Progllostic alld therapeutic implicatiolls: the t(l;19) provides markers that can be 
used for specific diagnosis and specific detection of residual disease during and after 
treatment. As already noted in BCR-ABL positive leukemias, molecular genetic analysis 
frequently detects translocations that are not observed with conventional cytogenetic 
techniques. Several studies suggest that 25% to 50% of leukemias with E2A-PBXI 
gene rearrangements are missed upon standard kmyotypic analysis (109, 110). 
While false-negative results are a common feature of cytogenetic techniques (often 
due to the lack of sufficient metaphases of leukemic cells), false-positive results fol-
lowing conventional cytogenetic analysis also occm: At least one case originally de-
scribed as a t(I;19) positive early pre-B-ALL was, when re-analyzed using molecular 
techniques such as FISH, detennined to be a t(l;22) (lll). Another example, that 
demonstrates the limited resolution of conventional cytogenetic analysis, is provided 
by t(I;19) positive common-B-ALL (Le. cytoplasmic Ig lIegative). In this inmlUno-
logical leukemic subtype, neither E2A nor E2A-PBXI gene remTangements are de-
tectable, despite presence of the t( 1; 19). These observations, which are attributable to 
the limited resolution of conventional cytogenetic banding techniques, suggest that 
the t(l;19) observed in common-B ALL (also known as t(I;19) positive early pre-B-
ALL) involves other, yet to be identified genes (91, 112, 113). These variant t(I;19) 
positive, butE2A-PBXl gene negative common-B-ALL, appear to have a better prog-
nosis than t( 1; 19)E2A-PDXI positive pre-B-ALL (1l4). It seems therefore, that the detec-
tion of the chimeric E2A-PBXl gene, rather than the detection of the abenant kmyotype, 
is of real prognostic value. 
Although some investigators still claim presence of the E2A-PBXl gene in t(l;19) 
positive common-B-ALL, Troussard et al. recently demonstrated that the cytoplasmic 
Ig negativity found in previously diagnosed t(l;19)E2A-PDXI positive conunon-B-ALL 
was due to technical limitations of conventional slide inununofluorescence analysis 
(115). Cytoplasmic Ig presence was revealed in all cases upon re-examination by flow 
cytometric analytical techniques (one case lacked sufficient material to be re-exam-
ined), indicating that E2A-PBXl gene rearrangements are typical for t(I;19) 
translocations in ALL with a pre-B inununophenotype (115). 
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Approximately 25% of childhood ALL has a pre-B immunophenotype. Within the 
pre-B-ALL group of patients, a similar propOliion can be identified by the presence of 
the t(1;19) translocation (116, 117). Initially, patients with a t(1;19) positive pre-B-ALL 
had a poorer prognosis than pre-B-ALL patients without t1us cytogenetic abnormality 
(117, 118). In the early 1990s, when the curative effects of new treatment protocols on 
patients with pre-B-ALL ALL were evaluated, it was demonstrated that the prognosis 
of all pre-B-ALL patients had significantly improved (119, 120). It was realized that a 
combination therapy of various chemotherapeutic dlUgs, when adnunistered accord-
ing to intensive treatment protocols to patients with pre-B-ALL, reduced the differ-
ence in prognosis between patients with a t(l ;19) positive pre-B-ALL and pre-B-ALL 
patients without this cytogenetic abnormality significantly (119, 120). 
Aim of the study 
The genetic basis of cancer is generally accepted. As exemplified by the prognostic 
and therapeutic implications of celtain tumor-specific genetic abnOlmalities, such as 
the poor prognosis of BCR-ABL positive leukenuas (20, 23, 80) versus the improved 
treatment outcome of E2A-PBXI positive leukemias (119, 120), it is obvious that 
accurate diagnostic techniques are extremely important. It is evident that an accurate 
identification of such tumor-specific genes is not only impOliant for primary diagno-
sis and therapy planning, but is also impOliant for detecting residual tumor cells dur-
ing and after treatment (25, 29). At present, a number of such diagnostic techniques 
exists (16, 25). Both indications as well as limitations of three of the most impOliant 
diagnostic techniques are briefly sununarized below: 
a. Conventional cytogenetic techniques are still the methods of fll'st choice for iden-
tifying and analyzing various chromosomal abnormalities in leukemic cells (25). 
The practical use of conventional cytogenetic techniques relies on its broad appli-
cability. In contrast to molecular genetic techniques, cytogenetic techniques ar'e 
not restricted by specific probes of which their use is linuted to the identification 
of a single chromosomal aberration. However, cytogenetic techniques are not velY 
sensitive since results depend on both the number of metaphases investigated as 
well as the linuted resolution of c1u'omosome banding. Moreover, the number of 
metaphases amenable to be analyzed varies with the type and odgin of the leuke-
nuc clone. In this respect, it is well acknowledged that ALL samples ar'e more 
difficult to analyze than ANLL samples, especially when these samples are ob-
tained from children (6). Only institutions with special experience in ALL 
cytogenetics ac1ueve successful karyotype analysis in almost every patient. Even 
then, some clyptic rearrangements escape detection by conventional cytogenetic 
analysis, which is exemplified by Ph chromosome negative, but BCR-ABL posi-
tive leukemias (121). 
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b. Contrary to conventional cytogenetic analysis, fluorescellt ill sifu hybridizatioll 
(FISH) techniques are not limited to a laborious analysis of metaphases (25). By 
using differently labeled probes, each directed against characteristic parts of a 
tumor-gene, specific chromosome abnollnalities are identifiable in intelphase cells. 
Yet, only a small number of such specific probes is presently available. Further-
more, depending on the co-localization of differently labeled hybridization sig-
nals to one spot, the sensitivity of the FISH technique is limited because artifactual 
co-localization may occur in normal cells. 
c. The polymerase chaill reactioll (PCR) is Cl1l1"ently the most sensitive method for 
detecting genetic abnormalities (25). In fact, by using PCR techniques, molecular 
genetic analysis frequently detects chromosomal abenations that are not observed 
kmyotypically. Especially during anti-cancer therapy, PCR analysis seems par-
ticularly useful to detect (low numbers of) residual tumor cells. However, some 
genetic abenations are not easily detected by direct amplification of genomic 
DNA (e.g. BCR-ABL positive leukemias). Tlus problem can be solved after re-
verse transcription of mRNA into cDNA, although strict precautions are required 
to prevent false positive (due to cross-contamination) or false negative (due to 
RNase) results. 
While cunent tumor-diagnostic techniques are based on the detection of either an 
abenant chromosome, abenant genes or abelTant mRNA, only few diagnostic tech-
niques exist that exclusively identify the abenant protein product of a tumor-specific 
gene. In tlus respect, immunologic teclnuques seem pmticulm-Iy useful to detect such 
tumor-specific proteins. Although present innnunologic techniques do not (yet) rely 
on the specific detection of tumor-specific proteins, improved, 11011 tumor-specific 
immunologic methods (e.g. double staining tecllluques and flow cytomel1y) have al-
ready increased the precision of tumor-diagnosis. The inllnunologic classification of 
leukemia, that is prinlm'ily based on the co-expression of celtain differentiation mark-
ers provides an eminent example. 
It is estimated that the exclusive detection of tumor-specific proteins will fUither im-
prove the diagnostic potential of currently used itmnunologic methods. 
The discovery of clumeric tumor-genes together with the introduction of the hybridoma 
tecllllology in 1975 by Kohler and Milstein (122), provided new tools for generating 
antibodies directed towm'ds tumor-specific antigens. From an immunological point of 
view it was assessed that only a celtain region of the tumor antigen would be unique 
for the tumor-specific proteitl. It is assumed that this so-called 'tumor-specific epitope' 
is not expressed on other cellulm' proteitls and might serve as a tumor-specific mm·ker. 
The ability to produce peptides with an anuno acid sequence, identical to the tumor-
specific epitope, offers an 0PPOItmuty to dit'ect the immune response, thereby diminish-
ing the chance to raising antibodies towards 1I01l-tumor-specific epitopes. 
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The generation of antibodies, specifically recognizing tumor cells: 
One of the first reports on a (polyclonal) antiserum, of which its generation is based 
on a peptide based immunization strategy, describes a (polyclonal) antisenun that 
specifically reacts with the tumor-specific epitope found in Ph chromosome positive 
leukemias (123). Tllis antiserum, wllich was termed 'BP-I' (from 'Break-Point-1 '), 
was derived by immunizing rabbits with a peptide conjugated to a protein-canier 
complex. The peptide that was used had an amino acid sequence identical to the (predic-
ted) amino acid sequence of the b,a, fusion-point epitope present in b,a,P21OBCR-ABL 
proteins. The BP-1 rabbit antiserum reacts with the fusion-point epitope present on 
the cognate b,a,P21OBcR-ABL protein. Its specific reactivity with the b,a, fusion-point 
epitope was confirmed as the BP-I antiserum did not detect related BCR-ABL pro-
teins, such as bJa,P210BCR-ABL. The bJa,P21QBcR-ABL proteins are identical with the 
b,a,P21OBcR-ABL proteins at their amino- and carboxyl-termini, but differ at the tumor-
specific fusion-point epitope. 
Based on a similar methodology, two other polyclona1 antisera have been reported, 
each of them specifically reacting with the tumor-specific fusion-point epitope present 
in cognate BCR-ABL proteins; i.e. BP-ALL specifically recogtlizes e,a,P190BcR-ABL pro-
teins (124), and BP-2 recogtlizes bJa,P210BcR-ABL proteins (125). 
From these experiments, it was concluded that fumor-specific fusion-point epitopes, 
as present on the chimeric BCR-ABL proteins, are allfigellically exposed and can 
serve as a new Ineans for tumor-specific diagnosis. 
Diagllostic problems alld questiolls to be solved: 
Even though the 'anti-BCR-ABL fusion-point' specific polyclonal antibodies specifi-
cally detect the tumor-specific fusion-point epitopes on tumor-specific BCR-ABL 
antigens, their intended use; i.e. the microscopic identification of intact, Ph chromo-
some positive tumor cells, had not heen realized (123, 124, 125). It appeared that 
specific problems needed to be solved before a tumor-specific diagnosis of leukemias 
by inununologic means was acllievable. In the next chapters oftllis thesis, we attempt 
to answer specific questions that are related to the generation of antibodies useful for 
the tumor-specific, immunological diagnosis of leukenlias. A btief introduction to 
these chapters is given below. 
In chapter 4 we question whether E2A-PBX1 chimeric proteins can be specifically 
detected by using a peptide based inunllllization strategy. These chimeric proteins are 
predominantly found in t( 1 ;19)E'A-P8x, positive pre-B -ALL. We demonstrate, by using 
essentially the same strategy as had been applied for the generation of the anti-BCR-
ABL fusion-point antibodies, that chimeric proteins, such as tumor-specific E2A-
PBX1 proteins, are also specifically detected. The antisenul1, which is tenned BP 1/19, 
was raised towards the tumor-specific fusion-point of E2A-PBX1 proteins. Tllis BP 
1119 antiserum specifically recognizes the tumor-specific E2A-PBX1 fusion-point; 
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both at the peptide as well as at the protein level. Tltis antiserum can also be used for 
the nticroscopic analysis of leukentias, since it specifically detects t(l ;19JE2MHXl positive 
cell lines. Only t(l; 19)E'A-PBXl positive cell lines display a characteristic, granular, nu-
clem' fluorescence pattern upon BP 1119 immunostaining. 
In chapter 5 we exantine the diagnostic use of BP 1119 antiserum in tumor diagnosis. 
We tested the specificity of BP 1/19 inll11unostaining on 27 different hematopoietic 
cell lines. BP II 19 innnunostaining proved specific, since the characteristic, granular 
nuclear staining pattern was only observed in all t(I;19)E'A-PBxl positive pre-B cell 
lines but was undetected in any of the other cell lines. The sensitivity of the inmumo-
staining tecllltique was determined at one t(l;19)E'A-PBxl positive cell among 10,000 
n01mal blood cells tln'Ough artificial mixing experiments. The diagnostic potential of 
BP 1119, considering tumor-specific recognition, was ascertained because antiselUm 
BP 1119 is capable to discriminate, at the cellular level, between previously diagnosed 
t(l;19) positive pre-B-ALL and t(I;19) negative ALL patients. 
In chapter 6 we investigate whether monoclonal anti-E2A-PBXI fusion-point anti-
bodies have the same diagnostic potential as the BP 1119 antiselUm. We demonstrate 
that monoclonal antibodies (which we termed ER-G04), have sintilar characteristics 
as the polyclonal antiserum regarding the specific recognition of the tumor-specific 
E2A-PBXI fusion-point epitope, at both the peptide as well as at the protein level. 
However, in contrast to the polyclonal BP 1119 antibodies, ER-G04 immunoglobulins 
are not capable to distinguish t( I ;19)E2A-PBXl positive pre-B cells from t( I ;19) negative 
pre-B cells. To prove that the limited use of ER-G04 antibodies is a matter of rela-
tively low expressed E2A-PBXI antigens, we demonstrate that ER-G04 antibodies 
are capable to specifically detect E2A-PBX I fusion proteins in COS cells transfected 
with cDNA that encodes E2A-PBXI proteins. 
In chapter 7 we exantine whether monoclonal antibodies, directed towards the tumor-
specific fusion-point epitope in ela,P 190BCR-ABL proteins can improve CutTent diagnostic 
tecilltiques used for diagnosing Ph cill'Omosome positive ALL. By using a similar 
strategy as was used in chapter 6, we demonstrate that these monoclonal antibodies, 
which are tenlled ER-FPI, specifically detect an ela2 fusion-epitope at both the peptide 
as well as at the protein level. To investigate whether the ela2 fusion-point of 
ela,PI90BCR-ABL proteins is antigenically exposed in intact, albeit fixed cells, we 
performed immunostaining experiments with ER-FPl antibodies on COS cells 
transfected with cDNA either encoding ela,PI90BCR-ABL, b,a,P210BcR-ABL or bJa, 
P2IOBCR-ABL proteins. Since ER-FPl antibodies specifically detect ela2 BCR-ABL 
transfected COS cells, and not b2a2 or b3a2 BCR-ABL transfected COS cells we 
conclude that the fusion-point epitope of ela,PI90BCR-ABL proteins remains intact despite 
cell fixation. However, analogous to ER-G04 antibodies, ER-FPI antibodies are also 
not capable to specifically distinguish leukentic tumor cells from normal, healthy cells, 
at the microscopic level. 
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In chapter 8 we question whether altel11ative immunological techniques can improve 
current diagnostic techniques that are used to specifically detect particular tumor types. 
We describe the development of a new, simple and rapid technique: the 'BCR-ABL 
dipstick' assay. The principle behind the BCR-ABL dipstick assay is based on the 
successive detection of two distinct antigenic sites on the BCR-ABL proteins by the 
combined specificity of two different antibodies. The combination of different anti-
bodies in this assay allows the exclusive detection of IUlIlor-specific BCR-ABL pro-
teins within 24 hours. Moreover, by choosing the proper combination of antibodies, 
tlus assay discrinunates between e,a2BCR-ABL proteins and b2a2P210BcR.ABL or 
b,a2P21OBcR.ABL proteins. The poor prognosis of Ph chromosome positive leukenuas, 
especially Ph positive ALL, could improve by an early adjustment of cUI1'ently used 
induction therapies. Yet, early therapy adjustment requires both a specific as well as a 
quick diagnosis, both of wluch could be provided by the BCR-ABL dipstick assay. 
References: 
1. Sachs L. The control of hematopoie''iis and leukemia: from basic biology to the clinic. Proc. Natl. 
Acad. Sci. USA t996; 93: 4742-4749 
2. Rowan RM. The blood and the bone marrow. In: Anderson JR (cds). Muir's textbook of patho-Iogy-
12th ed. Edward Arnold Ltd: London, 1985, 13.1-t3.38 
3. Goasguen JE, Bennett JM, Henderson ES. Biologic diagnosis of leukemias. In: Henderson ES, 
Lister TA, Greaves MF (eds). Leukemia-6th ed. \VB Saunders Comp: Philadelphia, 1996, 8-33 
4. Botti AC, Verma RS. The molecular biology of acute lymphoblastic leukemia. Anticancer Res 1990; 
10: 519-526 
5. Rozman C, Montserrat E Chronic lymphocytic leukemia. New EnglJ Med 1995; 333: 1052-1057. 
6. van der Plas D. Cytogenetic and molecular analysis of chronic and acute leukemia. Thesis 1991. 
Erasmus University Rotterdam. Rotterdam 
7. Barnett Ml, Eaves CJ. Chronic myeloid leukemia. In: Henderson ES, Lister TA, Greaves MF (eds). 
Leukemia-6th ed. WB Saunders Comp: Philadelphia, 1996,535-553 
8. Bennett 1M, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals 
for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. 
Br J Haematoll976; 33: 451-458 
9. Bennett 1M, Catovsl...}' D, Daniel M-T, Flandrin G, Galton DAG, Granick HR, Sultan C. The French-
American-British (FAB) co-operative group. The morphologic classification of acute lymphocytic 
leukaemia: concordance among observers and clinical correlations. Br 1 Haematol1981; 47: 553-
561 
10. Bennett 1M, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposal 
for the recognition of minimally differentiated acute myeloid leukemia (AML-MO). Br 1 Haematol 
1991; 78: 325-329 
11. Catovsky D, Matutes E, Buccheri V, Shetty V, Hanslip 1, Yoshida N, Morilla R. A classification of 
acute leukaemia for the 1990s. Ann Hemato11991; 62: 16-21 
12. Bennett 1M, Catovsky D, Daniel M-T, Flandrin G, Galton DA, Gralnick HR, Sultan C. TIle French-
American-British (FAB) co-operative group. Proposals for the c1assitication of chronic (mature) B 
and T lymphoid leukaemias. J Clin Pathol 1989; 42: 567-584 
13. Keating MI. Chronic lymphocytic leukemia. In: Henderson ES, ListerTA, Greaves MF (eds). Leuke-
mia-6th ed. WB Saunders Comp: Philadelphia, 1996,554-586 
44 Chapter 3 
14. Nowell pc, Hungclford DA. A minute chromosome in human chronic granulocytic leukemia. Sci-
ence 1960; 132: 1497 
15. Rowley 10. A new consistent chromosomal abnonnality in chronic myelogenous leukaemia identi-
fied by Quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293 
16. Hagemeijer A, Grosveld G. Molecularcytogcnctics ofleukcmia. In: Henderson ES, ListerTA, Greaves 
MF (cds). Lenkemia-6th ed. WB Saunders Camp: Philadelphia, 1996, 131-144 
17. Drexler HG, MacLeod RAP, Borkhardt A, Janssen JWG. Recurrent chromosomal translocatiolls 
and fusion genes in leukemia-lymphoma cell lines. Leukemia 1995; 9: 480-500 
18. Pui C-H, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in 
childhood acute lymphoblastic leukemia. Blood 1990; 76: 1449-1463 
19. Beishuizen A. Immunogenetic studies in childhood acute lymphoblastic leukemia: analysis at diag-
nosis and relapse. 111esis 1994. Erasmus University Rotterdam. Rotterdam 
20. Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, Belml F, Link M, Steuber P, Ragab A, 
Hirt A, Brock B, Land V. Pullen 1. Philadelphia cluomosome positive childhood acute lymphoblas-
tic leukemia: clinical and cytogenetic characteristics and treatment outcome. A pediatric oncology 
group study. Blood 1990; 76: 489-494 
21. Pui C-H, Ribeiro RC, Campana D, Raimondi SC, Hancock:ML, Sandlund JT, Rivera GK, Evans 
WE, Crist WM, Krance R. Prognostic factors in the acute and myeloid leukemias of infants, Leuke-
mia 1996; 10: 952-956 
22. Romana SP, Poirel H, Lecoinat M, Flexor MA, Mauchauffe M, Jonveaux P, Macintyre EA, Berger 
R, Bernard OA. High frequency of t(l 2;21) in childhood B-lineage acute lymphoblastic leukemia. 
Blood 1995: 4263-4269 
23. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. 
Blood 1995; 85: 1151-1168 
24. Adriaansen HJ. Heterogeneity in acute myeloid leukemia: basic and diagnostic studies. Thesis 1992. 
Erasmus University Rotterdam. Rotterdam 
25. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodologic ad-
vances and clinical significance. Blood 1995; 85: 1416-1434 
26. Bas JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689 
27. Rotter V, Prokocimer M. p53 and human malignancies. Adv Cancer Res 1991; 57: 257-272 
28. Hay H. The generation of diversity. In: Roitt I, Brostoff J, Male D (eds). Immunology-2nd ed. 
Gower Medical Publishing: London, 1989,6.1-6.12 
29. van Dongen JJM, Breit TM, Adriaansen HJ, Beishuizen A, Hooijkaas H. Detection of minimal 
residual in acule leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 
1992; 6: 47-59 
30. van Dongen JJM, Adriaansen HJ. Inullunobiology of leukemia. In: Henderson ES, Lister TA, Greaves 
MF (cds). Leukemia-6th ed. WB Saunders Camp: Philadelphia, 1996, 83-130 
31. Aplan PD, Lombardi DP, Kirsch JR. Stmctural characterization of SIL, a gene frequently dismpted 
in T-cell acute lymphoblastic leukemia Mol Cell Bioi 1991; 11: 5462-5469 
32. Breit TM. Mol EJ, \Volvers-Tettero LM, Ludwig \V-D, van \Vering ER, van Dongen JJM. Site-
specific deletions involving the tal-l and sil genes are restricted to cells of Ihe T-cell receptor ab 
lineage: T-cell receptor d gene deletion mechanism aftects multiple genes. J Exp Med 1993; 177: 
965-977 
33. Breit TM. Gene realTangements in human T-cells. Thesis 1994. Erasmus University Rotterdam. 
Rotterdam 
34. Korsmeijer S1. Chromosomal translocations in lymphoid malignancies reveal novel proto~oncogenes. 
Annu Rev hnmulloI1992; 10: 785-807 
Cancer: olle disease ? 45 
35. Green AR. Transcription factors, translocations and haematologicai malignancies. Blood Rev 1992; 
6: 118-124 
36. Cleary:rvn.,. Transcription factors ill human leukemias. Cancer Surv 1992; 15: 89~ 104 
37. Look AT. Oncogenic role of 'master' transcription factors in human leukemias and sarcomas: a 
deveiopmentalmodel. Adv Cancer Res 1995; 67: 25-57 
38. GoffSP, Gilboa E, Witte ON, Baltimore D. Structure of the Abelson murine leukemia vin1sgenome 
and the homologous cellular gene: studies with cloned viral DNA. Cell 1980; 22: 777-785 
39. Abelson HT, Rabstein LS. Lymphosarcoma: vims-induced thymic-independent disease in mice. 
Cancer Res 1970; 30: 2213-2222 
40. de Klein A, Geurts van Kessel A, Grosveld G, Bartram CR, Hagemeijer A, BootsmaJR, SpUIT NK, 
Heisterkamp N, Groffen J, Stephenson JR. A cellular oncogene (e-abl) is translocated to the Phila-
delphia chromosome in chronic myelocytic leukemia. Nature 1982; 300: 765-767 
41. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G. Locali-
zation of thee-abl oncogene adjacent to a translocation break point in chronic myelocytic leukemia. 
Nature 1983; 306: 239-242 
42. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia 
chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 
36: 93-99 
43. Heisterkamp N, Stam K, Groffen 1, de Klein A, Grosveld O. Structural organization of the bcr gene 
and its role in the Ph translocation. Nature 1985; 315: 758-761 
44. de Klein A, van Agthoven T, Groffel1 C, Heisterkamp N, Groffen J, Grosveld G. Molecular analysis 
of both translocation products of a Philadelphia-positive CML patient. Nucleic Acids Res 1986; 14: 
7071-7081 
45. Harihan IK, J.M. A. eDNA sequence for human bel', the gene that translocates to the abl oncogene 
in chronic myeloid leukemia. EMBO J 1987; 6: 115-119 
46. Selleri L, Nami F, Colo A, Zucchini P, Venturelli D, Donelli A, Torelli U, Torelli G. Philadelphia-
positive chronic myeloid leukemia with a chromosome 22 breakpoint outside the breakpoint cluster 
region. Blood 1987; 70: 1659-1664 
47. Selleri L, von Lindem M, Hermans A, Meijer D, Torelli G, Grosveld O. Chronic myeloid leukemia 
may be associated with several ber-abl transcripts including the acute lymphoid leukemia-type 7kb 
trallsctipt. Blood 1990; 75: 1146-1153 
48. van der Plas DC, Soekannan D, van Gent AM, Grosveld G, Hagemeijer A. Bcr-abl mRNA lacking 
abl exon a2 detected by polymerase chain reaction in a chronic myelogenous leukemia patient. 
Leukemia 1991; 5: 457-461 
49. Hennans A, Heisterkamp N, von Lindern M, van Baal S, Meijer D, van der Plas D, Wiedemann LM, 
Groffell J, Bootsma D, Grosveld G. Unique fusion of bel' and c-abl in Philadelphia chromosome 
positive acute lymphoblastic leukemia. Cell 1987; 51: 33-40 
50. Maurer J, Janssen UVG, Thiel E, van Denderell 1, Ludwig \V, Aydemir U, Heinze B, Fonatsch B, 
Harbott J, Reiter A, Riehm H, Hoelzer D, Bartram CR. Detection of chimeric ber-abl genes in acute 
lymphoblastic leukemia by the polymerase chain reaction. Lancet 1991; 337: 1055-1058 
51. Kurzrock R, Gutterman lU, Talpaz M. The molecular genetics of Philadelphia chromosome-posi-
tive leukemias. N Engl J Med 1988; 319: 990-998 
52. Berger R, Chen Sl, Chen Z. Philadelphia positive acute leukemia. Cytogenetic and molecular as-
pects. Cancer Genet Cytogenet 1990; 44: 143-152 
53. Melo JV. The molecular biology of chronic myeloid leukemia Leukemia 1996; 10: 751-756 
54. Ben-Neriah Y, Bernards A, Paskind M, Daley GQ, Baltimore D. Altemative 5' exons inc-abl mRNA. 
Cell 1986; 44: 577-586 
46 Chapter 3 
55. Walker Le, Ganesan TS, Dhut S, Gibbons B, Lister AT, Rothbard J, Young BD. Novel chimaeric 
protein expressed in Philadelphia positive acute lymphoblastic leukaemia. Nature 1987; 329: 851-
853 
56. Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow L, Crist W, Rovera G, 
Smith S, Witte ON. Expression of a distinctiveBCR-ABLoncogene in Ph-positive acute lymphocytic 
leukemia (ALL). Science 1988; 239: 775-777 
57. Chan Le, Karhi KK, Rayter SI, Heistcrkamp N, Eridani S, Powles R, Lawler SD, Groffen J, Foulkes 
10, Greaves MF, Wiedemann LM. A novel abi protein expressed in Philadelphia chromosome posi-
tive-acute lymphoblastic leukaemia. Nature 1987; 325: 635-637 
58. Shtivelman E, Lifshitz B, Gale RP, Roe EA, Canaani E. Altemative splicing ofRNAs transctibed 
from the human abi gene and from the ber-abl fusion gene. Cell 1986; 47: 277-284 
59. McWhirter JR, Wang JYl Activation of tyrosine kinase and microfilament-binding functions of c-
abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Bioi 1991; II: 1553-1565 
60. Konopka JB, \Vatanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia 
cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035-1042 
61. Pendergast Ai"!, Quilliam LA, Ctipe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, 
Schlessinger J, Gishizh..,), ML. BCR-ABL-induced oncogenesis is mediated by direct interaction 
with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175-185 
62. Sawyers CL.l1le ber-abl gene in chronic myclogenous leukaemia. Cancer Surv 1992; 15: 37-51. 
63. Puil R, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PO, Arlinghaus R, Pawson T. Bcr-abl 
oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13: 764-773 
64. Gaga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Altemative signals to RAS for hematopoietic 
transformation by the BCR-ABL oncogene. Cell 1995; 82: 981-988 
65. Rabbitts TH. Translocations, lllastcr genes, and differences between the otigins of acute and chronic 
leukemias. Cell 1991; 67: 641-644 
66. Voncken nv. Mouse models in leukemia. Thesis 1995. \Vageningen Agricultural University. 
\Vageningen 
67. \Velch PJ, \Vang JY. A C-temllnal protein-binding domain in the retinoblastoma protein regulates 
nuclear c-Abl tyrosine kinase in the cell cycle. Cell 1993; 75: 779-790 
68. \Velch PJ, \Vang JY. Abrogation of Retinoblastoma protein function by c-Abl through tyrosine ki-
nase-dependent and -independent mechanisms. Mol Cell BioI 1995; 15: 5542-5555 
69. Elefanty AG, Hruihan IK, Cory S. Ber-abl, the hallmark of chronic leukemia in man, induces mul-
tiple hematopoietic neoplasms in mice. EMBO J 1990; 9: 1069-1078 
70. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the 
P21 (jxrhbl gcne of the Philadelphia chromosome. Science 1990; 247: 824-830 
71. Kelliher MA, Knott A, McLaughlin J, Witte ON, Rosenberg N. Differences in oncogenic potency 
but not target cell specificity distinguish the two forms of the BCRlABL oncogene. Mol Cell BioI 
1991; 11: 4710-4716 
72. Gishizky ML, Johnson-WhiteJ, Witte ON. Efficient transplantation ofBCRlABL-induced chronic 
myelogenous leukemia like syndrome in mice. Proc Natl Acad Sci USA 1993; 90: 3755-3779 
73. Hariharan IK, Harris A\V, Crawford M, Abud H, \\'ebb E, Cory S, Adams JM. Abcr-v-abl oncogene 
induces lymphomas in transgenic mice. Mol Cell BioI 1989; 9: 2798-2805 
74. Heisterkamp N, Jenstcr G, Ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in 
bCllabl transgenic mice. Nature 1990; 344: 251-253 
75. Voncken JW, Kam1inen V, Pattengale PK, Genneraad WTV, Groffen 10, Heisterkamp N. BCRlABL 
P210 and P190 calise distinct leukemia in transgenic mice. Blood 1995; 86: 4603-4611 
Cancer: one disease ? 47 
76. Amoldus EPJ, Wiegant J, Noordenncer lA, Wessels JW, Beverstock GC, Grosveld GC, van der 
Ploeg M, Raap AK. Detection of the Philadelphia chromosome in interphase nuclei. Cyogenet Cell 
Genet 1990; 54: 108-111 
77. Tkachuk D, 'VestbrookC, AndreefM, Donlon T, Cleary M, Suryanarayan K, Homge M, Redner A, 
Gray J, Pinkel D. Detection ofber-abl fusion in chronic myelogenous leukemia by in situ hybridiza-
tion. Science 1990; 250: 559-562 
78. Hagemeijer A, Buijs A, Smit E, Janssen B, Creemers OJ, van der Plas D, Grosveld G. Translocation 
of BCR to chromosome 9: a new cytogenetic Valiant detected by FISH in two Ph-negative, BCR-
positive patients with chronic myeloid leukemia. Genes Chromosomes Cancer 1993; 8: 237-245 
79. Deveraj PE, Foroni L, Kitra-Roussos V, Secker-WalkerLM, Detection of BCR-ABL and E2A-PBXl 
fusion genes by RT-PCR in acute lymhoblastic leukemias with failed or nonnal cytogenetics. Br J 
Haematol1995; 89: 349-355 
80. Schlieben S, Borkhardt A, Reinish I, Ritterbach J, Janssen JWG, Ratei R, Schrappe M, Repp R, 
ZitlIDletID,lIln M, Kabisch H, Janka-Schaub G, Bm1ram CR, Ludwig 'V-D, Riehm H, Lampet1 F, 
Harbott J. Incidence and clinical outcome of children with BCRlABL-positive acute lymphoblastic 
leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the Gennan pediatric 
multicenter therapy trials ALL-BFM-90 and CoALL-05-92 Leukemia 1996; 10: 957-963 
81, Ephrussi A, Church GM, Tonegawa S, Gilbet1 ,v. B-lineage specific interactions of an immunoglobulin 
enhancer with cellular factors in vivo, Science 1985; 227: 134-140 
82. Kadesch T. Helix-loop-helix proteins in the regulation ofimlllunogiobulin gene trallscription. hUlllunol 
Today 1992; 13: 31-36 
83. Murre C, McCaw PS, Baltimore D, A new DNA binding and dimelization motif in immunoglobulin 
enhancer binding, daughterless, MyoD, and fIIyc proteins. Cell 1989; 56: 777-783. 
84. Henthorn P, KiIedjian M, Kadesch T. 1\vo distinct transcription factors that bind the immunoglobu-
lin enhancer ~lE5/KE2 motif. Science 1990; 247: 467-470 
85. Mellentin JD, MUlTe CM, Donlon TA, McCaw PS, Smith SD, Carroll Al, McDonald ME, Balti-
more D, Clemy ML. The gene for enhancer binding proteins El21E47 lies at the t(l; 19) breakpoint 
in acute leukemias. Science 1989; 246: 379-382 
86. Mellentin JD, Nourse J, Hunger SP, Smith SD, Cleary 1\1L. Molecular analysis of the t(1 ;19) break-
point cluster region in pre-B-cell ALL. Genes Chromosom Cancer 1990; 2: 239-247 
87. Nourse J, Mellentin JD, Galili N, Wilkinson J, Stanbridge E, Smith SD, Cle3.1Y 1\1L. Chromosomal 
translocation t(I;19) results in synthesis of a homeobox fusion mRNA that codes for a potential 
chimeric transcription factor. Cell 1990; 60: 535-545 
88. Kamps MP, Mume CM, SUIl X-H, Baltimore D, A new homeobox contributes the DNA binding 
domain of the t(l;19) translocation protein in pre-B ALL. Cell 1990; 60: 547-555 
89. Hunger SP. Galili N, CatToil AJ, Crist WM, Link M, Cleary ML. The t(l; 19)(q23;p 13) results in 
consistent fusion of E2A and PBXl coding sequences in acute lymphoblastic leukemias. Blood 
1991; 77: 687-693 
90, Izraeli S, Kovar H, Gadner H, Lion T, Unexpected heterogeneity in E2NPBX I fusion messenger 
RNA detected by the polymerasechaill reaction in pediatric patients with acute lymphoblastic leuke-
mitt Blood 1992; 80: 1413-1417 
91. Privitera E, Luciano A, Ronchetti D, Arico M, Santostasi T, Basso G, Biondi A. Molecular variants 
of the t(1;19) chromosomal translocation in pediatric acute lymphoblastic leukemia (ALL), Leuke-
mia 1994; 8: 554-559 
92, Kamps MP, Look AT, Baltimore D, The human t(1;19) translocation in pre-B ALL produces lllul-
tiple nuclear E2A-PBXI fusion proteins with differing transforming potentials, Genes Dey 1991; 
5: 358-368 
48 Chapter 3 
93. Murre C, McCaw PS, Vaessill H, Caudy M, Jan LY. Cabrera CV, Buskin IN, Hauschka SD, Lassar 
AB, 'Veintraub H, BaltimoreD. Interactions between heterologous helix-loop-helix proteins gener-
ate complexes that bind specifically to a common DNA sequence. Cell 1989; 58: 537-544 
94. Quang MW, Massari ME, Z\vart R, Murre C. A new transcriptional-activation lllotifrestricted to a 
class of Helix-Loop-Helix proteins is functionally conserved in both yeast and mammalian cells. 
Mol Cell Bioi 1993; 13: 792-800 
95. Lassar AB, Davis RL, Wright WE, Kadesch T, Murre C, Vorollova A, Baltimore D. Functional 
activity of myogenic HLH proteins requires helem-oligomerization with E121E47 proteins in vivo. 
Cell 1991; 66: 305-315 
96. Mtme C, Voronova A, Baltimore D. 8- cell- and myocyte-specific E2-box-binding factors contain 
EI2/E47-like subunits. Mol Cell Bioi 1991; II: II56-II60 
97. Schlissel M, Voronova A, Baltimore D. Helix-loop-helix transcription factor E47 activates genn-
line immunoglobulin heavy-chain gene transcription and rearrangement in a pre-T-celiline. Gene...;; 
Dev. 1991; 5: 1367-1376 
98. Baill G, Robanus-MaandagECR, IzonDJ, Amsen D, KruisbeekAM, \Veintraub BC, Krop I, Schlissel 
MS, Feeney AJ, van Roon M, van der Valk M, te Riele HPJ, Berns A, Murre C. E2A proteins are 
required for proper B cell development and initiation of immunoglobulin gene rearrangements. 
Cell 1994; 79: 885-892 
99. Aronheim A, Ohlsson H, Park C\V, Edlund T, \Valker MD. Distribution and characterization of 
helix-loop-helix enhancer-binding proteins from pancreatic B cells and lymphocytes. Nuc1eicAcids 
Res 1991; 19: 3893-3899 
100. van Dijk MA, Voorhoeve M, Murre C. Pbxl is converted into a transcriptional activator upon 
acquiring the N-tenninal region of E2A in pre-B-cell acute lymphoblastoid leukemia. Proc Natl 
Acad Sci USA 1993; 90: 6061-6065 
lOt. Lu Q, \Vright DD, Kamps MP. Fusion with E2A COllvel1s the Pbxl homeodomain protein into a 
constitutive transcriptional activator in human leukemias carrying the t( I; 19) translocation. Mol 
Cell Bioi 1994; 14: 3938-3948 
102. LeBIUIl DP, Cleary ML. Fusion with E2A alters the transctiptional properties of the homeodomain 
protein PBXI in t(l;19) leukemias. Oncogene 1994; 9: 1641-1647 
lO3. Monica K, LeBnm DP, Dedera DA, Brown R, Cleary ML. Transformation properties of the E2a-
Pbx 1 chimeric oncoprotein: fusion with E2a is essential, but the Pbxl homeodomain is dispensa-
ble. Mol Cell Bioi 1994; 14: 8304-8314 
104. Lu Q, Knoepfler PS, Scheele J, Wright DO, Kamps MP. Both Pbx I and E2A-Pbx I bind the DNA 
motif ATCAATCAA cooperatively with the products of multiple murine Hox genes, some of which 
are themselves oncogenes. Mol Cell BioI 1995; 15: 3786-3795 
105. Kamps !vIP, "'tight DD, Lu Q. DNA-binding by oncoprotein E2A-Pbxl is important for blocking 
differentiation but dispensable for tibroblast transformation. Oncogene 1996; 12: 19-30 
106. Pevemli FA, Ramqwist T, Saffrich R, Pepperkok R, Barone MV, Philipson L. Regulation of G 1 
progression by E2A and Id helix-loop-helix proteins. EMBO J 1994; 13: 4291-4301 
107. Kamps !vIP, Baltimore D. E2A-Pbxl, the t(1;19) translocation protein of human pre-B-cell acute 
lymphocytic leukemia, causes acute myeloid leukemia in mice. Mol Cell BioI 1993; 13: 351-357 
108. Dedera DA, Waller EK, LeBnm DP, Sen-Majumdar A, Stevens ME, Barsh OS, Cleary ML. Chi-
meric homeohox gene E2A-PBXl induces proliferation, apoptosis, and malignant lymphomas in 
transgenic mice. Ce111993; 74: 833-843 
lO9. Borowitz MJ, Hunger SP, Carroll AJ, Shuster 11, Pullen DJ, Steuber CP, Clem)' ML. Predictability 
of the t(l ;19)(q23;p13) from surface antigen phenotype: implications for screening cases of child-
Cancer: olle disease? 49 
hood acute lymphobla')tic leukemia for molecular analysis: a pediatric oncology group study. Blood 
1993; 82: 1086-1091 
110. Izraeli S, Janssen J\VG, Haas OA, Harbott J, Brok~Simoni F, \Valtller JV, Kovar H, Henn T, Ludwig 
\yD, Reiter A, Rechavi G, Bartram CR, Gadner H, Lion T. Detection and clinical relevance of 
cytogenetic abnormalities in pediatric acute lymphoblastic leukemia: a comparison between cy-
togenetic and polymerase chain reaction. Leukemia 1993; 5: 671-678 
Ill. Rieder H, Kolbus U, Koop U, Ludwig WD, Stollmallll-Gibbeis B, Fonatsch C. Translocation t(l ;22) 
mimicking t(1; 19) in a child with acute lymphoblastic leukemia as revealed by chromosome paint-
iug. Leukemia 1993; 7: 1663-1666 
112. Privetera E, Kamps MP, Hayashi Y, Inaba T, Shapiro TI, Raimondi SC, Belml F, Henderschot L, 
Carroll AJ, Baltimore D, Look AT. Different molecular consequences of the t( 1; 19) chromosomal 
translocation in childhood B-cell precursor acute lymphoblastic leukemia Blood 1992; 79: 1781-1788 
113. Pui C-H, Behm FG, Crist \VM. Clinical and biologic relevance of immunologic marker studies in 
childhood acute lymphoblastic leukemia. Blood 1993; 82: 343-362 
114. Pui C-H, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH, Sandlund JT, Crist 
WM, Bellin FG. IImmmologic, cytogenetic, and clinical characterization of childhood acute lym-
phoblastic leukemia with the t(I;19)(q23;pI3) or its derivative. J Clin Onco11994; 12: 2601-2606 
115. Troussard X, Valensi F, Salomon-Nguyen F, Debert C, Flandrin G, MacIntyre E. Correlation of 
cytoplasmic Igll (Cnm) and E2A-PBXl fusion transcripts in t(l ;19) B lineage ALL: discrepancy in 
Cnm detection by slide immunofluorescence and flow cytometry. Leukemia 1994; 9: 518~519 
116. Williams DL, Look AT, Melvin SL, Roberson PK, Dahl G, Flake T, Stass S. New chromosomal 
translocations correlate with specific immunophenotypes of childhood acute lymphoblastic leuke-
mia. Cell 1984; 36: 101-109 
117. Carroll AJ, Crist \VM, Pannley RT, Roper M, Cooper MD, Finley WHo Pre-B cell leukemia asso-
ciated with chromosome translocation 1;19. Blood 1984; 63: 721-724 
118. Crist WM, Carroll AJ, Shuster JJ, Belun FG, Whitehead M, Vietti TJ, Look AJ, Mahoney D, Ragab 
A, Pullen DJ, Land VJ. Poor prognosis of children with pre-B acute lymphoblastic leukemia is 
associated with the t(l;19)(q23;pI3). Blood 1990; 76: 117-122 
119. Raimondi SC, Bchm FG, Roberson PK, \Villiams DL, Pui C-H, Crist \VM", Look AT, Rivera GK. 
Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications 
of the t(I;19). J Clin Onc 1990; 8: 1380-1388 
120. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui C-H, Abromowitch M, Mirro J, Ochs JS, 
Look AT, Williams DL, Murphy SB, Dahl GV, KalwinsI..l' DK, Evans \VE, Kun LE, Simone JV, 
Crist WM. IIllproved outcome in childhood acute lymphoblastic leukemia with reinforced early 
treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66 
121. van der Plas DC, Hermans ABC, Soekannan D, Smit EME, de Klein A, Smadja N, Alimena G, 
Goudsmit R, Grosveld G, Hagemeijer A. Cytogenetic and molecular analysis in Philadelphia nega-
tive CML. Blood 1989; 73: 1038-1044 
122. KohlerG, Milstein C. Continuous cultures of fused cells secreting antibody of predefined speciticity. 
Nature 1975; 256: 495-497 
123. van Denderen J, Hemtans A, Meeuwsen T, Troelstra C, Zegers N, Boersma \V, Grosveld G, van 
Ewijk W. Antibody recognition of the tumor-specifc hcr-ab! joining region in chronic myeloid 
leukemia. JExp Med 1989; 169: 87-98 
124. van Denderen J, van der Plas D, Meeuwsen T, Zegers N, Boersma \V, Grosveld G, van Ewijk \V. 
Iuulluno!ogic characterization of the tumor-specific bcr+abl jUllction ill Philadelphia chromosome-
positive acute lymphoblastic leukemia. Blood 1990; 76: 136-141 
50 Chapter 3 
125. van Denderen J, ten Hacken P, Berendes P, Zegers N, Boersma \V, Grosveld G, van Ewijk \v. 
Antibody recognition of the tumor-specific b3-a2jullction of ber-abl chimeric proteins in Philadel-
phia-chromosome-positive-Ieukemias. Leukemia 1992; 6: 1107-1112 
Chapter 4 
Specific immunologic recognition of the tumor-specific 
E2A-PBXl fusion-point antigen in t(1;19)-positive pre-B-cells 
P. Berendes1, A. Hoogeveen2, M.A. van Dijk3, J. van Denderen1,4 and W. van Ewijkl 
IDepartmellf of Immunology; and 2MGC Departmellf of Clinical Genetics, 
Erasmus University Rotterdam, Rotterdam; 3Departmenf of Immunology. Academic 
Hospital Utrecht, Utrecht; alld 4Departmellt of Pat!lOlog)\ Academic Hospital Vrije 
Ulliversiteit, Amsterdam, The Netherlands 

53 
Specific immunologic recognition of the tumor-specific 
E2A-PBXl fusion-point antigen in t(1;19)-positive pre-B-cells 
The t( 1; 19) trallslocatioll is aile of the II/Ost commollly observed chromosomal 
trallslocatiolls ill childhood acute lymp//Oblastic leukemia (ALL). Its presellce amollg 
pre-B-ALL cases, has beell associated with a poor progllosis. 711'0 gelles, E2A alld 
PBX1, are ill valved ill this t(1;19) trallslocatioll. As a cOllsequellce, parts of the E2A 
alld PBX1 gelles are fused, resultillg ill a chimeric E2A-PBX1 gelle, encodillg chi-
meric E2A-PBX1 proteillS. As such, the am ilia acids sequellce at the fusion site repre-
sellts a ullique tumor-specific determillalll. We report all the gelleratioll ofa polyc/ollal 
alltiserum, fe/7Iled BP 1/19, raised agaillst the tumor-specific E2A-PBX1 jUllctioll of 
E2A-PBX1proteills. The specificity of alltiserum BP 1119 for the E2A-PBX1 fusioll-
poillt is demollstrated at the peptide alld at the proteill lel'el. Furthermore, specific 
bindillg of alltiserum BP 1119 to t(1; 19) positive cells was showlI usillg immullojluo-
rescellce techlliques. This study shows that: (1) the tumor-specific fusion-poilll epitope 
all E2A-PBX1 proteills is presellled ill all alltigellicfashioll alld, (2) this particular 
fusioll-poillt epitope call be used ill immunological marker allalysis by usillgjluores-
cellce microscopy. 
Introduction 
The t(l;19)(q23;pI3) translocation is, with approximately 5-6% of childhood ALL 
cases, one of the most common cytogenetic abe11'ations observed in childhood ALL 
(I). This particular translocation is found in 1% of all children with an early pre-B-
ALL (cytoplasmic Ig negative) and in 25% of all children with pre-B-ALL (cytoplas-
mic Ig positive) (2). 
Two different transcription factor encoding genes are involved in tlus translocation: 
the PBX1 gene, derived from c1n'OInosome I, and the E2A gene derived from chromo-
some 19 (3, 4). As a result of the translocation, both genes are interrupted and 
translocated, resulting in a chimeric E2A-PBX1 fusion gene on chromosome 19. 
The E2A-PBXI fusion gene leads, after transcliption and translation, to different E2A-
PBX I proteins (5). Differences between those proteins probably result from alterna-
tive splicing. Since E2A-PBXI proteins are only found in t(l;19)' pre-B-ALL, 
E2A-PBXI proteins are per definition tumor-specific. 
However, chimeric E2A-PBXI proteins consist of patts of normal cellulat' proteins, 
i.e. E2A and PBXI proteins. Therefore, the actual detenninants on the chimelic E2A-
PBXI protein that at'e tndy tumor-specific, occur exclusively at the joining region 
between E2A and PBX!. Due to the translocation process, a new amino acid se-
quence is created at this joining region, not occurring in n0I111al E2A or in the normal 
PBXI proteins. 
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In the present study we investigate whether the E2A-PBXI junction is antigenically 
exposed on the chimeric protein. Olll' data show that the joining region ofE2A-PBXl 
proteins can indeed be recognized by polyclonal antibodies, both at the protein and at 
the cellular level. 
Materials and methods 
Cel/lil/es 
Sup-B27 (a generous gift fromDrS Smith, Department of Pediatric Hematology, University 
of Chicago, IL, USA) and 697 (a generous gift from Dr JJM van Dongen, Department of 
Immunology, Erasmus University, Rotterdam, the Netherlands) are cell lines (6) derived 
from patients formerly diagnosed as t( I; (9) positive pre-B-ALL. Nalm-6 and ALLIMIK are 
cell lines (7) derived from t(l;19) negative pre-B-ALL patients. Since pre-B cells do not 
express PBX 1 proteins, we used the K562 cell line as a PBX protein containing positive cell 
line (8). The K562 cell line was derived from a patient during blast crisis of CML (9). 
Cells were cultured in RPMI medium supplemented with 10% fetal calf serum. 
Peptides 
A multiple antigenic peptide (MAP) was constmcted, essentially as described by Tam (10). 
This MAP consists of a small immullogcllically inert core matrix of lysine residues with 
CJ.- and £-amino groups for anchOling eight copies of the E2A-PBXl peptide. Monomeric 
peptides cOlTesponding to parts of the amino acid sequences of the E2A , E2A-PBXI and 
PBXl proteins. were elongated during synthesis with a cysteine residue at their carboxyl 
terminal ends. These peptides were coupled to sulfosuccinimidyl-4-(N-maleimidomethyl) 
cyclohexane-l-carboxylate (Sulfo-SMCC) activated bovine senun albumiu (BSA) (Pierce, 
Rockford, IL, USA) via their cysteine residues. 
IlIllllllll iza Ii 0 II 
Mice (l2-week-old female BALB/c) were innnunized by intraperitoneal injection of 200 fll 
of an emulsion of 50 flg MAP antigen in 0.083 M sodium phosphate buffer, 0.9 M NaC!, pH 
7.2 and an equal volume of 'Oil in Water' adjuvant (Solvay-Duphar, Weesp, The Nether-
lands). Mice were given booster injections after 4,24 and 38 weeks with the same dose of 
antigen in the same type of adjuvant. Test and final bleeds were taken from the retro-orbital 
plexus, 2 weeks after each injection. 
In this paper we show the results which were obtained with se11l111 of one ofthese mice (BP 11(9). 
E1lzyme-li1lked immllllOSorba1lt assay (ELISA) 
Allfibody capture assay: Wells of polivinylchloride microtiter plates (Falcon 3911; Becton 
Dickinson, Oxnard, CA, USA) were coated with 150 III of BSA-peptide conjugate 
(I Ili/ml) in phosphate buffered saline (PBS), ovel1light at 4 "C (the composition of PBS in 
this and in further experiments is: 9.38mM Na,HPO" 0.88 mM KH,P04, 2.68mM KCI, 137 
mM NaCL, pH 7.8). Free sites were blocked with 0.2% gelatine and 0.05% Tween-20 in 
PBS (30 min 37 "C). Dilutions of either pre-immune senun or BP 1/19 in PBS supplemented 
with 0.05% 1\veen-20 were incubated for Ih at 37"C. Bound antibodies were detected with 
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goat anti-mouse Ig conjugated to horseradish peroxidase (Central Laboratory of the Blood 
Transfusion Service, Amsterdam, The Netherlands) and 3,5,3,5'-tetramethyl-benzidine GR 
(l\1erck, Darmstadt, Germany) as substrate. After 15 min at room temperature, the reaction 
was stopped by the addition of 2M Hel and absorbance was measured at 450 urn, 
Antigen competition assay: Due to the hydrophobic nature of the peptides (especially E2A-
PBXI), the peptides were dissolved in 6 M guanidine-HCI, 0.0 I M phosphate buffer, pH 7.0. 
Peptides concentrations were determined, using EHman's reagent (Pierce), by comparing the 
peptide solutions against a standard curve prepared from cysteine. 
Peptides were diluted in the 6 M guanidine-HCI, 0.01 M phosphate buffer, pH 7.0. BP 1/19 
in a 10.5 dilution was added to different peptide concentrations and allowed to react for 1 h at 
room temperanll·e. These mixnlres were tested on E2A-PBX 1-BSA conjugate (I ;tglm!) coated 
plates. After 1 h incubation at 37°C, bound antibodies were detected as described above. 
bll11ll1ll0blot analysis 
Cells were harvested and washed with PBS. Next, the cells were solubilized (2 x 10' 
cells/ml) in sodium dodecyl sulfate (SDS) sample buffer (60 mM Tris-HCI, pH 6.8, 10% 
glycerol, 10 mM EDTA, 2% SDS, 2% p-mercaptoethanol, and 0.03% bromophenol blue) 
and boiled for 10 min. These samples (10 flVwell) were subjected to 10% SDS-PAGE and 
transferred to nitrocellulose (Mini Protean; Bio Rad, Richmond, CA, USA) in 25 mM Tris, 
190 mM glycine and 20% methanol. Nitrocellulose sheets were blocked in low-fat milk for 
60 min and subsequently washed tlu'ee times with 0.5% Tween-20 in PBS. All further washes 
were performed in this particular buffer. 
Sheets were then incubated for 2h at room temperature in the presence of a 10-3 dilution of 
BP 1119 in 0.5% Tween-20 in PBS. Following three washes, goat anti-mouse Ig conjugated 
to alkaline phosphatase (Tago, Burlingame, CA, USA) was added to a 10.3 dilution and incu-
bation was allowed to proceed for Ih. The blot was washed twice with PBS-1\veen and 
fInally with 0.15 M veronal-acetate, pH 9.6. For visualization of antibody-antigen complexes, 
we used the alkaline phosphatase substrate nitro blue tetrazolium/5-bromo-4-chloroindoxyl 
phosphate (NBTIBCIP) as described by Blake et al. (II). 
Specificity comrals: Anti-E2A moAb (G98-27 1. 1.3, a generous gift from Drs G Bain and C 
Murre, Dep31tment of Biology, University of California, San Diego, CA, USA), 0.2 ;tglml in 
0.5% Tween-20 in PBS was added with or without 10.3 diluted BP 1/19 to blots containing 
proteins from cell Iysates of 697 and Nalm-6. After 2h incubation the blots were further 
treated as described above. 
Bacterially expressed PBXla was biotinylated using N-hydroxy-succinimido-biotin (NHS-
biotin; Sigma) to determine its respective molecular weight through electrophoresis and blot-
ting. Biotinylated PBXla proteins were visualized using alkaline phosphatase labeled 
streptavidin (South. Biotechn. Ass., Birmingam, AL, USA) and NBTIBCIP as substrate. 
In vitro translated E2A-PBXla, E2A-PBXlb and PBXla proteins were used, together with 
bacterially expressed PBXla proteins to determine the specifIcity of BP 1/19. The protein 
samples were boiled in the sample buffer mentioned above, eiectrophoretically separated, 
and blotted. After blocking, the blot was incubated with 10-3 diluted BP 1119 in 0.5% Tween-
20 in PBS for 2 h at room temperature. Visualization of proteins recognized by BP 1/19 was 
established by using the same protocol as described above. 
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Imlllullofluorescence 
697 and Nalm-6 cells were separately washed twice with ice-cold PBS. To discriminate these 
two cell lines from one another, membrane proteins of 697 (respectively Nalm-6 cells) were 
biotinylated with N-hydroxy-succinimido-biotin (NHS-biotin; Sigma) as previously described 
(12), distinguishing them from non-biotinylated Nalm-6 (respectively 697 cclls). Biotinylated 
cells were washed twice in ice-cold PBS and mixed at a 1: 1 ratio with non-biotinylated cells. 
Cells were attached to poly-L-Iysine (Sigma) coated slides (10 min room temperature). Next, 
the cells were fixed using 4% parafonnaldehyde (10 min room temperature) and penneabilized 
with methanol (2 min room temperature). E2A-PBXI proteins were identified by incubation 
with antisennn BP 1/19 diluted (10-3) in PBS containing 3% BSA. After 45 min incubation 
and three subsequent washes in PBS containing 0.025% 1\veen-20, incubation was proceeded 
with 10.2 diluted FITC-conjugated to goat anti-Ig antibodies (DAKO, Denmark) and 5 x lO-
s diluted streptavidin-Cy3 conjugate (Sigma) in PBS containing 2% NHS and 3% BSA. As a 
specificity control \ve used the anti-E2A moAb Yae (Santa CIUZ Biotechn.,Santa Cmz, CA, 
USA). Yae recognizes the N-proximal part of E2A proteins, and therefore also recognizes 
E2A-PBXl proteins. 1\vo micrograms ofYaelml were used on a slide containing biotinylated 
697 cel1s and non-biotinylated Nalm-6 cells. Fluorescence was analyzed using confocal 
microscopy on a Bio Rad MRC-600 confocal system. 
Results 
Peptides 
Based on the previously published nucleotide sequence (3-5), a peptide was constructed 
con'esponding to the E2A-PBXI junction in E2A-PBXI proteins. The MAP approach 
was chosen because of its ability of raising anti-peptide sera which recognize the 
protein of which the peptide forms a prui (10,13). 
The MAP system we constructed, consists of a small immunogenically ineli (10) core 
matrix of lysine residues with u- and E-amino groups capable of anchoring eight cop-
ies of the E2A-PBXl peptide (Figure I a). This macromolecule has a moleculru' weight 
of 16 kDa, which is large enough to serve as an immunogen on its own. 
As controls, we synthesized peptides corresponding to the sequences in the nonnal 
E2A and PBXl protein, which occur just around the respective fusion-point ofE2A-
PBXl (3,4,8) (Figure lb). 
Antibody binding to E2A-PBXl at the peptide level 
Antiserum BP 1I19 was raised against the E2A-PBXI MAP. This antiserum is liable 
to contain different antibodies with specificities to different epitopes expressed at the 
E2A-PBXl peptide. To elucidate these specificities, PVC plates were coated with 
maleimide-activated BSA conjugated to either E2A, E2A-PBXI or PBXI-peptides. 
BP 1I19 showed strong reactivity against E2A-BSA and E2A-PBXI-BSA conjugates 
(Figure 2a). This latter observation indicates that BP 1I19 hardly contains any anti-
bodies specific for either PBXI or BSA. Therefore, we conclude that the strong reac-
a 
b 
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Figure 1 (a) Schematic representation of the multiple antigenic peptide (MAP), consisting of 
eight fusion-point E2A-PBXl peptides connected to each other via a lysine core matrix. The molecu-
lar weight of MAP is approximately 16 kDa. (b) Schematic representation of the E2A, E2A-PBXl and 
PBX 1 synthetic peptides. The amino acid sequence of E2A-PBX1 is identical to the sequence of the 
E2A peptide up to the fusion-point, thereafter the amino acid sequence resembles PBX 1. For coupling 
to a carrier protein each peptide was elongated with a cysteine 
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Figure 2 (a) Binding characteristics in an ELISA system of graded dilutions of antiserum BP 
1119 to E2A peptides (,), E2A-PBXI peptides C ) and PBXI peptides (U. All peptides were 
conjugated to maleimide activated BSA. (b) Inhibition study of the binding of 10.5 diluted BP 1119 to 
either graded concentrations of E2A and PBXl free peptides (e) or to equimolar graded concentra-
tions of E2A-PBXl peptide (: -'). Inhibition is expressed as: [l-{(absorbtion in the presence of pep-
tide)/(absorbtion in the absence of peptide)}] x 100%. Each point represents the mean of a duplicate 
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tivity against the E2A-PBXl peptide is caused by antibodies directed against E2A 
and likely also by antibodies against the fusion-point epitope. 
To further elucidate whether antiserum BP 1119 contains antibodies specific for a 
E2A-PBXl fusion-point epitope, we pelformed inhibition experiments. Figure 2b 
shows that preincubation ofBP 1119 with the cognate E2A-PBXl peptide completely 
abrogated binding ofBP 1119 to E2A-PBXl peptides conjugated to BSA. Preincubation 
of BP 1119 with a mixture ofE2A and PBXl peptides (equimolar to the E2A-PBXl 
dilutions) did not show any inhibition at all (Figure 2b). 
These data indicate that antisenllll BP 1119 indeed contains antibodies which specifi-
cally recognize an E2A-PBXl fusion-point epitope present on the E2A-PBXl peptide. 
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Figure 3 Immunoblot analysis of antiserum DP 1119. Nalm-6, ALLIMIK, 697 and Sup-B27 are 
of human pre-B lymphoid cellular origin. Nalm-6 and ALL/MIK are t( I; 19)- cell lines, while 697 and 
Sup-B27 are t(l; 19Y cell lines. K562 is a tel; 19)" human erythroid cell line. Each lane represents 2 x 
lOs of the respective cells. Molecular weight in kDa is indicated left, E2A-PBXl proteins arc indicated 
at the right side of the lanes 
Figure 4 Immunoblot analysis of E2A cross-reactivity of antiserum BP 1/19. Blots were incu-
bated with BP 1119 (a), with a mixture ofBP 1119 and anti-E2A (moAb 098-271.1.3) antibody (b) or 
with this anti-E2A antibody alone (c), Each lane represents 2 x 1()5 oflhe respective cells. E2A-PBXI 
proteins are indicated left, E2A proteins are indicated at the right side of the lanes 
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Antibody binding to E2A-PBXl at the protein level 
Binding of antiserum BP 1119 to E2A-PBXl proteins was tested by immunoblotting 
lysates of several cell lines. For the detection of the chimeric E2A-PBXl proteins, 
lysates of t(1;19) positive pre-B cell lines, i.e. 697 and Sup-B27, were employed. 
Lysates of Nalm-6 and ALLIMIK served as t(I;19) negative pre-B cell controls. As 
the source of normal PBX proteins the K562 cell line (erythroid) was employed (8). 
Figure 3 clearly shows the detection of E2A-PBXl proteins in t(I;19) positive cell 
lines (lanes 3 and 4) but not in t(1;19) negative cell lines (lanes 1,2 and 5). 
Since E2A-PBXl proteins were recognized by BP 1119, we conclude that antiserum 
BP 1119 does contain antibodies which recognize E2A-PBXl proteins. 
To elucidate whether antiserum BP 1119 contains antibodies specifically recognizing 
aji/sion-point epitope on the E2A-PBXl proteins and not its counterparts, i.e. E2A or 
PBX 1 proteins, two control experiments were pelformed. 
First, we investigated whether E2A proteins were recognized by BP 1119. We used 
moAb 098-27l.l.3, an anti-E2A antibody recognizing the C-terminal part of E2A 
proteins as our control antibody (14). Blots were incubated with BP 1119 (Figure 4a), 
moAb 098-271.1.3 (Figure 4c) or a mixture of both (Figure 4b). The data from this 
experiment indicate that E2A proteins are not recognized by BP 1119. Only blots 
incubated with moAb 098-271.1.3 (as single incubation or in combination with BP 1119) 
show E2A proteins at approximately 75 kDa. This protein band is clearly missing in 
2 
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Figure 5 Immunoblot analysis of 
PBXl cross-reactivity of antiserum BP 
1119. Blot containing 1 III ill \'i(m trans-
lated E2A-PBXla protein (lane I). 1111 
ill vitro translated E2A-PBXlb protein 
(lane 2), 1 ~ll ill v;lro translated PBXla 
protein (lane 3), bacterially expressed 
PBXla protein: 100 ng (lane 4). 40 ng 
(lane 5). Proteins were detected through 
BP 1/19 incubation. Alkaline phos-
phatase-conjugated streptavidin was 
used to detect the biotinylated bacteri-
ally expressed PBXla protein (40 ng, 
lane 6). Molecular weight in kDa is in-
dicated left 
60 Chapter 4 
the blot incubated with BP 1/19 alone. Therefore, we conclude that antiserum BP 1119 
does not cross-react with E2A proteins. 
Since PBXl proteins are not expressed in lymphocytes (8) we had to design another 
experimental set-up to investigate ifBP 1119 would cross-react with PBXl proteins. 
Instead of using anti-PBX I antibodies as a control, we now used ill vitro translated 
PBX I proteins or bactedally expressed PBX la proteins. 111 vitro translated E2A-PBX I a 
proteins and E2A-PBXlb proteins were used as positive controls. Bacterially expressed 
PBXla proteins were biotinylated to indicate the molecular weight of recombinant 
PBXla proteins. The data from Figure 5 indicate that only ill vitro translated E2A-
PBXI proteins are recognized by BP 1/19. 111 vitro translated PBXla and bacterially 
expressed PBXla are not recognized by BP 1/19. Therefore, we conclude that BP 1/19 
does not recognize PBX I proteins. (These data are in agreement with our ELISA 
results.) 
Figure 6 Specificity analysis of the reactivity of antisentm BP 1119 on mixtures of t(l; 19)+ 697 
cells and t(l; 19)- Nulm-6 cells using double immunofluorescence. (a), (d) and (g) represent phase 
photographs of mixtures of t(1;19)+ 697 cells and t( I; 19)- Nahn-6 cells. To discriminate the two cell 
lines from each other, either 697 cells (b) and (h) Of Nalm-6 cells (e) were biotinylated prior to mixing 
both cell lines. Streptavidin Cy-3 was used to indicate the localization of the respective biotinylated 
cell line. Cellular mixtures (a) and (d) were incubated with antiserum BP 1119, followed by FlTC-
labeled goat anti-mouse immunoglobulins. A nuclear staining pattern «c) and (f») can be observed in 
either biotinylated (b) or nOll-biotinylatcd (e) t(1; 19)+ 697 cells only. Anti-E2A moAb (Yae), followcd 
by FITC-Iabeled goat anti-mouse immunoglobulins, was used on a cellular mixture (g) to demonstrate 
that biotinylated to ;19)+ 697 cells (h) show the same pattem of tluorescence as to; 19)- Nalm-6 cells 
(i) upon incubation with this non-fusion-point specific antibody 
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Altogether, BP 1119 is also at the protein level specific for E2A-PBXI proteins, as 
neither E2A nor PBXl proteins are recognized by BP 1119. 
Alltibody billdillg at the cellllla/' level 
We investigated whether BP 1/19 can be used to discriminate t(l; 19)+ cells from t(1 ;19)' 
cells, at the single cellleve!. A mixture of both cell types, i.e. t(l ;19)' 697 cells mixed 
with t(I;19)- Nahn-6 cells, was examined. However, before using tlus cell nuxture as 
a tool to validate the specificity of BP II 19, we first needed to distinguish the two cell 
populations from one another by means other than innnunostaitung with BP 1119. 
Therefore, before nuxing both cell populations, we biotinylated only one particular 
cell line. Subsequent incubation with streptaviditl Cy-3 allowed us to discriminate 
biotinylated cells frolllnon-biotinylated cells. 
Fit'st, we incubated a mixture of biotinylated t(l;19)' 697 cells and non-biotinylated 
t( I; 19)' Nalm-6 cells with BP 1/19. Subsequent incubation with a mixture of streptavidin 
Cy3 and FlTC-labeled goat anti-mouse innnunogiobulins allowed us to evaluate the 
specificity ofantisel1lmBP 1/19. Cells in Figure6c, which correspond to the biotinylated 
t( I; 19)' 697 cells in Figure 6b, show fluorescent granular nuclei with non-fluorescent 
nucleoli. In contrast, nuclei from those cells which correspond to the t(l; 19)- Na11ll-6 
cells are negative. 
Thus, these data show that antisel1lm BP 1119 is able to discrinunate t(I;19)' cells 
from t(I;19)- cells at the single ceilleve!. 
However, to exclude the possibility that the biotinylating process on itself itlfluences 
the detection of t( 1 ;19)+ cells among t( I; 19)- cells tln'ough non-specific binding of BP 
1/19 to biotin, a control experiment was performed. In this experiment we biotinylated 
t(l ;19)- Nalm-6 cells instead of t(l;19)' 697 cells (Figure 6e). Binding of BP 1/19 is 
visualized itl Figure 6f: cells with fluorescent nuclei are clearly detected among non-
fluorescent cells. As expected, the fluorescent cells itl Figure 6f correspond to the 
non-biotittylated cells in Figure 6e. Thus, this experitnent shows that the detection of 
t(l;19)+ cells among t(l;19)- cells, using BP 1119, is not affected by the biotinylation 
process and is exclusively caused by binding of BP 1/19 to t(l; 19)-positive cells. 
Finally, to show that t(l;19)-positive cells can only be specifically detected through 
recognition of the tumor-specificji,sioll-poillf of E2A-PBXI proteins, and not by de-
tecting E2A-PBXI protein expression alone, we used another anti-E2A (Yae) anti-
body (15). This antibody recognizes both E2A and E2A-PBXI proteins. Figure 6i 
clearly shows that biotinylated 697 cells can not be discdnunated frolllnon-biotinylated 
NaiIn-6 cells through the use of Yae antibody. 
Therefore, we conclude that BP 1119 is able to distinguish t( I; 19)+ cells from t( I; 19)-
cells through a specific nuclear stainitlg itl t(l;19)' cells only. 
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Discussion 
In this study we have shown that the fusion-point in E2A-PBXI proteins, as it is 
expressed in t(I;19)+ pre-B-ALL, can act as an accurate target for immuno-diagnostic 
purposes. Immunization of mice with the appropriate peptide led to the generation of 
a new polyclonal antiserum BP 1119, which specifically detects the fusion-point epitope 
present on E2A-PBXI proteins in t(1 ;19)+ pre-B cell lines. The specificity ofBP 1119 
for the E2A-PBXI fusion-point epitope was confirmed at the peptide, the protein and 
at the single cell level. 
BP 1119 shows high avidity towards E2A-PBXI peptides and proteins. However, BP 
1119 also recognizes E2Apeptides. Our peptide inhibition studies using cognate E2A, 
E2A-PBXI and PBXI peptides, indicate that the reactivity ofBP 1119 towards E2A-
PBXljilsion-pointepitopes can be totally blocked by E2A-PBXI peptide pre-incuba-
tion. In contrast, preincubation ofBP 1/19 with a mixture ofE2A and PBXI peptides 
does not iuhibit the reactivity of BP 1119 towards E2A-PBXI peptides at all. There-
fore, the avidity of BP 1119 towards E2A-PBXI jilsion-point epitopes is likely to be 
higher than its avidity towards E2A epitopes. 
By comparing protein bands on Western blots visualized after incubation with BP 
1119 with or without an anti-E2A antibody (098-271.1.3), we clearly demonstrate 
that the E2A proteins are not recognized by BP 1119. Therefore, although BP 1/19 
cross-reacts with E2A peptides, E2A proteins are not detected by BP 1119. In this 
respect, it is acknowledged that anti-peptide sera do not always react with the cognate 
protein (16). Likewise, reactivity against PBXI was excluded in our immunoblot ex-
periments using recombinant PBXla proteins. 
Together, these results demonstrate that BP 1119 contains antibodies which recognize 
the E2A-PBXI fusion-point epitope specifically. 
Most impOitantly, BP 1/19 enables us to specifically detect the tlllllor-specific fusion-
point epitopes on E2A-PBXI proteins in t(1 ;19)+ cells. Cells harboring the t(I;19), i.e. 
697, incubated with BP 1/19 show a specific nuclear staining pattern, whereas t(l; 19)' 
cells, i.e. Nalm-6, do not. If BP 1119 were to contain anti-E2A andlor anti-PBX I 
reactivity, both cell types would have shown a similru' staining pattern. We were also 
able to distinguish other t(1;19)+ cells from t(1;19)' cells, i.e. t(I;19)+ Sup-B27 cells 
could be discriminated from t( I; 19)' ALLIMIK cells and normal blood cells (data not 
shown). The specific staining pattem we noticed, a granular nuclear fluorescence that 
spares the nucleoli, is similar to the staining pattel11 observed by Kamps et al. (4,5). In 
those repOited experiments, NIH-3T3 cells infected with virus encoding p77E2MBXI, 
showed a nuclear fluorescence of E2A-PBX I proteins upon staining with anti-PBX I 
polyclonal antibodies. However, due to sensitivity problems of the anti-PBX I anti-
bodies, Kamps et al. (5) were only able to demonstrate stdct nuclear localization of 
E2A-PBXI proteins in virus (encoding E2A-PBXI) infected cells, but not in t(I;19)+ 
cells. Likewise, anti-E2A antibodies can not be used to discriminate t(1;19)+ cells 
from t(I;19)- cells. 
Although the amino acid sequence we used as a t(1 ;19) tllillor-specific marker is rela-
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tively consistent in t(1;19)+ pre-B-ALL (17), variants in fusion-point sequences have 
been described. In a min0l1ty of t(1;19)+ pre-B cell cases, Izraeli ef al. (18) reported 
three patients with a 27-bp inselt at the E2A-PBXI junction, while Numata ef al. (19) 
reported a new fusion-point ofE2A-PBXllocated downstream of the expected E2A-
PBXI fusion-transcript. We do not expect the 27-bp insert described by Izraeli ef al. 
(18) to impair the use ofBP 1/l9 as a tool to detect t(1;19)+ cells, since these tran-
scripts seem to co-exist with the conventional E2A-PBXI proteins which are recog-
nized by BP 1119. Fmthermore, it remains to be elucidated whether these aberrant 
chimeric mRNAs lead to translation into their respective chimeric proteins. 
The relatively simple use of antibodies specifically recognizing t(1;19)+ pre-B-ALL 
cases using inlUmnofiuorescence techniques is potentially useful as a supplement to 
existing techniques (eg. cytogenetic analysis and reverse transcriptase polymerase 
chain reaction). Children with a t(I;19) positive pre-B-ALL appear to have a worse 
prognosis as compared to t(l; 19) negative pre-B-ALL cases (20, 21). This poorer 
prognosis can be improved by an intensified chemotherapeutic protocol (22). Accu-
rate diagnostic techniques, such as tumor-specific antibodies, may be helpful when 
choosing the most appropriate therapy. 
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Specific diagnosis of tel; 19)E2A-PBXl positive ALL by polyclonal 
antibody BP 1/19 
77le t( 1;19) is one of the most frequently occurring chromosomal translocations in 
childhood acute lymphoblastic leukemia (ALL)_ This translocation results from the 
reciprocal exchange of chromosomal material between the two chromosomes involved. 
As a consequence, a nell' chimeric gene, tel7lled E2A-PBX1 is generated_ The close 
association of this particular chromosomal translocation lI'ith pre-B-ALL provides 
several tUlllor-specific markers for both diagnosis as lI'ell as detection of residual 
t(i;19)E2A-P.x, leukemic cells during and after treatlllent_ At diagnosis, convelllional 
cytogenetics and reverse transcriptase polymerase elwin reaction (RT-PCR) are used 
for identifying the tumor-specific chromosomal aberration or the tumor-specific E2A-
PBX1 mRNA, respective/y_ 771e RT-PCR technique can also be used for detection of 
slllallnulllbers of residual leukemic cells during and after leukemia treatment_ 
Here, lI'e report on the specific diagnosis of t(1; 19)"A-PBX' positive pre-B-ALLs by 
using imlllunofluorescence microscopy_ The specific detection of the chimeric E2A-
PBX1 proteins at the cellular level with our recently described polyclonal antisemlll 
BP 1119, enables us to distinguish t(1;19)E2A-PRX' positive pre-B-ALLs ft"OlII t(1;19) 
negative precursor-B-ALLs_ The specificity and sensitivity of the BP 1119 
immllllOstaining technique are evaluated and discussed in view of currelllly used di-
agnostic lIIethods_ 
Introduction 
The t( I; 19) is one of the most common cytogenetic abenations observed in childhood 
acute lymphoblastic leukemia (ALL) and is associated with approximately 25% of 
cases with a pre-B immunophenotype (1)_ Molecular studies have shown that t(I;19) 
results in fusion of the E2A gene, a basic Helix Loop Helix (b-HLH) coding gene on 
chromosome 19, with PBX1, a homeobox coding gene on chromosome 1 (2,3)_ The 
E2A-PBX1 fusion-gene, located on chromosome 19, expresses fusion mRNAs com-
posed of 5' E2A sequences and 3' PBXI sequences_ The fusion-site between E2A and 
PBX I mRNA sequences is highly conserved in different t(1; 19) positive leukemias 
(4)_ This conserved fusion-site has been successfully utilized to detect t( I; 19) positive 
pre-B-ALLs by reverse transcriptase polymerase chain reaction (RT-PCR) (5, 6, 7)_ 
In a previous study we have shown that tltis fusion-point in mRNA leads to a consist-
ent fusion-point epitope at the protein level, whlch can be used as an inununological 
target. We demonstrated that BP 1119, a polyclonal antiserum from ntice inulllutized 
with a peptide resembling the antino-acid sequence of the E2A-PBXI fusion-point 
epitope, is capable of recogttizing the E2A-PBXI fusion-point specifically, both at the 
peptide, the protein and at the microscopic level (8)_ 
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In the present study, we evaluate the application of BP 1119 immunostaining for spe-
cific diagnosis of t(1; 19)E'A-PBXI positive leukemias. Specificity and sensitivity of the 
BP 1119 staining technique were both determined on various human hematopoietic 
cell lines. Moreover, blood or bone manow samples from patients previously diag-
nosed as t(1;19) positive pre-B-ALL revealed the characteristic nuclear staining of 
E2A-PBXl proteins upon BP 1119 inullunostaining. 
Materials and methods 
Cell samples 
eel/lines. Twenty-seven human cell lines were used to study the expression ofE2A-PBXl 
proteins and E2A proteins (see also Table I): two precursor-B-celllines derived from pa-
tients with severe combined immunodeficiency (SCID) (RF and YF); 12 precursor-B-cell 
lines (REH; HAL-OI; BY173; TOM-I; NALM-6; 207; SMS-SB; MIK-ALL; 697; SUP-
B27; RCH-ACY and UoC-BS); two Burkitt cell lines (NAMALWA and RAn); two mature 
B-celllines (KCA and CAN-I); two plasma cell lines (L363 and LP-I); three T -cell lines 
(MOLT-4; HUT-78 and DND-41); two myeloid cell lines (KCL-22 and KYO-I) and two 
erythroid cell lines (LAMA-84 and K562) (9, 10, II). Ali cell lines were cultured in RPMI-
1640 medium supplemented with 10% fetal calf serum (FCS). 
Leukemic cell samples. Cell samples were obtained from 14 patients with precursor-B-
ALL. Mononuclear cells (MNC) were isolated from peripheral blood (PB) or bone marrow 
(BM) by Ficoll-Paque (density: 1.077 g/ml; Phannacia, Uppsala, Sweden) density centrifu-
gation. Immunologic and cytogenetic analysis were perfonued as pmt of the diagnostic 
procedure. Remaining cells were stored in liquid nitrogen. 
Immllltof/llorescellce staining technique 
Cell lines. Cell lines were harvested in their logarithmic growth phase and washed twice 
with ice-cold phosphate buffered saline (PBS: 9.38 mM Na,HPO" 0.88 mM KH,PO" 2.68 
mM KCI, 137 mM NaC!, pH 7.8). Cells were attached to poly-L-Lysine (Sigma, St Louis, 
MO, USA) coated slides (10 min, room temperature, RT). Next, the cells were fixed using 
4% parafoI'lnaldehyde (10 min, RT) and permeabilized with methanol (2 min RT). Cells 
were either incubated with antiserum BP 1/19 (I: 1000 in PBS containing 3% BSA) or with 
anti-E2A monoclonal antibody (moAb) G98-27 1. 1.3 (a generous gift from Drs G Bain and 
C Murre, Department of Biology, University of California, San Diego, CA, USA) at a con-
centration of 2 !lg / ml PBS containing 3% BSA. After 45 min incubation and three subse-
quent washes with PBS containing 0.025% T\veen-20, incubation was proceeded (30 min, 
RT) with 10.2 diluted fluorescein isothiocyanate conjugated to goat anti-mouse immunoglobu-
lin antisenun (GaM-FITC; DAKO, Glosstrup, Denmark). Excess reagent was washed off 
and slides were mounted in glycerol I PBS (9: I), containing I mg phenylenediamine I m!. 
Artifidal mixing. Cryopreserved PB-MNC cells were carefully thawed and resuspended in 
ice-cold RPMI-1640 medium supplemented with 10% FCS. After washing with ice-cold 
PBS, PB-MNC were mixed with biotinylated t(1;19) positive 697 cells. Cells were bio-
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tinylated as described previously (12). Biotinylated cells were detected by 5 x 10-5 diluted 
streptavidin-Cy3 conjugate (Sigma, St Louis, MO, USA). 
Leukemic cell samples. Clyopreserved leukemic cell samples were carefully thawed and 
resuspended in RPMI-1640 medium supplemented with 10% FCS. Next, samples were 
washed twice in ice-cold PBS; fixation, permeabilization and ill1ll1Ullostainillg were per-
formed as described above. 
Microscopes. Immunofluorescence was evaluated using a Zeiss Axioscop fluorescence mi-
croscope (Carl Zeiss, Oberkochen, Germany), equipped with a 100 Watt mercury lamp and 
phase contrast facilities and contains a x63, NA 1.4, Planapochromat oil immersion objec-
tive (Zeiss), Micrographs were recorded by using a cOllfocallaser scanning microscope. 
equipped with an air-cooled 488 nm argon laser (CLSM 410 Invert Confocal Microscope, 
Zeiss). The sensitivity of the CLSM (i.e. gain and offset) was set at a constant level. From 
this point on, no further readjustments were made and t(I;19) positive and t(l;19) negative 
samples were recorded successively. 
Results 
Detel1nination of the specificity of the BP 1119 illllllllllojluoJ'escence staining technique 
To investigate whether BP 1119 can be used as a diagnostic tool, allowing specific 
diagnosis of t( I; 19)E2A-PBxl positive pre-B-ALL by immunofluorescence nlicroscopy, 
we evaluated the specificity of BP 1/19 inununostailling on an extended panel of 
hematopoietic cell lines representing various differentiation stages. 
Table I presents the data of the inununofluorescence microscopic evaluation of E2A-
PBXI proteill expression in twenty-seven cell lines. E2A-PBXI proteins were de-
tected by antiserum BP 1119 followed by Oo:M-FITC. Only cell lines with previously 
reported t(l;19) translocations (i.e. 697, SUP-B27, RCH-ACV and UoC-BS) (II) 
showed a speckled nuclear staining that spared the nucleoli. Nuclear staining was not 
observed upon BP 1119 illllllunostaining in cells with cln'omosomal abenations other 
than t(l;19) (II). 
However, the negative BP 1119 nuclear stailling in t( I ;19) negative cells could also be 
explained by inefficient fixation and permeabilization procedures. SillCe cellular mem-
branes are in principle ilnpermeable to antibodies, intra-nuclear staining is only possi-
ble when cells are properly fixed and permeabilized. To assure immunoglobulin 
accessibility to the nuclei, we examined the nuclear staining pattems ofE2A proteins 
by using ilnmunofluorescence microscopy. As E2A proteins are ubiquitously expressed 
in the nuclei of various cell types (13, 14), immunofluorescence analysis of anti-E2A 
protein stailling would address our contentions considering nuclear permeability. MoAb 
098-271.1.3 was chosen for its unique reactivity towards E2A proteins (8, 14). 
Table I presents the data of the immunofluorescent microscopic evaluation of E2A 
protein expression in twenty-seven cell lines. Almost all cell lines tested showed an 
anti-E2A protein staining pattern, comparable to the speckled nuclear staining pattem 
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TableI. 
Immunostaining ofE2A-PBXl m\(1 E2A proteins in HlllllanHematopoietic Cell Lines 
Hematopoietic cell lines 
B-ceillilles 
SCID cell lines 
RF 
YF 
precursor-B-celllines 
REH (CJl-) 
HAL-Ol (CJl-) 
BVl73 (Cfl-) 
TOM-I (CJl-) 
NALM-6 (CJl+) 
207 (CJl+) 
SMS-SB (CJl+) 
MIK-ALL(ql+) 
697 (CJl+) 
SUP-B27 (CJl+) 
RCH-ACV (ql+) 
UoC-BS (CJl+) 
Burkitt cell lines 
NAMALWA 
RAJ! 
Mattlfe cell lines 
KCA (IgM+) 
CAN -I (Ig0+) 
Plasma cell lines 
T-cell lilies 
Myeloid cell lilies 
Elythmid cell lilies 
L363 
LP-I 
MOLT-4 (SmCD3-) 
HUT-78 (SmCD3+) 
DND-41 (SmCD3+) 
KCL-22 
KYO-J 
LAMA-84 
KS62 
t(l;19)(q23;p13)' BP 1/19b 
_1,2 
+1,2 
+1,2 
+1,2 
+' 
++ 
++ 
++ 
+ 
a chromosomal aberrations other than 1(1;19) are not presented by this table. 
098-271.1.3' 
+ 
+ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
+++ 
++ 
++ 
(-) 
++ 
++ 
++ 
++ 
+ 
+ 
+ 
+ 
+ 
b SP 1119 polyclonal antibody, recognizing the tumor-specific E2A-PBXI fusion-point epitope (8). 
c 098-271.1.3 monoclonal antibody, recognizing the carboxyl terminus of E2A proteins (14). 
I as documented by the Department of Cell Biology and Genetics, Erasmus University Rotterdam. 
2 as documented by Drexler et al. (11). 
3 as documented in ATCC, CELL LINES and Hybridomas, 8th edition, 1994. 
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observed upon anti-E2A-PBXI protein staining by BP 1/19 antiserum. However, de-
pending on the cell line investigated, the intensity of nuclear fluorescence varied from 
a strong fluorescence, as observed in the NAMALWA cell line, to practically non-
detectable in the CANol cell line. Since almost all cell lines (except CANol) displayed 
the expected nuclear anti-E2A fluorescence patterns, we conclude that intra-nuclear 
staining by antibodies is, in principle, possible upon the fixation and permeabilization 
procedures we used. 
Therefore, we conclude that among the twenly-seven hematopoietic cell lines tested, 
BP 1119 exclusively detects the t(1;19)E2A-PllXI positive cell lines. 
Detenllillatioll of the sellsitivity oflhe BP 1119 immullojluorescellce stailling technique 
To determine the sensitivity of the BP 1119 immunofluorescence staining technique, 
artificial mixtures of 697 cells (i.e. a t( 1; 19)E2A-PllXI positive cell line ) and nonnal PB-
MNC were examined. To exclude false positive staining by BP 1119 antibodies, we 
decided to label t(1; 19) positive cells also in a different way. Therefore, t(l; 19) posi-
tive cells were biotinylated before mixing them with normal PB-MNC. Subsequent 
incubation with Cy-3 conjugated to streptavidin permitted us to discriminate between 
biotinylated t( 1; 19) positive cells and normal PB-MNC, independent of the inlllllll0-
staining results with BP 1119. 
Figure 1 A typical example of the sensitivity analysis of the BP 1119 staining technique. The 
sensitivity was determined by evaluating BP 1/l9 nuclear staining oft(1;19) positive cells mixed at 
different ratios with Ilannal PB-MNC, by using double immunofluorescence microscopy. BOllndBP 1119 
antibodies ,,,ere detected with FITe-conjugated to second step reagent. To identify all t(l; 19) positive 
cells independent of BP 1119 staining, t(1;19) positive cel1s were biotinylated before mixing with 
normal PB-MNC. Biotinylated cells were detected by a Cy-3 fluorochrome conjugated to streptavidin. 
(a), (b) and (c ) represent micrographs of the same field of observation. In these micrographs: (a) a 
typical nuclear staining can be observed in five cells upon evaluating BP 1/19 staining, (b) represents 
the bright-field micrograph of the mixture of biotinylated t(l; 19) positive cells and normal peripheral 
blood cells, (c) identifies all biotinylated I( 1; 19) positive cells by using Cy-3 conjugated to streptavidin. 
Comparing figures (a) and (c) demonstrates that all biotinylated I( 1; 19) positive cells are identitied by 
BP 1/19. 
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Figure I shows an example from the sensitivity analysis of the BP 1119 iml11unostaining 
technique. Typical intranuclear fluorescent speckled nuclei are observed in all biotiny-
lated t(1 ; 19)E2A.P8xl positive cells upon evaluating BP 1/19 inllllunostaining. This re-
sult indicates that antiserum BP 1119 specifically detects t(1 ; 19)E2A.PBxI positive cells. 
False positive staining is excluded since nuclei of nOlmal PB-MNC are not stained by 
BP 1119 (Figure 1). 
To determine the maximum sensitivity of the BP 1119 staining technique, rutificial 
mixtures of different ratios between t( 1; 19)E2MBXI positive cells and normal PB-MNC 
were examined. An almost pelfect cOll'elation between biotinylated t(1; 19)E2A-PBXI posi-
tive cells and BP 1/19 staining was observed. Although not all t(I;19)E2A.P8xI positive 
cells were identified upon evaluating BP 1/19 itmllunostaining (i.e. BP 1119 inulluno-
staining was observed in approximately 80% of all biotinylated t( 1; 19)E2A-PBXI positive 
cells), E2A-PBXl proteitl staining was still detected in almost all biotinylated t(I;19)E2A·P8xI 
positive cells upon examination of 104 mixtures of biotinylated t(1;19)ElA.PBxI posi-
tive cells and normal PB-MNC. 
Call BP 1119 be appliedjor specific diagllosis ojt(1;19)"lURXI positive pre-B-ALL? 
To investigate the value of antiselum BP 1119 for diagnosing t(1;19)E1A.PBxI positive 
pre-B-ALL, clyopreserved leukemic PB or BM samples from thirteen children at diag-
nosis were examined by using fluorescence microscopy. Illllllunologic alld cytoge-
netic data were available from all samples: four t(1;19) positive pre-B-ALL; four 
t(1; 19) negative pre-B-ALL; four t(l; 19) negative common-ALL and Olle blast crisis 
in chronic myeloid leukemia (CML). All samples were simultaneously processed and 
E2A-PBXl protein expression was evaluated by using a CLSM. 
As can be expected in PB or BM samples from patients examined at first diagnosis; 
50% to 70% of cells from t(1; 19)E2A-PBXI positive samples demonstrated the character-
istic nucleru' fluorescence ofE2A-PBXl proteitls upon BP 1/19 immunostaining (Fig-
ures 2e and 2g). Compru'able results were found itl all four investigated t( I; 19) positive 
pre-B-ALL. In contrast, control samples derived from leukemic patients without cy-
togenetically detectable t( I; 19) did not demonstrate the characteristic nuc1eru' fluOl'es-
cence staining pattern. Typical BP 1119 staining of t(I;19) negative PB samples and 
t(1;19) negative BM samples are represented by Figures 2f and 2h, respectively. Al-
though a low level of background immunofluorescence can be observed in t(1; 19) 
Figure 2 BP 1119 staining of t(1;19) positive and t(1;19) negative blood or bone marrow sam-
ples from patients suffering from acute lymphoblastic leukemia. The bright-field micrographs (a-d) 
represent the same microscopic field as observed in adjacent fluorescence micrographs (e-h). A typical 
BP 1119 staining is observed in samples derived from patients with a t(1;19) positive pre-B ALL: 
approximately 50% of peripheral blood cells (a and e) and approximately 70% of bone marrow cells (c 
and g) demonstrate the typical nuclear fluorescence. In contrast, BP 1119 staining of peripheral blood 
(f) or bone marrow (h) cells, derived from patients suffering from respectively t(I; 19) negative c-ALL 
or t(1;J9) negative pre-B ALL does not result in the typical BP 1/19 nuclear staining, although few 
cytoplasmic fluorescent dots can be observed in either peripheral blood cells (b and f) or bone marrow 
cells Cd and bl. 
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negative cells, sometimes superimposed by a bright cytoplasmic fluorescent dot (Fig-
ures 2f and 2h), the typical nuclear fluorescence observed in t(1; 19) positive samples 
is clearly absent (cf Figures 2e and 2f or 2g and 2h), 
Thus, while the characteristic speckled nuclear pattern is detected in all t(I;19) posi-
tive pre-B-ALL, none of the t(1;19) negative samples demonstrated this pm1icular 
nuclem' fluorescence upon BP 1/ 19 staining, These results indicate that BP 1/19 can 
be applied for specific diagnosis of t( 1; 19)E1MBXI positive ALLs, by using uml1lmo-
fluorescence microscopy, 
Discussion 
The t(I;19) was recognized as a non-random recurring translocation in childhood 
ALL in the em'ly 1980s (15, 16), The abenant t(1; 19) kmyotype has been identified in 
25% of pediatric pre-B-ALL (15, 17), Initially, the detection oft(1; 19) proved to be of 
prognostic value, as the t(1; 19) was associated with poor prognosis (18), Later on, 
when treatment protocols itnproved, the prognosis of the t( 1; 19) positive pre-B-ALL 
improved concurrently (19, 20), 
The close association of the t(1; 19) or its products (i.e, the chimeric fusion-gene, 
fusion-mRNA, or chimedc fusion-protein) with leukemia, provides excellent tumor-
markers for both diagnosis of the t( 1; 19)E2MBXI positive leukemias as well as monitor-
ing residual disease dUting or after treatment. To date, a number of diagnostic techniques 
m'e available to distinguish between leukemic cells and theu' normal hematopoietic 
counterpm1s (21), When considering applicabilty and sensitivity of the assay in tu-
mor-diagnosis, it is realized that each of these techniques has its own specifications, 
At primmy diagnosis, conventional cytogenetics is generally the method of first choice, 
as it permits unambiguous identification of the various cln'omosomal abnormalities 
occurring in different leukemias (1), However, the success of conventional cytogenet-
ics largely depends on the number of metaphases that can be examined, Thus, if leuke-
mic cells die in short-term culture or do not enter mitosis, a false negative result may 
be obtained; a phenomenon likely to occur when small numbers of leukemic cells are 
present. In contrast to the relatively low sensitivity of cytogenetic analysis, the PCR 
teclmique is extremely sensitive: allowing detection of a single leukemic cell among 
10' to 106 normal cells (21), Yet, the PCR cannot be used for detecting the genetic 
t(1;19) abnormality at the DNA level. As fusion-points are scattered in a large E2A-
PBX1 fusion intron, PCR amplification of the tumor-specific fusion-point at the DNA 
level would result in sequences of too variable length, The PCR procedure can be 
applied after reverse transcription (RT) ofmRNA into cDNA, Since fusion-poults m'e 
highly consistent at the mRNA level in most t(1; 19)E1A,PBxl positive cases (4), the RT-
PCR method has been applied successfully for both specific diagnosis as well as the 
specific detection of minimal residual disease (5, 6,7), Residual t(I;19)E1MBXI posi-
tive tumor cells are sometimes still detected by RT-PCR 84 months after chemo-
therapy had been stm'ted (7), It is difficult to verify reduction of residual disease during 
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or after treatment. Premature mRNA degradation and/or variable efficiency of reverse 
transcription are among the causes that hamper accurate quantification of residual 
tumor cells by using RT-PCR techniques (22). 
Contrmy to conventional cytogenetics and RT-PCR techniques, immunologic tech-
niques appem- to identify more clearly patients at a high risk of relapse (22). Moreo-
ver, immunofluorescence techniques are commonly available in clinical settings, are 
relatively simple, and require only a few hours to obtain a result. However, single 
immunological marker analysis by tumor-specific antibodies is stili not suitable for 
distinguishing neoplastic cells from normal hematopoietic cells. The ClllTent immu-
nologic strategy for detecting residual disease takes advantage of the observation that 
combinations of single leukocyte mm'kers may be found on malignant cells that are 
normally not observed in PB or BM (22). Although donble immunological mm-ker 
analysis gives excellent results in T-ALL and a large part of acute myeloid leukemias 
(AML), tIus teclnuque is oflin1ited value in ALL ofB-celllineage (21, 22). 
In the present study we show that t(l;19)E2A-PBXI positive ALL with a pre-B immuno-
phenotype are specifically detected through specific E2A-PBXl protein staining with 
our BP 1I19 antiselUm, by using single immunological marker analysis. 
Specificity analysis on a large panel of cell lines, representing various hematopoietic 
differentiation stages, showed that t( I; 19)E1A-PBXI positive cells exclusively display the 
characteristic nuclear fluorescence upon BP 1/19 immunostaining. None of the t( I; 19) 
negative cell lines stained by BP IIl9 showed noticeable staining beyond background. 
In contrast, almost all hematopoietic cell lines tested demonstrated, upon staining 
with anti-E2A antibodies, a nuclem' granulm' fluorescence pattem that spm'ed the nu-
cleoli. Although E2A proteins m'e considered to be ubiquitously expressed among 
vm-ious cell types (13, 14), anti-E2A protein staining of the mature B cell line CAN-l 
by moAb G98-271.1.3, unexpectedly did not result in a noticeable nuclear fluores-
cence. Our recent Westem blotting experiments (according to the method described 
previously (8» confilmed the absence of E2A proteins in CAN-l cells (results not 
shown). 
The sensitivity of the BP 1I19 immunostaining technique was deternuned as one 
t(1;19)E1A-PBxl positive cell among 10,000 normal PB-MNC. However, one should 
realize that, due to variable expression ofE2A-PBXl proteins, not all t(l ;19) positive 
cells are detected. This variable protein expression not only concerns E2A-PBXl 
proteins in t(1;19) positive cells, but also E2A proteins in all cell lines tested when 
stained for E2A protein expression. The noticed vm'iability of E2A-PBXl and E2A 
protein expression between investigated cell lines probably accounts for differences 
in cell cycle progression (23). Indeed, nutotic cells m'e difficult to identify uponBP IIl9 
or G98-271.l.3 immunostaining. The absence of nuclem' staining in nutotic cells can 
be explained by breakdown of the nuclear envelope in cells entering mitosis, causing 
E2A-PBXl proteins and E2A proteins to disperse throughout the cytoplasm. Pulford 
ef al. found similar results upon inmlllnostaining for TALI protein expression (24). 
TALl proteins belong to the same b-HLH fanuly of transcription factors as E2A pro-
teins (24). 
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Final proof of specific immunostaining by BP 1/19 antibodies was provided by 
mlalyzing the immunofluorescence pattel11s of samples from t(l ;19) positive and t(l ;19) 
negative leukemic patients. A clem' granulm' nuclear staining was observed in t(l; 19) 
positive ALL PB and BM samples, but not in t(I;19) negative ALL PB or BM sam-
ples. Although nuclear staining was absent in t(l; 19) negative samples, we did ob-
serve a diffuse background staining that was sometimes superimposed by a bright 
cytoplasmic fluorescent dot. These cytoplasmic fluorescent dots probably explain our 
failure to distinguish t(I;19)E2A.PBx, positive cells from t(I;19) negative cells when 
using BP 1119 in preliminaIY flow cytometric studies (data not shown). 
Although BP 1119 is a powerful reagent (1:1000 dilutions are optimal) and small 
aliquots can be used for fluorescence microscopy (50 J.l1 of diluted BP 1119 per sam-
ple), monoclonal antibodies directed towaI'ds the tumor-specific fusion-point ofE2A-
PBXI proteins would be favored. Moreover, such fusion-point specific antibodies 
should allow double or even triple labeling studies on the same PB sample or BM 
sample. 
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The t( 1; 19) c!lIvmosomal trallslocation is obselwd ill 25% of pediatric pre-B-cell 
acute lymphoblastic leukemias (ALL) alld results ill the expressioll of chimeric E2A-
PBX1 pmteills. As such, E2A-PBX1 pmteills can be considered as tumor-specific 
markers that could be useji"for diagnosing t(J;19)E2A-PRXI positive ALL and monitor-
ing residual t( 1; 19)"'A-PBX1 positive leukemic cells dlldllg alld after leukemia treat-
mellt. HOll'evel; since the tllmor-specific E2A-PBX1 pmteins cOllsist of amino-acid 
sequellces also presellt ill 1/011 tumor-specific E2A alld PBX1 pmteins, the exe/usive 
identification of E2A-PBX1 pmteins usillg allfibodies is hampered by non tumor-spe-
cific epitopes also present on E2A- and PBX1 pmteins. One of the most obvious anti-
genic determinants that can be applied as a tllmor-specific target is located at the 
jilsion-point of E2A-PBX1 pmteills. III a previous Stll{~l' lI'e have demollstmted that 
the E2A-PBXI jilsiOIl-poillf is presented ill all alltigellicfashionll'hich alloll's specific 
idelltification of t(J;I9)E2A-PRXI positive cells by usillg fluorescellce miclVscopy. We 
11011' report Oil the gellemtioll of all anti E2A-PBXl jilsioll-poillt specific monoe/onal 
alltibod)\ termed ER-G04. Its reactivity tOll'ards the jilsioll-poillt epitope of E2A-
PBXI PlVteillS lI'as COli firmed at the peptide, the proteill, and at the celllliar level. We 
sholl' that this alltibody is IIOt ollly of pmctical illterest cOllsidering diagllosis of 
t(J;19)E2A-PBX1 positive ALL, but is also of academic illterest, sillce moAb ER-G04 
recognizes novel intmlllle/ear structures ill E2A-PBX1 tmllsfected COS-cells. 
Introduction 
The chromosomal translocation t(1;19), found in 5% to 6% of pediatric acute lym-
phoblastic leukemia, results in the expression of chimeric E2A-PBXl fusion proteins 
(1). The pathogenetic relation of t(I;19) with neoplasia was suggested in the early 
1980s, as t(l ;19) was recognized as a non-random recUtTing translocation in child-
hood acute lymphoblastic leukemia (2, 3). Immunophenotyping has shown this par-
ticular translocation to be present in 20-25% of pediatric pre-B-ALL (4, 5, 6). 
TheE2A gene (encoding transcription factors: El2, E47 (7) and E2-5 (8), collectively 
known as E2A proteins), located within chromosome band 19p13, was found to be 
rearranged in t(1; 19) positive pre-B-ceilleukemias (9). Nourse et al. and Kamps et al. 
discovered that the t( I; 19) results in replacement of the 3' terminus of E2A with exons 
from the PBX1 gene (a homeobox gene) on chromosome I (10, 11). Since its discov-
ery, the involvement in leukemogenesis of E2A-PBXl and its products have been 
implicated by several studies (12, 13, 14). 
It has been suggested that the detection of the E2A-PBX1 gene or its products, rather 
than the detection of the aberrant karyotype is of prognostic value (15). Variant t( 1; 19) 
positive leukemias, lacking E2A or PBX1 aberrations, appear to have a better progno-
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sis than t(l;19) positive leukemias with rean-anged E2A-PBXl genes, when treated 
with less intensive chemotherapy (15). 
The fusion ofE2A and PBXI genes in t(I;19)E2A.PBxl positive leukemias results in a 
remarkable consistent fusion-point at the mRNA level (16). The specific detection of 
the E2A-PBXI fusion-point by reverse transcriptase polymerase chain reaction (RT-
PCR) has been shown to be a powerful tool, at both diagnosis as well as remission of 
t( I; 19)E2A·PBxl positive leukemias (17, 18). 
We have recently demonstrated that the fusion-point of the chimedc E2A-PBXI pro-
tein is presented in an antigenic fashion (19). Our BP 1119 polyclonal antiserum, 
specifically detects t(l; 19)E2HBXl positive ALLs by immunofluorescence microscopy 
(submitted). 
We now report on the establishment of a new hybddoma cell line, producing mono-
clonal antibodies directed towards the fusion-point epitope of E2A-PBXl proteins. 
The reactivity of this monoclonal antibody (moAb), which we termed ER-G04 was 
tested at the peptide, the protein and at the cellular level. We show that this antibody is 
not only of practical interest considedng diagnosis of t( I; 19)E2A.PBxl positive ALL, but 
is also of academic interest since moAb ER-G04 recognizes novel intranuclear struc-
tures in E2A-PBXI transfected COS-cells. 
Matel'ials and methods 
Cel/lilles 
RCH-ACV (a generons gift from Dr M Cleary, Laboratory of Experimental Pathology, De-
partment of Pathology, Stmrford University School of Medicine, Stanford, CA, USA), SUP-
E27 (a generous gift from Dr S Smith, Department of Pediatric Hematology, University of 
Chicago, lL, USA) and 697 are ceUlines fOlmerly diagnosed as t(l ;19) positive pre-B-ALL (10, 
20, 21). NALM-6 and REH cell lines were used as t(l;19) negative pre-B-cell controls. 
HAL-OI (a generous gift from Dr K Ohyashiki (First Department of Internal Medicine, To-
kyo Medical College, Tokyo, Japan) is derived from a patient diagnosed as t(17; 19) pro-B-
ALL (22). SP 2/0 cells were used as a fusion partner for hybridoma formation. The trans-
formed monkey kidney epithelial cell line, COS, was used for transfection experiments. 
Peptides 
Peptides have been described previously (19). The MAP antigen consists of eight E2A-
PBXl peptides anchored to a branched core-matrix of lysine amino acids. The amino acid 
sequences of monomeric E2A, E2A-PBXI and PBXI peptides are given in Figure lb. 
IlIIlIIullizaliou alld productioll oflhe ER-G04 hybridollla 
BALB/C mice were immunized by intraperitoneal (ip) injection of 200 fll of an emulsion of 
50 flg MAP antigen in 0.083 M sodium phosphate buffer, 0.9 M NaCI, pH 7.2 and an equal 
volume of Complete Freund's Adjuvant. These mice were given repeatedly booster injec-
tions (minimal time interval of one month between booster injections) ip with the same dose 
of antigen in Incomplete Freund's Adjuvant. Seven days after the final booster the spleen 
from one mouse was removed and a cell suspension was prepared. For fusion, SP 2/0 cells were 
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mixed with spleen cells at a ratio of 1:5. Cell fusion was induced with PEG-4000 (72% w/v 
in RPM!). Next, cells were spun down and resuspended in RPM! supplemented with 10% 
fetal calf semm, 40 U li.-6/ml, hypoxanthine (104 M), azaserine (I Jlg/ml), p-mercaptoethanol 
(5 x 10" M). Cells were distributed in 96-wells culture plates at a density of 4 x 10' cellsl 
well. Initial screening of hybrid om as was performed by evaluating the reactivity of hybIidoma 
supernatants in ELISA (MAP antigen) and Western blot (recombinant E2A-PBXI'). Cell 
culture supernatant of ER-G04 was affinity purified using Gammabind G Sepharose beads 
(Pharmacia Biotech AB, Uppsala, Sweden). ER-G04, an IgG! type antibody, was conju-
gated to FITC according to Harlow and Lane (23). 
Alltigell competitioll assay (ELISA) 
The antigen competition assay was pClfonned essentially as described previously (19). First, 
peptide concentrations were determined using Ellman's reagent (Pierce, Rockford II, USA). 
Next, the peptide concentration ofE2A-PBXI fusion peptides was equilibrated to the pep-
tide concentration of the mixhlre of E2A and PBXl peptides, according to the formula: 
x mol E2A-PBXI peptide I y ml = (x mol E2A peptide + x mol PBXI peptide) I y ml 
Various amounts of peptides (as indicated in Figure I) were pre-incubated with 5 ng ER-
G04 antibody for two hours at room temperature (RT). These mixtures were tested on MAP 
antigen coated PVC plates (I Jlg/ml). Bound antibodies were detected with goat anti-mouse 
illllllunoglobulins conjugated to alkaline phosphatase (GaM-AP; Tago, Burlingame, CA, 
USA) (I: 1000 v/v) and p-nitro phenyl phosphate (pNPP) as substrate (Sigma, St Louis, MO, 
USA). 
lVeslem bIoi 
Nuclear extracts were prepared as described by Schreiber et al. (24), with some modifica-
tions. Briefly, 107 cells were washed once in Tris buffered saline. Next, cells were swollen in 
Iml hypotonic buffer (10 mM HEPES pH 7.9; 10 mM KCI; 0.1 mMEDTA; 0.1 mM EGTA; 
I mM DTT; 0.5 mM PMSF) at 4"C. After the cell membranes were lysed through the addi-
tion of NP-40 to a final concentration of 0.5% nuclei were pelletcd by centrifugation in an 
Eppendorf centrifuge. After removal of the supernatant, the pelleted nuclei were resuspended 
in 100 JlI of high salt extraction buffer (20 mM HEPES pH 7.9; 0.4 M NaCI; I mM EDTA; 
ImM EGTA; I mM DTT; I mM PMSF). Nuclei were vigorously rocked for 30 min at 4 'c 
and subsequently centrifuged to remove the nuclei and particular matter. Nuclear extracts 
were collected, diluted (I: I v/v) in sample buffer and boiled for 5 min. Western blotting was 
performed as described previously (19). 
The following concentrations of antibodies were used: ER-G04 at 2.5 flg/ml, moAb Yae 
(Santa Cruz Biotechn., Santa Cmz, CA, USA) at 0.5 Jlg/ml and rabbit polyclonal antibody 
PBX 1/2/3 (Santa Cruz Biotechn.) at 0.5 flg/m!. Bound antibodies were detected by either, 
peroxidase conjugated goat anti-mouse immunoglobulins (DAKO, Gloshup, Denmark) 
(1:2000 v/v), Ga.M-AP (Tago) (1:2000 v/v) or alkaline phosphatase conjugated goat anti-
rabbit immunoglobulins (DAKO) (I: 1000 v/v). For visualization of antibody-antigen com-
plexes, we either used the enhanced chemoluminescent (ECL) Western blotting system, as 
instructed by the manufacturer (Amersham Int., Little Chalfont, UK), or the NBTIBCIP method 
as described previously (19). 
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Plasmids 
E2A-PBXl3 plasmid 
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E2A-PBXI' plasmid conlains Ihree copies of an E2A-PBXI fusion-poinloligonucleotide 
(GATCCCGGCCTCCCGACTCCTACAGTGTTTTGAGTATCCGAGGAGCCCAGGAGATC) 
inserled in Ihe BamHI sile of pET21 B (Invilrogen BV, Leek, The Nelherlands). The 
recombinant E2A-PBX13 fusion-protein was expressed and purified as instructed by the 
manufacturer. Recombinant E2A-PBXIJ fusion-protein is expressed as a 10 kDa protein and 
conlains Ihree copies of Ihe amino acid sequence SRPPDSYSVLSIRGAQEI. 
E2A, E2A-PBXl (a 01' h) alld PBXla SV-40-plasmids 
The E2A SV-40 plasmid conlains fullienglh EI2 inserled downslream of Ihe lranscription 
slarl sile oflhe SV-40 promolor pJ3Q (25) (a kind gift of Dr G Bain, Deparlmenl of Biology, 
UniversilY of Califomia, San Diego, CA, USA). E2A-PBXla, E2A-PBXlb and PBXla 
cDNAs, cloned downslream of Ihe SV -40 promolor inlhe pJ3Q veclor, were described pre-
viously (26). Plasmids were purified by equilibriulll cenlrifugation in CsCI-elhidium bro-
uude density gradients. 
E2A-PBXlla alld E2A-PBXlh CMV-plasmids 
The E2A-PBXl (a or b) CMV-plasmids conlain Ihe EcoRIfHilldill fragmenl from previ-
ously described E2A-PBXI (a or b) effeclor plasmids pJ3Q (26). The compIele coding se-
quence of E2A-PBXI (a or b) was cloned downslream of Ihe Iranscriplion slarl site of Ihe 
CMV promolor in pcDNAII Amp (Invitrogen). 
III vitro trallslalioll 
Translalions were pelformed using RNA lranscribed ill vitro from E2A-PBXI (a or b) CMV 
plasmids and previously described PBX I effeclor plasmids using SP6 polymerase (Promega, 
Madison WI, USA) (26). RNA was lranslaled ill vitro using a nuclease Irealed rabbil relicu-
locyte lysate (Promega) under conditions recolllmended by the supplier. The ill vitro transla-
lion produCls were diluled in sample mix (1:9 1'/1') and analyzed by Weslern blolling. 
T/'{/Ilsjeclioll 
One Ilg of either plasmid was inlroduced inlo COS cells using 10111 LipofeclAMINE reagens 
(om eo BRL), according to the manufacturer's instructions. Two days after transfection, 
COS cells were Irypsinized and dislribuled on fibronectin coaled 4-wells slides (Nulacon). 
Each well on Ihe fibroneclin coaled 4-wells slide conlained either E2A, E2A-PBXla, E2A-
PBXlb or PBXla lransfecled COS cells. 
Double imlllullofluorescence staillillg 
Three days after transfection, COS cells cultured on fibronectin coated 4~wells slides were 
washed in ice-cold PBS, fixed with 4% paraformaldehyde in PBS (10 min, roomlemperalure 
(RT)) and permeabilized with melhanol (2 min, RT). Nexl, slides were rinsed in PBS con-
laining 0.025% Tween-20, followed by a 45 min incubalion in blocking solulion (2% BSA, 
0.1 % sodium azide, 0.2% Tween-20, 6.7% glycerol). Slides were eilher incubaled wilh a 
mixlure ofbiolinylaled anli-E2A moAb G98-271.1.3 (1Ilg/ml) (moAb G98-271.1.3, a gen-
erous gift from Drs G Bain and C MUlTe, Department of Biology, University of California, 
San Diego CA, USA) and FITC-Iabeled ER-G04 (5 flg/llll) or with a mixlure of poIyclonal 
rabbil antibody PBX 1/2/3 (2 Ilg/ml) (Sanla Cmz) and FITC-Iabeled ER-G04 (5 Ilg!ml). 
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After 45 min incubation and three subsequent washes in PBS containing 0.025% Tween-20, 
incubation was proceeded with either 10-5 diluted streptavidin-Cy-3 conjugate (Sigma. St 
Louis MO, USA) or 1:30 (v/v) diluted TRITC-conjugated to anti-rabbit immunoglobulins 
(GuR-TRITC; Supertechs, Bethesda MD, USA). Fluorescence was evaluated using a confocal 
laser scanning microscope, equipped with an air-cooled 488 llln argon laser (CLSM 410 
Invert Confocal Microscope, Zeiss, Oberkochen, Germany). 
Results 
Specificity analysis of moAb ER-G04 at the peptide level 
Initial screening ofhybddomas was perfOlmed by evaluating the reactivity ofhybddoma 
snpelllatants with E2A-PBXl peptides in ELISA (MAP antigen) and recombinant 
E2A-PBX 13 protein, using Westel11 blotting. After seven fusions, one hybddoma, which 
we termed ER-G04 (Greek: ergon -labor, phol1ls - carrying: carrying a specific activ-
ity), was selected for further subc1oning, Ig-purification and subsequent analysis. 
To determine the specificity of moAb ER-G04, an antigen competition assay was 
performed within an enzyme-linked immunosorbant assay (ELISA), as described pre-
viously (19). To this plll]lose, ER-G04 immunoglobulins (Ig) were either preincubated 
with E2A-PBXl peptides, or with a mixture ofE2A and PBXl peptides (equimolar to 
E2A-PBXl peptides). After preincubation, the peptidelER-G04 Ig mixtures were al-
lowed to react with E2A-PBXl peptide (MAP antigen) coated on PVC plates. 
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Figure la Peptide inhibition study to delineate the antigenic determinant recognized by moAb 
ER~G04. To this purpose either graded concentrations of a mixture of monomeric E2A- and PBX 1 
peptides CO) or graded concentrations of monomeric E2A-PBXl peptides (: :) were used to examine 
their respective capacity to inhibit binding ofER-G04 antibodies to the octamcric E2A-PBXl (MAP 
antigen) peptide complex, inunobilized on the solid phase. Inhibition is expressed as: [l-{ (absorbtion 
in the presence of peptide)/(absorbtion in the absence of peptide)} J x 100%. Each point represents 
the mean of a duplicate 
Figure Ib Schematic representation of the amino acid sequence of monomeric E2A, E2A-PBXl 
and PBXl synthetic peptides. The amino acid sequence of E2A-PBXI peptide is identical to the 
amino acid sequence of E2A peptide up to the fusion-point, thereafter the amino acid sequence of 
E2A-PBXI peptides resembles the amino acid sequence of the PBXI peptide. 
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Figure I sholVs that preincubation of moAb ER-G04 with cognateE2A-PBXl peptides 
completely abrogates binding of ER-G04 antibodies to E2A-PBXl peptide coated 
plates. In contrast, preincubation of moAb ER-G)4 with a peptide mixture (1:1) of 
E2A and PBXI peptides (eql1imolar to E2A-PBXl peptide preincubations) barely 
affects binding of ER-G04 to E2A-PBXl peptides. 
These data show that ER-G04 reacts primarily with peptides containing an E2A-
PBXl fusion point amino acid sequence. 
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Figure 2a Immunoblot analysis of tile reactivity of moAb ER-G04. Nuclear extracts of t( 1; 19)F2A.PBXl 
positive human pre-B-cell lines; i.c. 697, RCH-ACV, SUP-B27 and, t(I;19) negative human pre-B-
cell lines; i.e. NALM-6, REH and t(17;19)E1A.HlF positive human pro-B-celliine HAL-OI, were used to 
examine the specificity of moAb ER-G04. The localization of E2A-PBXl proteins is indicated at the 
left. 
Figure 2b Immunoblot analysis of the reactivity of anti-E2A moAb Yae. A similar blot as Figure 
2a, containing the same nuclear extracts, was used to demonstrate the localization of respectively, 
E2A-PBXI proteins, E2A proteins and E2A-HLF proteins. TIle localization of E2A-PBX 1 proteins is 
indicated left, the localization ofE2A proteins and E2A-HLF proteins are indicated at the right side of 
the blot. 
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Specificity analysis of ER-G04 at tlte protein level 
To elucidate whether moAb ER-G04 can be used fot· specific recognition of the fu-
sion-point epitope in E2A-PBXI proteins, we analyzed the reactivity of moAb ER-
G04 on immunoblots derived from several hematopoietic cell lines. As a control for 
E2A-reactivity, Yae antibody was employed. Yae antibody is directed against the amino-
proximal part of E2A proteins and recognizes both E2A proteins and E2A-PBXI 
proteins (27). For the detection of E2A-PBXI proteins we used a Western blotting 
procedure with nuclear extracts from t(l; 19)E2A-PBXl positive cell lines (i.e. 697, RCH-
ACV and SUP-B27). As t(I;19) negative controls, nuclear extracts from NALM-6, 
REH (both pre-B-celliines) and HAL-OI cell line (t(17;19)E2AHLF positive pro-B cell 
line were employed. The t(l7;19) in the HAL-OI cell line creates a chimedc fusion 
gene, termed E2A-HLF, located on c!u'omosome 19. In this rearrangement, E2A se-
quences are joined with those of a gene for hepatic leukemia factor (HLF). As a result 
of the t(17;19), chimeric E2A-HLF proteins are expressed in the nuclei of HAL-OI 
cells. 
Figure 2a represents a Western blot incubated with ER-G04 antibodies. E2A-PBXI 
proteins are detected by moAb ER-G04 in t(l ;l9)E2A-PBxl positive cell lines (lanes I, 
3, and 5), but not in t(l;19) negative cell lines (lanes 2, 4 and 6). A similar blot, now 
incubated with moAb Yae (Figure 2b) shows the localization ofE2A-PBXI proteins 
(lanes 1,3 and 5), E2A proteins (Figure 2b: all lanes) and E2A-HLF proteins (Figure 
2b: lane 6). Neither E2A, nor E2A-HLF proteins are recognized by ER-G04 antibod-
ies (cf Figures 2a and 2b). 
From these data, we conclude that ER-G04 recognizes E2A-PBXI proteins and does 
not cross-react with E2A proteins nor with E2A-HLF proteins. 
So fm', reactivity of ER-G04 to PBXI proteins could not be excluded. Since PBXI 
proteius me not expressed in lymphocytes (28), we decided to analyze, by Western 
blot, the reactivity of ER-G04 towards ill vitro translated PBX I a and PBX2 proteins. 
As positive control for the reactivity of moAb ER-G04, both kinds of ill vitro trans-
lated E2A-PBXI (a and b) proteins were employed. The data presented in Figure 3a 
indicate that both ill vitro translated E2A-PBXI proteins (lanes a and b) m'e recog-
nized by ER-G04, whereas ill vitro translated PBXl proteins and ill vitro translated 
PBX2 proteins are not recognized by ER-G04 (lanes c and d). 
To confirm the efficiency of the ill vitro translation of PBXla proteins and PBX2 
proteins, we incubated a similar blot with a polyclonal antibody termed PBX 112/3 
(Figure 3b). AntiselUm PBX 112/3 is directed against the carboxyl terminus found in 
E2A-PBXla, PBXla and PBX2 proteins. E2A-PBXlb proteins contain a differen-
tially spliced PBXI carboxyl terminus (28), which is not recognized by polyclonal 
antibody PBX 112/3. Figure 3b shows the localization of E2A-PBXla (lane a) and 
both PBXla and PBX2 proteins (lanes c and d) upon incubation with PBX 112/3 
polyclonal antibody. Thus, although PBXla and PBX2 proteins were efficiently trans-
lated ill vitro, they are not recognized by ER-G04. 
Together, the Western blotting experiments indicate that moAb ER-G04 exclusively 
recognizes an E2A-PBXI jllsiol1-poilll epitope at the protein level. 
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Figure 3a Immunoblot cross-reactivity analysis of moAb ER-G04 to ill vitro translated PBXIa 
and PBX2 proteins. Each lane represents, as indicated at the top if the bolt. either ill vitro translated 
E2A-PBXla proteins O,.d), in vitro translated E2A-PBXlb proteins (1 !ll), ill vitro translated PBXIa 
proteins (1 Ill) and ill vitro translated PBX2 proteins (l ~il). As is demonstrated, MoAb ER-G04 only 
recognizes ill vitro translated E2A-PBXl (a and b) proteins. 
Figure 3b Immunoblot analysis of a similar blot as used in Figure 3a, containing the same amounts 
of ill vitro translated E2A-PBXla, E2A-PBXlb, PBXIa and PBX2 proteins. Rabbit polyclonal anti-
body PBX 112/3, recognizing the carboxyl-terminus ofE2A-PBXla, PBXla and PBX2 proteins was 
employed to indicate the localization of ill vitro translated E2A-PBXla, ill vitro translated PBXla and 
ill vitro translated PBX2 proteins. 
Specificity allalysis of ER-G04 at the cellular level 
We next examined whether moAb ER-G04 distinguishes between t( I; 19)E2HDXl posi-
tive pre-B-celllines and t(l; 19) negative cell lines, using fluorescence microscopy. 
Despite multiple attempts, using different fixation and staining protocols, we were 
unable to distinguish t( I; 19)E2MBXl positive cell lines from t( I; 19) negative cell lines. 
The characteristic nuclear staining pattern of t(1 ;19)E2MBXl positive cells, we usually 
observe upon incubating t(l ;19)"2MBxl positive cell lines with our E2A-PBXI fusion-
point specific polyclonal antiserum BP 1119 (19), was not noticed upon incubations 
with ER-G04 antibodies. Both t(I;19)E2MDXl positive cell lines and t(I;19) negative 
cell lines show, besides a faint nuclem' staining, reactivity of the ER-G04 antibody in 
the cytoplasm. 
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At this point, it can be argued that: I) the fusion-point epitope ofE2A-PBXI proteins 
is destructed as a result of fixation (29) or 2) E2A-PBXI protein expression is too low 
to be detected by moAb ER-G04. To investigate both possibilities, COS cells were 
transfected with an expression vector (pJ3Q) containing full length E2A-PBXla. Three 
days after transfection, COS cells were stained with ER-G04 followed by GaM-
FlTe. Immunofluorescence was evaluated by using confocal laser scanning microscopy 
(CLSM). 
To our surprise, CLSM analysis ofER-G04 staining ofE2A-PBXla transfected COS 
cells revealed, at high magnification, strikingly different nuclear staining pattems, 
generally excluding the nucleoli (Figures 4a to 4c). By comparing different nuclear 
staining patterns of various E2A-PBXla transfected COS cells, we noticed that all 
nuclei stained by moAb ER -G04 displayed a diffuse nuclear pattelll (Figure 4a), of-
ten superimposed by a punctate pattem (Figure 4b) or a patchy nuclear pattem (Figure 
4c). 
To ensure that these nuclear structures indeed represent E2A-PBXla proteins, we 
next transfected COS cells with the pJ3Q expression vector, now containing either 
full length E2A, E2A-PBXla, E2A-PBXlb or PBXla cDNAs. The four differently 
transfected COS cells were grown separately on wells of a 4-wells slide and analyzed 
by double immunofluorescence. To tlus purpose, 4-wells slides were either incubated 
with a mixture ofFlTC-labeled ER -G04 and biotinylated anti-E2A moAb G98-271.1.3 
(Figures Sa and Sb) or were incubated with a nuxture of FlTC-labeled ER-G04 and 
rabbit polyclonal antibody PBX 112/3 (Figures Sc to Sh). MoAb G98-271.1.3, di-
rected towards the carboxyl ternunus of E2A proteins (19, 30), was chosen to confilm 
the effectiveness of the E2A-transfection procedure. PBX 112/3 antibodies were em-
ployed to ensure both specific E2A-PBXla protein staining in E2A-PBXla transfected 
COS cells as well as PBXla protein expression in PBXla transfected COS cells. PBX 
112/3 antibodies do not recogluze E2A-PBXlb proteins. 
Figure 4 Immunofluorescence analysis of moAb ER-G04 staining on COS cells transfected 
with an E2A-PBXla containing pJ3Q expression yector. Bound ER-G04 antibodies were detected by 
FITC-conjugated to goat anti-mouse immunoglobulins. 
Different nuclear staining patterns can be observed in E2A-PBXla transfected COS cells (a, b, c). All 
E2A-PBX 1 a expressing COS cells, stained by moAb ER -004, display a diffuse nuclear pattern (a), 
often superimposed by a punctate nuclear pattern (b) Of by a patchy nuclear patlem (c). 
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Figure 5 Specificity analysis of the reactivity of moAb ER-G04. COS cells were transfected 
with either an E2A (a, b), an E2A-PBXla (c, d), an E2A-PBXlb (e, D or a PBXin (g, h) containing 
pJ3Q expression vector. Micrographs of cells depicted in the left panel (a, c, e, g) represent the same 
microscopic tield as is observed in the right panel of micrographs (b, d, f, h), 
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FlTe-labeled ER-G04 antibody was used to demonstrate binding to E2A-PBXla (c) and E2A-PBXl b 
proteins (e), but not to E2A (a) or PEXIa (g) proteins. Biotinylated anti-E2A moAb 098-271.1.3 was 
employed to verify E2A protein expression in E2A transfected COS cells (b). The Cy-3 fluorochrome 
conjugated to streptavidin was used to identify bound biotinylated 098-271.1.3 antibodies. Rabbit 
polyclonal antibody PBX 112/3 (recognizing E2A-PBXla proteins but not E2A-PBXlb proteins), was 
used to confmn that E2A-PBX I proteins are indeed localized in discrete nuclear structures in E2A-
PBXl transfected COS cells Cd). Bound PBX 1/2/3 immunoglobulins were identified by TRITC-
labeled goat anti-lllouse immunoglobulins (GaR-TRITe), As E2A-PBX lb proteins are not recognized 
in E2A-PBXlb transfected COS cells, artefactual staining by either PBX 112/3 immunoglobulins or 
GaR-TRITC immunoglobulins is excluded (cfd and D. PBX 112/3 antibodies were also used to ensure 
PBXIa protein expression in PBXla transfected COS cells (h). 
The particular localization ofE2A-PBX! (a or b) proteins in discrete nuclear stmctures in E2A-PBXl 
(a orb) transfected COS cells, is not observed in E2A transfected COS cells nor is it observed in PBXl 
transfected COS cells, upon staining for E2A- or PBXIa protein expression, respectively. In contrast, 
both E2A and PBXIa transfected COS cells display a diffuse nuclear staining, sparing the nucleoli, 
when stained with the appropriate antibodies (098-271.1.3 or PBX 112/3, respectively). 
Figure 5 shows micrographs of double staining experiments of COS cells transfected 
with either E2A (Figures 5a and 5b), E2A-PBXla (Figures 5c and 5d), E2A-PBXlb 
(Figures 5e and 5f) and PBXla (Figures 5g and 5h) plasmids. First, to ensure that the 
particular nuclear stmctures observed in E2A-PBXla transfected COS cells indeed 
represent E2A-PBXI proteins, E2A-PBXla and E2A-PBXlb transfected COS cells 
were analyzed upon double staining with FITC-Iabeled ER-G04 antibodies and poly-
clonal PBX 1/2/3 antibodies. The staining patterns observed upon FITC-Iabeled ER-
G04 staining in E2A-PBX I a transfected COS cells (Figure 5c) were completely iden-
tical to the staining pattellls observed upon PBX 1/2/3 immunoglobulin incubation, 
followed GaR-TRITC (Figure 5d). Any pm1icular nuclear pattern detected upon FITC-
labeled ER-G04 antibody staining of E2A-PBXla transfected COS cells (e.g. dif-
fuse, punctate and patchy) was also observed upon PBX 1/2/3 double staining. 
Fut1hermore, the particular nuclem' structures observed in E2A-PBXla transfected 
COS cells were also detected in E2A-PBXI b transfected COS cells upon FITC labeled 
ER-G04 staining (Figure 5e). In contrast, E2A-PBXlb transfected COS cells were 
not stained by PBX 1/2/3 antibodies (Figure 5f). These results, i.e. a positive PBX 
1/2/3 antibody staining in E2A-PBXla transfected COS cells (Figure 5d) versus a 
negative PBX 1/2/3 antibody staining in E2A-PBXlb transfected COS cells (Figure 
5f) verify specific staining with PBX 1/2/3 antibodies: specifically reacting with E2A-
PBXla proteins, but not with E2A-PBXlb proteins. Thus, at the cellular level, E2A-
PBXla proteins are specifically detected as distinct nuclear stmctures in E2A-PBXla 
transfected COS cells. Furthermore, the data from these double staining experiments 
indicate that E2A-PBXI proteins are specifically recognized by moAb ER-G04. 
Specific binding of ER-G04 antibodies towards the fusion-point epitope of E2A-
PBXI proteins was further investigated by double inununofluorescence studies of 
differently (i.e. E2A, E2A-PBXla, E2A-PBXlb and PBXla) transfected COS cells. 
The clear-cut nuclear fluorescence in E2A-PBXla (Figure 5c) and E2A-PBXlb (Fig-
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ure 5e) transfected COS cells upon FITC-Iabeled ER-G04 staining, was not observed 
in FlTC-Iabeled ER-G04 stained E2A transfected COS cells (Figure 5a) nor was it 
observed in PBXI transfected COS cells (Figure 5g). To COnfll'Jll intracellular E2A or 
PBXla protein expression, COS cells were double stained with biotinylated anti-E2A 
moAb G98-271.1.3 or rabbit polyclonal PBX 112/3 immunoglobulins (Figures 5b and 
5h, respectively). To our surprise, while distinguishing transfected cells from non-
transfected cells, we noticed that the particular nuclear stmctures observed in E2A-
PBXI (a or b) transfected COS cells, were not found in E2A transfected COS cells, 
nor were they found in PBXla transfected COS cells. In fact, E2A transfected COS 
cells and PBXla transfected COS cells stained with either biotinylated anti-E2A moAb 
G98-271.1.3 or polyclonal antibody PBX 112/3, both displayed a clear diffuse stain-
ing of the nuclei that spm'ed the nucleoli (Figures 5b and 5h, respectively). 
In conclusion, refening to the contentions stated above, these date indicate that the 
fusion-point epitope of E2A-PBXI proteins, as it is recognized by ER-G04, is not 
affected by the fixation procedures we used. Yet, under the present experimental con-
ditions, ER-G04 antibodies do not specifically recognize E2A-PBXl proteins in 
t(l;19)E1A-pnxl positive tumor-cell lines. E2A-PBXI protein expression in these 
t(l; 19)E2A-pnXI positive tumor-cell lines is probably too low to be specifically recog-
nized by a single antibody. In spite of this, moAb ER-G04 revealed novel distinct 
subnuclear structures, consisting of E2A-PBXI proteins, in E2A-PBXI transfected 
COS cells. Similar distinct subnuclear structures were not detected in E2A transfected 
COS cells, nor were they detected in PBXl transfected COS cells upon staining with 
the appropdate antibodies. 
Discussion 
In the present study we report on the generation of ER-G04, a new monoclonal anti-
body directed towards the tumor-specific fusion-point of E2A-PBXI proteins. The 
specificity of ER-G04 was evaluated at the peptide, the protein and at the cellular 
level. Moreover, ER-G04 allows detection of yet undefined nuclear structures inE2A-
PBXl transfected COS cells. 
The specificity of ER-G04 was evaluated by determination of the antigenicity of 
E2A-PBX1, E2A and PBXI peptides. Peptide inhibitions me methods of first choice 
to assess the comparative antigenicity of the peptides analogues (31). Accordingly, 
considering the antigenicity of the investigated peptides for moAb ER-G04, we found 
E2A-PBXI peptides to be more antigenic than a mixture ofE2A and PBXl peptides. 
Therefore, the epitope recognized by ER-G04 consists of amino acids located at both 
sides of the E2A-PBXI fusion-point. However, we also found reactivity of ER-G04 
towards immobilized E2A peptides, whereas no reactivity ofER-G04 towm'ds immo-
bilized PBXl peptides could be detected (data not shown). Therefore, it is likely that 
E2A derived amino acids contribute to a large extent to the antigenicity of the fusion-
point epitope ofE2A-PBX1. 
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Yet, by comparing the reactivity of moAb ER-G04 with other E2A-PBXl recogniz-
ing antibodies (i.e. Yae and PBX 112/3) in Western blotting experiments, we clearly 
demonstrated that the fusion-pont epitope on E2A-PBX1 proteins is specifically rec-
ognized by moAb ER-G04. Neither E2A proteins, E2A-HLF proteins nor PBXl pro-
teins are recognized by ER-G04. 
To this point the results of ER -G04 are comparable with the ELISA data and Western 
blotting data found with our fusion-point specific polyclonal antibody BP 1119 (19). 
However, in contrast to the polyvalent BP 1119 irrununoglobulins, ER-G04 antibod-
ies do not discriminate between t(l; 19)E1A-PBXI positive cell lines and t(l; 19) negative 
cell lines at the cellular level. 
To eliminate epitope malformation (e.g. caused by fixation) (29), as a reason for the 
inability ofER-G04 to distinguish t(1;19)E1A.PBXI positive cells from t(l;19) negative 
cells at the cellular level, we pelfonned a series of transfection experiments. Subse-
quent double inununofluorescence studies on COS cells, transfected with either E2A, 
E2A-PBXla, E2A-PBXlb or PBXla plasmids, demonstrated that the E2A-PBXl 
fusion-point eptitope, as it is recognized in E2A-PBX1 (a and b) transfected COS 
cells by moAb ER-G04, is not destmcted as a result of fIxation or permeabilization 
procedures. 
Yet, while moAb ER-G04 specifically recognizes anE2A-PBXl fusion-point epitope, 
ER-G04 does not distinguish t(l;19)E2A-PBXI positive tumor-cell lines from t(l; 19) nega-
tive cell lines. The exclusive detection ofE2A-PBX1 proteins in t(l;19)E1A-PBXI posi-
tive tumor-cell lines is probably hampered by a relatively low concentration of 
E2A-PBXl proteins. Cross-reactive epitopes present on non-related cellular proteins, 
likely obscure exclusive E2A-PBXl protein detection in t(l ;19)E2A-PBXI positive cells. 
In spite of tlus, E2A-PBXla and E2A-PBX1b transfected COS cells show a muque 
discrete nuclear staining pattern upon ER-G04 incubation. Tlus particular pattern 
varied from a diffuse nuclear staining to a punctate or even to a patchy nuclear stain-
ing. The punctate and patchy patterns appear as bright foci superimposed on a diffuse 
nucleoplasnuc staining. While punctate patterns were already detected two days after 
the transfections were started, patchy patterns were observed one day later. Since 
patchy patterns were detected three days post-transfection, we suggest that the ap-
pearance of patchy patterns is related to increasing E2A-PBX1 protein concentra-
tions. 
H is unlikely that the observed unique distribution of E2A-PBXl proteins in COS 
cells transfected with E2A-PBX1 expression constructs, is caused by artefacts other 
than the ones caused by overexpression. As discussed above, as both ER -G04 and 
PBX 112/3 antibodies recogluze these structures through specific binding to E2A-
PBXl proteins, staining artefacts are excluded. Additional experiments, using other 
fixatives (methanol I acetone (1:1 v/v) 10 min -20 'C; acetone 2 min RT; I % formal-
dehyde 2 min RT) resulted in identical stmctures upon incubation with ER -G04 or 
PBX 1/2/3 antibodies (data not shown). Moreover, these patticular E2A-PBXI nu-
clear stmctures were also found in E2A-PBXl transfected HeLa and E2A-PBXl 
transfected HEp-2 cells (data not shown). In addition, identical stmctures in E2A-
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PBXl transfected COS cells have been observed by Cleary and co-workers (personal 
communication M Cleary, December 1996). These investigators also recognized dif-
ferences in nuclear distribution: discrete nuclear structures of E2A-PBXl (a or b) 
proteins on the one hand, a diffuse nuclear distdbution ofE2A and PBXl proteins on 
the other. 
Similar distinct subnuclear structures, termed 'nucleru' bodies', have been recently 
described concerning immunofluorescence studies of other nuclear proteins, e.g. PML 
(32), WT-l (33) and GATA (34). Lru'sson et al. showed that proteins derived from the 
tumor-suppressor gene lVT-l (Wilms' tumor) either co-localize with splicing factors 
or co-localize with DNA in transcription factor domains (33). The nuclear protein 
PML (associated with acute promyelocytic leukemia) and the transcription factor 
GATA, each display a unique distribution. Neither PML proteins nor GATA proteins 
co-localize with proteins associated with either replication, transcription or post-
transcriptional processing (32, 34). 
Both Dyck ef al. and Elefanty ef al. demonstrated the presence of these novel class of 
nuclear bodies in leukemic cell samples and non-transfected cell lines (32, 34). Yet, 
pat1icular nuclear E2A-PBXl protein structures, identical to the ones detected in E2A-
PBXl transfected COS cells, are not observed in t(l ;19)E2A-PBx, positive tumor-cell 
lines (19). The granulat' nuclear fluorescence detected upon antiserum BP 1/19 incu-
bation in t(I;19)E2A-PBx, positive tumor-cells (19) may, however, reflect a condensed 
punctate nuclear pattern in the small nuclei of t(1; 19)E2A-PDx, positive cells. Patchy 
structures on the other hand, are probably a prelude of cell death since they are not 
observed in t(1; 19)E2A-PBx, tumor-cell lines. This notion finds supp0l1 in the difficul-
ties we encountered in ttying to establish stable E2A-PBXl transfected cell lines (un-
published observations). 
The close association of E2A-PBXl proteins and leukemogenesis is beyond doubt 
(13, 14). At present, one hopes to ul11'avel the mechanism of E2A-PBXl proteins in 
leukemia development by trying to identify tm-get-genes of the transcriptional activa-
tor protein E2A-PBXl (26, 35, 36). Detailed studies at the cellulru' level, e.g. co-
localization of E2A-PBXl proteins with proteins involved in either replication, 
transcription or post-transcriptional processes, might shed new light on the still ob-
scure role of E2A-PBXI proteins in leukemia development. 
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The Ph chromosome, resulting from the t(9;22) translocation, is the most frequently 
observed cytogenetic aberration in adult acute lymphoblastic leukemia (ALL)_ 1\1'0 
genes, BCR and ABL, are involved in this translocation. As a consequence, parts of 
the BCR and ABL genes are fi/sed, resulting ill chimeric BCR-ABL genes ellcoding 
chimeric BCR-ABL proteills. Three BCR-ABL genes and proteins have been identi-
fied: eIa,P 19(JBCR.ABL, b,a,P21(JBcR.AllL, and bJa,P21(JBcR.ABL. Since these chimeric gel/es 
only occur in Ph-chromosome-positive leukemic cells, they are per defillition tumor-
specific markers. Ph-cillvmosome-positive ALL is corre/ated with a bad prognosis. 
Therefore, the detection of chimeric BCR-ABL proteins is of prime importance for 
ALL diagnosis. III the present stud)\ we report on the genemtion of a monoclonal 
antibody termed ER-FP 1, raised against the tumor-specific eIa,BCR-ABLjunction in 
P19(JBCR.ABL. We sholl' that ER-FP1 reacts highly specifically with eIa,P19(JBCR.AllL in 
different assays. The reactivity of ER-FP 1 with eI{/'P I9(JBcR-AllL in soluble form was 
analyzed ill all imml/lwprecipitation assay; specificity was confirmed by peptide inhi-
bitioll studies. Binding of ER-FP1 to ej{/,P19(JBCR-ABL at the single ceilleve/was de-
tected by /Ising illllll/mof/I/orescence techniques. Immullological double-staining 
experiments /lsil/g ER-FP 1 and a monoclol/al antibody recognizing all BCR-ABLpro-
teins confirmed the specificity of ER-FP 1 for the eIa,jusion point. 
Int.-oduction 
The Philadelphia (Ph) chromosome (22q-) occurs in more than 90% of all patients 
with chronic myeloid leukemia (CML) (1). Although a marker for CML, the Ph chro-
mosome is not exclusively specific for CML. In acute lymphoblastic leukemia (ALL) 
the Ph clu'omosome is also observed (2). Here, the Ph chromosome is the most fre-
quently occurring chromosomal aberration with an incidence of25-30% in adult ALL 
and 2-5% in childhood ALL (3). Moreover, presence of a Ph chromosome in leukemic 
cells of ALL patients is associated with a poor prognosis (4,5). Therefore, accurate 
diagnosis of Ph-positive ALL is of utmost impOltance. 
The Ph translocation is the result of a reciprocal translocation between chromosomes 
9 and 22, t(9;22)(q34;qll) (6,7). 1\1'0 genes are involved in the translocation: theABL 
gene on chromosome 9 and the BCR gene on chromosome 22 (8). During the translo-
cation process both genes are interrupted and exchanged, resulting in a functional 
chimeric gene on the Ph chromosome comprising BCR and ABL sequences. Break-
points on chromosome 9 are scattered over a 200-kb distance but always found 5' of 
ABL exon a2 (8-10). In contrast, the chromosome 22 breakpoints are found to occur in 
two well defined areas of the BCR gene, either in the minor breakpoint cluster region 
(m-BCR) or in the major breakpoint cluster region (M-BCR) (11). The m-BCR is 
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localized in the intron between the first (el) and the second (e2) BCR exon (12,13). A 
break in the m-BCR results in a chimeric gene encoding a 190-kDa protein with an 
ela2 BCR-ABLjunction, ela,PI90"cR.A"L (14-16). The M-BCR spans a 5.S-kb region 
in the middle of the BCR gene including five exons (bl-b5). M-BCR breakpoints 
occur either between exon b2 and b3 or between exon b3 and b4 (S-IO). As a conse-
quence, two different chimeric genes are generated encoding 21O-kDa proteins with 
different BCR-ABLjunctions, b,a,P2IOBcR.ABL and b3a,P2IO"cR.A"L, respectively (17). 
B,a,P210BCR.ABL and b3a,P210BcR.ABL differ only in 25 amino acids encoded by the 
BCRexon b3. 
As described previously, the majOlity of the ALL patients with BCR-ABL realTangements 
express the ela2 BCR-ABL mRNA, Le. S5% of all children and 6S% of all adults 
(IS). This means that the ela,PI90BcR.ABL protein is a powelful tumor-specific marker 
for antibody diagnosis of Ph-chromo some-positive ALL. However, the chimeric mol-
ecule is composed of parts of the non-tumor-specific proteins, BCR and ABL. The 
only tumor-specific epitope of the protein is formed by the junction between BCR and 
ABL (19). 
In the present study we demonstrate the clinical and diagnostic potential of a monoclonal 
antibody, termed ER-FP1, which was raised against the ela, BCR-ABL junction in 
ela,PI90"CR.ABL. Our data indicate that ER-FPl specifically reacts with ela,PI90BCR.AHL in 
different test systems: using the tyrosine kinase assay, ela,P 190"cR.A"L is recognized in 
celllysates; inul1unofluorescence analysis allows detection of ela,_P190BcR.ABL at the 
single cell level. 
Materials and methods 
Cel/lilles 
TOM-I, BY 173 and K562 are Ph-positive cell lines derived from ALL (TOM-I) and CML 
patients, respectively (20-22). Monse SP2/0 cells were nsed as fusion partner for the produc-
tion of monoclonal antibodies. AU cell were cultured in RPM! medium supplemented with 
5% fetal calf serum. 
Patients 
Patient L. is a 52-year-old male ALL patient. He carried a standard Philadelphia transloca-
tion, t(9;22)(q34;qll). Diagnosis precursor B-ALL was based on immunologic and 
hematologic criteria at presentation. Blast cells were isolated by Ficoll-Hypaque centrifuga-
tion and after clyopreservation stored under liquid nitrogen. 
Patient W. is a 23-year-old male CML patient without evidence of a Philadelphia chromo-
some. However, as described by Hagemeijer el al. (23) (patient I) the BCR and l1BL genes 
were actually rearranged resulting in a chimeric b2a2BCR-ABL gene, localized on chromo-
some 9. Clinical and laboratory data are extensively described by Hagemeijer e/ al. (23). 
After T-cell depletion the blood cells were cryopreserved and stored under liquid nitrogen. 
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Peptide synthesis, pnrification and cO/vugation 
The following peptides were synthesized con'esponding to the respective BCR-ABL junc-
tions: 
SPeta2: H G D A E* A L Q R P V 
SPb1al: C N K E E* A L Q R P 
SPb3a2: C F K Q s S K* A L Q 
Residues indicated with an asterisk are newly fonned as a result of the translocation process. 
SPc,al was synthesized using Fmoc chemistty on an automated Millgen 9050 continuous 
Synthesizer (Millipore, Milford, MA, USA), SPb,a, and SPbla, were synthesized as described 
previously (24), All peptides were purified as described previously (24). 
Peptides were coupled to canier molecules either via l-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) or glutaraldehyde. 
Immunization amI production of ER-FPl hybridoma 
BALB/c mice were immunized with 25 ~g SPe,a, coupled via EDC to the carrier Keyhole 
Limpet Hemocyanin. The peptide-carrier complex was emulsified in Complete Freund's 
Adjuvant and injected in the hind footpad of the mice (25). After 4 weeks the mice were 
boosted i.p. with the same dose of antigen in hlcomplete Freund's Adjuvant. Three days after 
the booster the popliteal lymph nodes were removed and cell suspensions were made. For 
fusion, SP210 cells were mixed with immune lymph node cells at a ratio of 1 :2. Cell fusion 
was induced with PEG-4000 (72% w/v in RPM!). Next, the cells were spun down and 
resuspended in RPMI supplemented with 10% fetal calf senUll, 40 U IL-6/ml, hypoxanthine 
(104 M), azaserine (1 fLg/mI), 2-mercaptoethanol (5 x 10-' M) and antibiotics and plated in 
96-well culture plates at a density of 8 x 10' cells per well. ER-FP I was selected after screen-
ing of the supernatants for specific reactivity with the cognate peptide in an ELISA. Cell 
culture supernatant ofER-FPl was affinity purified using rat-anti-mouse-immunoglobulins 
coupled to Sepharose beads. ER-FPI is an IgG2a type antibody. 
ELlSA 
Reactivity of hybridoma supematant with synthetic peptides was tested in a sensitive micro 
ELISA system as previously described (24). ELISA trays were coated with 10 ~l of a dilu-
tion of 10 ~g/mi SPe,a, conjugated to BSA through glutaraldehyde. 
Antisem 
BP-ALL is a polyclonal antisemm raised in rabbits against the e,a2 BCR-ABL junction in 
e,a2P190IlcR-ABL (19). The anti-BeR antisenUll is a polyclonal antiserum raised against se-
quences encoded by the first HeR exon (24). 8E9 is a monoclonal antibody (IgGI) directed 
against ABL proteins (26). 8E9 is a generous gift of Dr J. Wang (University of California, 
San Diego, USA). 
Protein tyrosine kinase reaction 
Reactivity of monoclonal antibodies with native proteins was tested by an inullulloprecipitation 
followed by an auto phosphorylation reaction as described previously (24). Briefly, 
5-10 x 106 cells were lysed and incubated with monoclonal or polyclonal antibodies. To 
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precipitate the antigen-antibody complexes, protein-G Sepharose beads (Phannacia. Swe-
den) were used instead of protein-A Sepharose beads. The precipitation was followed by an 
autophosphOlylation reaction using 20 IlCi (y-["PJ) ATP. Next, the beads were washed, boiled 
in sample buffer and run at 6% polyacrylamide gels. Subsequently, the gels were dried and 
autoradiographed using Fuji (RX-NIF) films. 
Tralls/eclion 0/ COS cells 
COS cells were grown on sterilized glass plates at a density of I x 10' cells/cm'. Cells were 
transfected with pCDX plasm ids compdsing full lengths cDNA encoding e\a,PI90BCR-AB", 
b2a2P210BcR-ABL or bja2P210BcR-ABL, Transfection was mediated by calcium phosphate (27). 
Immullofluorescellce analysis 
Transfected COS cells grown on glass plates were fixed for 20 min by using a 3% 
para formaldehyde solution diluted in PBS at room temperature. Next, the cells were washed 
three times in phosphate-buffered saline (PBS) and penneabilized with 100% ice-cold metha-
nol for 20 min. After washing the cells twice in PBS, cells were blocked for 5 min in PBS-
0.5% BSA and incubated with first stage antibodies. All following reactions were carried out 
for 30 min at room temperature. Between the various incubations cells were thoroughly washed 
three times with PBS-0.5% BSA. The penneabilized cells were first incubated with the anti-
ABL monoclonal antibody 8E9 (IgG I). Subsequently the cells were incubated with an opti-
mal dilution of a fluorescein isothiocyanate (FITC) labeled goat anti-mouse IgG I (Southern 
Bioteclmology, Birmingham, USA). Next, ER-FPI (IgG2a) was applied, followed by an 
incubation with an optimal dilution oftetramethylrhodamine isothiocyanate (TRITC)-labeled 
goat anti-mouse IgG2a (Southern Biotechnology). 
Fluorescence was evaluated using a Zeiss fluorescence microscope. Two filter combinations 
were used: Zeiss filter combination 14 (BP 510-560; FT 580; LP 590) for the evaluation of 
TRITC labeling and Zeiss filter combination 19 (BP 484/20; FT 510; LP 515) for evaluation 
of FITC labeling. 
Results 
Billdillg of ER-FP110 jlll/ctioll-specific sYllthetic peptides 
ER-FPl was raised against the ela2 junction in e\a,PI90BcR-ABL. Reactivity with the 
cognate peptide SPe\a, was detelmined by using a micro-ELISA system. To detect in 
the same experiment any cross-reactivity ofER-FPl with ABL derived a2 amino ac-
ids, ER-FPI (21lg/ml) was preincubated overnight at 4 °C with or without various 
concentrations of the free peptides, SPb2a, or SPb,a2' As a positive control ER-FPl 
was preincubated with SPela2' The following day the samples were tested for residual 
anti-SPela2 activity in the ELISA system, in which the Terasaki trays were coated with 
SPel a2 conjugated to BSA. Figure I shows that a peptide dose-related inhibition of the 
antibody was observed. The ER-FPI reaction is reduced to lO% upon preincubation 
with the highest dose of peptide. In contrast, preincubation with either SPb2a2 or SPb,a2 
does not significantly influence binding ofER-FPl in the ELISA, indicating that ER-
FP-l does not recognize ABL derived a2 residues. 
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Figure 1 Relative binding of ER-FPl to BSA-glutaraldehyde-SPc]al in an ELISA after prein-
cubation of 2 J1g/ml ER-FPl with various concentrations SPc]al (a), SPb2a2 (..6.) or SPbJa2 (e) 
These data indicate that ER -FP 1 has a moderate, but specific affinity for the junction 
representing peptide SPela2. 
Binding of ER-FPl to native BCR-ABL chimeric proteins 
Binding of ER-FP 1 to native proteins was detemuned in an i1lllnunoprecipitation re-
action followed by autophosphOlylation. As source for BCR-ABL proteins ALL and 
CML cell lines were used, harbOling the respective chimedc proteins ela,PI90BcR.ABL 
(TOM-I), b,a,P21OBCR-ABL (BVI73), and b3a,P2lOBCR.ABL (K562). In Figure 2a re- pre-
sentative inununoprecipitation analysis with ER-FPI is shown. ER-FPI clearly pre-
cipitates a 190-kDa protein from the lysate of TOM-I cells, whereas no precipitation 
of either b,a,P210BCR-ABL or b3a,P210RcR-ABL can be observed in the lanes containing 
inullunoprecipitations of BVl73 or K562lysates. These results indicate that in the 
native protein the ela, BCR-ABL junction is recognized by ER-FP1. 
In order to exclude any reactivity ofER-FPI with ABL-derived a, sequences we per-
formed peptide inhibition studies with SPela, and other a, comprising sequences such 
as SPb,a, and Spb,a,. ER-FPI (1.8 l1g1ml) was incubated ovelllight with the respec-
tive peptides in various concentrations (200 l1g1ml and 20 Ilglml). Next, lysates of 
TOM-I cells were precipitated with the pre-absorbed ER-FPl. As positive control 
TOM-I cells were precipitated with ER-FPI without addition of peptides. As shown 
in Figure 3 reactivity ofER-FP 1 with ela,PI90BcR-ABL was abrogated completely after 
incubation with 200 l1g1ml SPela, (SPela" lane 1). After incubation with 20 glml SPela, 
only a faint band is visible (SPela" lane 2). However, preincubation with 200 l1g1ml 
SPb,a, or SPb3a, had no inhibiting effect on the precipitation of ela2PI9QBCR-ABL by ER-
FPI ( SPb,a, and SPb3a" lanes 1 and 2). 
From these results we conclude that ER-FPI reacts specifically with native protein 
ela,PI90BcR.ABL. Moreover, the reactivity is specific for the ela, junction and not di-
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rected against a, sequences, since binding of ER-FP I to e,a,P 190BCR-ABL is not inhib-
ited after preincubation with other peptides comprising a,-derived amino acids. 
K562 BV173 TOM-l o 2 2 2 
-
_ 11.111 _ II. -P190 
Figure 2 Figure 3 
Figure 2 Junction specificity analysis ofER-FPI. 10 x 106 TOM-I, K562 or BVl?3 cells were 
lysed and precipitated with 30 flg!ml ER-FPl. TOM-l cells express c,alPI90BcR.ABL. K562 cells ex-
press b3a2P21OBCR-AflL, and BV173 cells express b131P21OBCR-ABL 
Figure 3 Epitope specificity analysis of ER-FP I. 5 x 106 TOM-l cells (c,alP190BCR-ABL) were 
lysed and precipitated with either l.8 J.lg/ml ER-FPl (lane 0) or with 1.8 J..lg/ml ER-FPl after 
preincubation with synthetic peptides (SPc,a2. SPb131 or SPbJal) in various concentrations. ER-FP 1 
was preincubated with either 200 flg/ml (lanes 1) or with 20 J..lglml (lanes 2) 
Reactivity of ER-FPl with leukemic cells of all ALL (flld a CML patient 
In order to determine whether ER-FPI reacted with e,a,PI90BCR-ABL from freshly ob-
tained leukemic cells we incubated Iysates of blast cells from patient L. with ER-FPI. 
Blast cells were isolated from the peripheral blood of this patient by Ficoll-Hypaque 
centrifugation. Next, cells were lysed and incubated either with ER-FPI or, as control, 
with the e,a, junction-specific polyclonal antiserum BP-ALL. As a control T-cell de-
pleted blood cells derived from a Ph-negative CML patient with a b,a, rearranged 
BCR-ABL mRNA were analyzed. Figure 4a clearly shows that ER-FPI reacts with 
e,a,PI90BCR-ADL derived from leukemic blast cells of ALL patient L. (lane I). The 
reaction pattem obtained after precipitation with ER-FPI or with BP-ALL (lane 2) is 
highly similar. After incubation of celllysates of CML patient W. with ER-FPI no 
proteins were precipitated (Figure 4b, lane 2). However, patient W. actually expressed 
P2IOBCR-ADL proteins, since a strong P2IOBCR-ABL band was observed after precipitation 
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with an antisemm directed against the amino-terminal part of BCR (Figure 4b, lane 
I). These data indicate that ER-FPI also reacts highly specifically with the ela, BCR-
ABL junction in leukemic cells. As such, ER-FPI can be applied in ALL diagnosis 
using the tyrosine kinase assay. 
2 2 
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Figure 4 Imlllunoprecipitation analysis 
of ALL and CML patients. 10 x 106 Ficoll en-
riched leukemic blast cells of patient L. were 
lysed and precipitated with 30 ~g/m1 ER-FPI 
(panel (A). lane I) or 50 fil polyelonal antise-
rum BP-ALL (panel (A), lane 2). 20 x 106 T-
cell depleted blood cells of patient \V. were 
lysed and precipitated with 30 ~g/ml ER-FPI 
(panel (B), lane 2) or 50 fil polyclonal anti-BCR 
antiserum {panel (B), lane 1) 
Immunofluorescence analysis of ER-FPI was carried out on COS cells transfected 
with an expression plasmid (pCDX) containing a full length cDNA encoding 
ela,PI90BCR.ABL. As controls, COS cells were transfected with expression plasmids 
containing cDNAs encoding either b,a,P2IOBcR.ABL or b,a,P2IOBcR.ABL. To investigate 
whether ela,P190BcHBL was recognized by ER-FPl double immunological staining 
experiments were callied out using ER-FPI and the anti-ABL antibody 8E9. Binding 
ofER-FPI was visualized by applying a TRITC-Iabeled goat-anti mouse IgG2a. For 
the detection of anti-ABL binding, FITC-Iabeled goat-anti mouse was used. Figure 5 
shows fluorescence photographs of ela,P190BcR.ABL transfected COS cells after incu-
bation with ER-FPI (a) and anti-ABL (b). These micrographs show a stdking over-
lapping staining pattern indicating that the same molecules are detected by both 
monoclonal antibodies in a highly specific way. Most of the antibody binding is local-
ized in the cytoplasm associated with the cytoskeleton. Also, the illller smface of the 
cell membrane is intensely stained. Moreover, next to the nucleus a brightly fluores-
cent area is visible, probably indicating binding of the antibodies to the Golgi appara-
tus. Binding ofER-FPI to untransfected cells is at the background level. These cells 
also fail to show specific staining by the anti-ABL antibody 8E9 (Figure 5b). 
As a final specificity control, immunological staining experiments were perfOimed on 
P21OBCR.ABL transfected COS cells using ER-FPI and the anti-ABL antibody 8E9 (Fig-
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ures 5c - Sf). ER-FP I shows a weak background staining of all cells, either transfected 
or untransfected (Figure 5c, and 5e). The antibodies did not react with the P21 OBCR-ABL 
proteins, since the pattern obtained after ER-FPI incubation is completely different 
from the specific staining pattern with 8E9 (Figure 5d, and Sf). Staining with 8E9 
shows that P2IOBCR-ABL and P190BCR-ABL both have the same highly characteristic sub-
cellular localization. 
From these data we conclude that native ela2P190BCR-ABL is recognized by ER-FPI in a 
highly specific way at the single cell level. 
Figure 5 Immunofluorescence analysis of ER-FPI. COS cells were transfectcd with pCDX 
plasmids comprising full length eDNA encoding cta2PI90BCR-ABL (a) and (b), b2a2P2IOBcR.AIlL (c) and 
(d) and bJa2P2IOBCR-ABL (e) and (f). Transfected cells were double-labeled with ER-FPl, detected with 
TRITe-labeled goat-anti mouse IgG2a (a), (c), and (e) and with anti-ABL antibody SE9, detected with 
FITC-Iabeled goat-anti mouse IgG I (b), (d) and (I) 
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Discussion 
The Philadelpia chromosome is the most frequently occurring chromosomal aberra-
tion in ALL (3). Because this type of leukemia has a bad prognosis in comparison 
with Philadelphia-negative ALL, accurate diagnosis is highly important. To this pur-
pose, several techniques are now available, either detecting the Ph chromosome or the 
molecular reatl'angement caused by the translocation. 
In the past years we have focussed on the detection of the vat'ious BCR-ABL chimeric 
proteins, i.e. ela,P190BCR.ABL, b,a,P21OBcR-ABL and b,a,P21OBCR-ABL. We have demon-
strated that the BCR-ABL junctions in all chimeric proteins at'e expressed as anti-
genic determinants on the respective proteins (19, 24, 28). In these studies we raised 
polyclonal antisera directed against synthetic peptides cOlTesponding to their respec-
tive BCR-ABL junctions. 
Now we report on the reactivity of a monoclonal antibody ER-FP I, raised against a 
synthetic peptide cotTesponding to the ela, BCR-ABLjunction in ela,P190BcR.ABL. We 
show evidence that ER-FPl reacts specifically with ela, peptides in an ELISA as well 
as with native ela,P190BcR-ABL molecules in immunoprecipitation experiments. 
Specificity of ER-FPl was fmiher confirmed in both systems by peptide inhibition 
studies. ER-FPl could also be applied in immunofluorescence analysis. COS cells 
transfected with DNA encoding the complete ela,P190BCR-ABL protein were stained 
with ER-FPl. The staining pattern of ER-FPl was strikingly sinillar to the staining 
pattern obtained after staining transfected COS cells with a monoclonal antibody against 
ABL, indicating that the same molecules were recognized. Our results on the localiza-
tion of ABL proteins correspond closely to eat'lier repotis by van Etten et al. (29) and 
McWhitier and Wang (30, 31). These authors describe association of activated-ABL 
proteins with the cytoskeleton, resulting in a fine reticular staining pattern. For the 
first time our data show specific reactivity with native chimeric proteins at the single 
cell level. This study indicates that the antigenic determinant formed by the ela,junc-
tion, is saved by our fixation procedure. 
We have performed innnunofluorescence and flow cytometry studies with ER-FPI 
with CML and ALL cell lines using this protocol as well (data not shown). Unfortu-
nately, in these experiments we only observed a very strong background staining in all 
cells, either comptising P190BCR.ABL or P21OBCR-ABL. A feasible explanation for tltis 
phenomenon is that the expression of ela,P190BcR-ABL is too low in ALL cell lines, 
where specific staining does not rise above background. Altematively, it is possible 
that the same epitope fotmed by the ela,junction in P190BCR.ABL is also expressed by 
other, yet unknown, intracellular proteins. In Western blotting experiments we ob-
served binding of ER-FPl to many proteins, which could cause the background im-
munofluorescence (data not shown). However, compating both the immunofluorescence 
and the Western blotting data is not quite cOlTect, because ela,P19QBCR-ABL is not recog-
nized by ER-FPl on the Western blot. Nevertheless, whenever cross-reacting epitopes 
are specifically recognized by ER-FPI, diagnosis of Ph-positive ALL by using ER-
FPI in standard immunofluorescence techniques will be difficult. More refined im-
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munofluorescence analysis by which specific staining patterns can be observed, e.g. 
using confocallaserscanmicroscopy, might resolve tins problem. Preliminmy results 
of such an experiment in which we performed double-labeling ofP 190BCR.ABL positive 
and negative cells with ER-FPI and anti-actin, indicate that there is co-localization of 
e,a,PI9O"CR.ABL witil actin (data not shown). Also in PI9O"CR.ABL negative cells we observed 
co-localization. However, the number of double-positive cells and the intensity of the 
fluOl=ence was higher in the P 19O"CR.ABL positive cells than in tile P 19O"CR-ABL negative cells. 
The background staining both in the P 19oscR.ABL 
positive and in the PI90BCR.ABL negative cells revealed a fine granulm' staining pattem 
in the nucleus and in the cytoplasm, whereas the double stained material was closely 
related under the cell membrane. Further analysis of the co-localization pattern, which 
is present in almost all Pl90BcR.ABLpositive and in a small number ofP210BCR.ABL cells, 
may provide, in the future, the answer to the specific detection ofPI90BCR.ABL in rou-
tine immunofluorescence studies of tumor cells. 
In summary, at present utilization of ER-FPI in diagnosis of Philadelphia-clu'omo-
some-positive ALL is Iinnted to the tyrosine kinase assay. To apply ER-FPI in routine 
immunofluorescence diagnosis, more work is needed to solve the background prob-
lem and to selectively filter out and enhance the double-labeling signal. 
Acknowledgements 
11lis work was suppDlted by the Netheriarlds Cancer Foundation (Stichting Koningin Wilhelmina 
Fonds), grant number IKR 90·22. The authors gratefully acknowledge Tar van Os for excellent 
photographic assistance. We thank Dr Jean Wang for the 8E9 antibody and Dr 11'0 Touw for 
providing the cells of patients L. and W. We are indebted to Judith Boer and Mamten Fornerod 
for their help in the COS cell transfection assay. 
References 
1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Sci-
ence 1960; 132: 1497 
2. Sandberg A. Kohno S, \Vake N, rvlinowada 1. Chromosomes and causation of human cancer and 
leukemia. XLII. Ph' positive ALL: an entity within myeloproliferative disorders? Cancer Genet 
Cytogenet 1980; 2: 145·174 
3. Priest JR, Robison L. McKenna R\V, Lindquist LL, \Varkentin PI, LeBien TW, \Voods \VG, Kersey 
JH, Coccia PF, Nesbit ME. Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 
1980; 56: 15·22 
4. Bloomfield CD, Goldman AI, Alimena G, Berger R, Borgstrom GH, Brandt L, Catavsky 0, de la 
ChapelleA, Dewald GW, Garson OM, GarwiczS, Golomb HM, Hossfeld DK, L'1wlwr SO, Mittelman 
F, Nilsson P, PietTe RV, Philip P, Prigogina E, Rowley JD, Sakurai M, Sandberg AA, Secker \Valker 
LM, Tricot G, Van den Bergh H. van Orshoven A, Vuopio P, Whang-Peng J. Chromosomal abnor-
malities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 1986; 
67: 415-420 
5. Crist WA, Carroll A, Shuster J, Jackson J, Head 0, BorowitzM, BehmF, Link M, Steuber P, Ragab 
A, Hilt A. Brock B, Land V, Pullen J. Philadelphia chromosome positive childhood acute lymphob-
Recogllitioll of P J90BeR.ARI. by ER-FP 1 109 
lastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A pediatric oncol-
ogy group study. Blood 1990; 76: 117-122 
6. Rowley JD. A new consistent chromosomal abnonnality in chronic myelogenous leukemia identi-
fied by quinacrine fluorescence and Gicmsa staining. Nature 1973; 243: 290-293 
7. de Klein A, Geurts van Kessel A. Grosveld G, Bartram CR, Hagcmeijer A, Bootsma D. Spurr NK, 
Heisterkamp N, Groffcn J, Stephenson JR. A cellular oncogene is translocated to the Philadelphia 
chromosome in chronic myelocytic leukemia. Nature 1982; 300: 765-767 
8. Heisterkamp N, Stephenson JR, Groffcn], Hanscn PF, de Klein A, Bartram CR, Grosveld O. Locali-
zation ofthec-ablollcogene adjacent to a translocation breakpoint in chronic myelocytic leukaemia. 
Nature 1983; 306: 239-242 
9. Grosveld G, Verwoerd T, van Agthoven T, de Klein A, Ramachandran KL, Heisterkamp N, Stam K, 
Groffen J. TIle chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chi-
meric ber-abl transcript. Mol Cell Bio11986; 6: 607-616 
to. Shtivelman E, Lifshitz B, Gale RP, Roe EA, Canaalli E. Alternative splicing of RNAs transcribed 
from the human obI gcne and from the her-obi fused gene. Cell 1986; 47: 277-284 
11. Gale RP, GoldmanlM. Rapid progress in Chronic Myelogenous Leukemia. Leukemia 1988; 2: 321-
324 
12. Hennans A, Heisterkamp N, von Lindem M, van Baal S, Meijer D, van der Pbs D, Wiedemann L, 
Groffen J, Bootsma D, Grosveld G. Unique fusion of her and c-abl genes in Philadelphia chromo-
some positive acute lymphoblastic leukemia. Cell 1987; 51: 33-40 
13. Hermans A, Gow J, Selleri L, von Lindem M, Hagemcijer A, Wiedemann L, Grosvcld G. Bcr-abl 
oncogene activation in Philadelphia Chromosome-positive acute lymphoblastic leukemia. Leukemia 
1988; 2: 628-633 
14. Clark SS, McLaughlin J, Crist WM, Champlin TR, Witte 0. Unique fonns of the ABL tyrosine 
kinase distinguish Ph positive CML from Ph positive ALL. Science 1987; 235: 85-88 
15. Chan LC, Karhi KK, Raytcr SI, Heisterkamp N, Eridalli S, Powles R, Lawler SD, GroffenJ, Foulkes 
JG, Greaves MF, WiedemanIl LM. A novell ABL protein expressed in Philadelphia chromosome 
positive acute lymphoblastic leukemia. Nature 1987; 325: 635-637 
16. Kurzrock R, Shtalrid M, Romero P, Kloetzer \VS, Talpaz M, TrujiloJM, BlickM, BeranM, Guttennan 
m. A novel c-ABL protein product in Philadelphia positive acute lymphoblastic leukemia. Nature 
1987; 325: 631-635 
17. Bcn-Ncriah Y, Daley GQ, Mes-Masson AM, \Ville 0, Baltimore D. The chronic myelogenous leuke-
mia-specific P210 protein is the product of the ber-abI hybrid gene. Science 1986; 233: 212-214 
18. Maurer J, Janssen L\VG, Thiel E, van Dcndcren J, Ludwig J, Aydemir 0-, Heinze B, Fonatsch C, 
Harbott J, Reiter A, Riehm H, Hoelzer D, Battram CR. Detection of chimeric her-abl genes in acute 
lymphoblastic leukemia by the polymerase chain reaction. Lancet 1991; 337: 1055-1058 
19. van Denderen J, van der Plas D, Meeuwsen T, Zegers N, Boersma \V, GrosveJd G, van Ewijk W. 
Immunologic characterization of the tumor-specific BCR-ABL jUllction in Philadelphia chromo-
some-positive acute lymphoblastic leukemia. Blood 1990; 76: 136-141 
20. Lozzio CE, Lozzio BB. Human chronic myelogenous leukemia ccll line with positive Philadelphia 
chromosome. Blood 1975; 45: 321-334 
21. Pegoraro L, MateraL, Ritz J, Levis A, Palumbo A, Biagini G. Establishment of a Ph-positive human 
cell line (BYI?3), J Natl Cancer Inst 1983; 70: 447-454 
22. Okabe M, Matsushima S, Moriaka M, Kobayashi M, Abe S, Sakurada K, Kakinuma M, Miyazaki T. 
Establishment and characterization of a cell line, TOM-I, derived from a patient with Philadelphia 
chromosome-positive acute lymphoblastic leukemia. Blood 1987; 69: 990-998 
23. Hagemeijer A, Euijs A, Smit E, Janssen B, Creemers G-J, van der Plas D, Grosveld G. Translocation 
110 Chapter 7 
of ber to chromosome 9: a new cytogenetic variant detected by FISH in two Ph negative, bcr-
positive patients with chronic myeloid leukemia. Genes Chrom Cancer 1993; 8: 237-245 
24. van Denderen J, Hennans A, Meeuwsen T, Troelstra C, Zegers N, Boersma 'V, Grosveld G, van 
Ewijk W. Antibody recognition of the tumor-specific BCR-ABL joining region in chronic myeloid 
leukemia. J Exp Med 1989; 169: 87-98 
25. Mirza IH, Wilkin TJ, Cantarini M, Moore K. A comparison of spleen and lymphnode cells as fusion 
pmtners for the raising of monoclonal antibodies after different routes of immunisation. J Imm Meth 
1987; 105: 235-243 
26. Richardson 1M, Marla AO, Wang JYJ. Reduction of protein tyrosine phosphorylation dUling differ-
entiation of human cell line K562. Cancer Res 1987; 47: 4066-4070 
27. Chen C, Okayama H. High efficiency tranSfOlTIlation of mammalian cells by plasmid DNA. Mol 
Cell BioI 1987; 7: 2745-2752 
28. van Denderen J, ten Hacken P, Berendes P, Zegers N, Boersma 'V, Grosveld G, van Ewijk \Y. 
Antibody recognition of the tumor-specific b3-a2junction in BCR-ABL chimeric proteins in Phil a-
delphia-chromosome-positive leukemias. Leukemia 1992; 6: 1107-1112 
29. van Etten RA, Jackson P, Baltimore D. TIle mouse type N c-abl gene product is a nuclear protein, 
and activation of transfonlling ability is associated with cytoplasmic localization. Cell 1989; 58: 
669-678 
30. McWhirter JR, \Yang JYJ. Activation of tyrosine kinase and microfilament-binding functions of c-
ABL by BCR sequences in BCR-ABL fusion proteins. Mol Cell BioI 1991; II: 1553-1565 
31. McWhirter JR, \Yang JYJ. An actin-binding function contributes to transfomlation by the BCR-
ABL oncoprotein of Phi In delphia chromosome-positive hunmn leukemins. EMBO J 1993; 12: 1533-
1546 
Chapter 8 
The BCR-ABL dipstick assay: a simple and rapid method 
for detecting Ph+ leukemias 
P. Berendes
'
, J. Veen1l1an', J. van Denderen2 and W. van Ewijk' 
IDeparfment of 1I1lmU1101og)~ Erasmlls University Rotterdam, Rotterdam; and lDeparlmcnt of 
Pathology, Academic Hospital \lrije Ulli\'crsiteit, Amsterdam, The Netherlands 

113 
The BCR-ABL dipstick assay: a simple and rapid method for 
detecting Ph+ leukemias 
The reciprocal translocation t(9;22)( q34;qIl), observed in chronic myeloid leukemia 
(CML), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML), 
resultsfromfusion between two genes: BCR and ABL. Depending on the localization 
of the breakpoint in the BCR gene, different tumor-specific BCR -ABL genes are gen-
erated. These BCR-ABLgenes are transcribed and translated illlo tumor-specific BCR-
ABL mRNAs and tumor-specific BCR-ABL proteins, respectively. Therefore, different 
diagnostic targets are available, each allowing for specific diagnosis oft(9;22) posi-
tive leukemias. While conventional cytogenetics relies on the detection of the charac-
teristic chromosomal aberration (i.e. the Philadelphia chromosome: a minute 
chromosome 22q-), other techniques are used to specifically detect the BCR-ABL 
fusion-gene (e.g. fluorescent in situ hybridization) or the BCR-ABLfilsionmRNA (e.g. 
reverse transcriptase polymerase chain reaction). Although all of the aforementioned 
techniques are ",ell established and reliable, none of these techniques can be easily 
pel/armed on a routine and short-term basis. Yet, especially in ALL, presence of the 
Ph chromosome is associated with poor prognosis. To improve the poor prognostic 
outcome, Ph positive ALLs require early identification to permit intensive induction 
regimens or altel'llative treatlllent protocols. 
We present a ne", diagnostic technique, termed 'the BCR-ABL dipstick assay'. This 
technique is based on the exclusive detection of BCR -ABL proteins and is designed to 
identify Ph' leukemias at first diagnosis in a rapid and simple fashioll. The principle 
and the applications of the BCR-ABL dipstick assay are evaluated and discussed in 
view of current diagnostic methods. 
Introduction 
The Philadelphia chromosome (Ph): a minute chromosome 22q-, originally identified 
by Nowell and Hungerford in 1960 (1), was the first karyotypic aberration found to be 
tumor-related (1,2). To date, the Ph cln'omosome is identified in various hematopoietic 
disorders, e.g. chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), 
and acute myeloid leukemia (AML), in both adults and children (3). 
The Ph chromosome is generated by the reciprocal translocation between the long 
arms of chromosome 9 and 22: t(9;22)(q34;qll) and involves the ABL gene on chro-
mosome 9 and the BCR gene on cln'omosome 22 (3). Both genes are interrupted and 
rearranged, resulting in a tumor-specific BCR-ABL fusion-gene on chromosome 22q-
and a tumor-specific ABL-BCR fusion-gene on chromosome 9q+. 
While reports on the ABL-BCR fusion-gene are still limited (4), BCR-ABL fusion-
genes have been extensively studied over the past two decades. Depending on the 
chromosomal localization of the breakpoints, different BCR-ABL fusion-genes can be 
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identified, Although breakpoints are scattered over long distances in the ABL gene, 
they mostly occur 5' of exon a2 (5), In contrast, breakpoints in the BCR gene are 
clustered within two regions: a major breakpoint cluster region (M-BCR), comprising 
five exons termed bl to b5 (6, 7, 8), and a minor breakpoint cluster region (m-BCR), 
located 5' of the M-BCR in the BCR gene (9), 
In most CML patients and in approximately 30% of Ph' ALL patients (10, II), break-
points are evenly distributed in the M-BCR: either located between exon b2 and b3 or 
located between exon b3 and b4 (12,13, 14), Breakpoints in Ph' ALL are in majority 
(± 70%) found within the m-BCR region (10, II), localized in an intron between exon 
el and e2, As breakpoints are scattered over long distances (especially in the ABL 
gene), different fusion-point introns inBCR-ABL genes m'e generated, AlthoughBCR-
ABL genes m'e highly vm'iable between Ph' patients when considering the BCR-ABL 
fusion-point intron's length and nucleotide sequence, fusion-points ofBCR-ABL tran-
scdpts m'e highly consistent. Thus, depending on the original BCR -ABL gene rear-
rangement, a single BCR-ABL mRNA is usually detected: a 7 kb mRNA comprising 
an e I a2 junction (9) or, a 8,5 kb mRNA that either comprises a b2a2 or a b3a2 junc-
tion (12, 14), Since the translational reading frames in the processed chimeric BCR-
ABL mRNAs are maintained, chm'acteristic chirnedc BCR-ABL proteins m'e expressed 
by Ph' leukemic cells, Based on the variation of the BCR-ABL fusion-point, either 
ela,PI90BcR.ABL, b,a,P2IOBcR.ABL or b3a,P21OBcR.ABL proteins are detected (15, 16). 
While Ph cln'omosomes are almost invariably present in CML cases, Ph chromo-
somes are less often detected in leukemic cells from patients suffering from AML or 
ALL. Still, 5% of AML cases, 25% to 30% of adults with ALL and 3% to 5% of 
children with ALL are diagnosed as Ph positive (17,18), Reflected by a high rate of 
treatment failure and mortality in Ph' leukemias, in both adults and children, Ph chro-
mosomes are halhllmked as significant risk-factors considering treatment failure (19, 
20), The inlportance of identifying risk-features, such as the Ph chromosome, is be-
yond doubt. Cunent treatment protocols may be improved through the identification 
of the t(9;22) at an early time-point of the disease. At present, Ph' leukemias are 
identified by a number of techniques, either detecting the abenant chromosome, the 
gene, the mRNA or the aberrant protein, Yet, each of these techniques is characterized 
by typical specifications and limitations which should be considered before diagnos-
ing t(9;22)(q34;qll) positive leukemias (21), 
In this study we report on a new diagnostic technique: the BCR-ABL dipstick assay, 
TillS assay was developed to discriminate between Ph' leukemias and Ph' leukemias 
at diagnosis in a relatively rapid and simple fashion. The underlying principle of the 
BCR-ABL dipstick assay is based on the exclllsive detection of tumor-specific BCR-
ABL proteirls. The principle and the applications of the BCR-ABL dipstick assay are 
evaluated and discussed in view of currently used diagnostic methods, 
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Materials and methods 
Cell samples 
Cell lines: Six Ph' cell lines were used to examine the specificity of both the sepharose-
Western blotting procedure as well as the BCR-ABL dipstick assay: two b]a, Ph' cell lines: 
LAMA-S4 (22) and K562 (23), two b,a, Ph' cell lines: KCL-22 (24) and BV-173 (25), and 
two e,a, Ph' cell lines: TOM-I (26) and ALLIMIK (27). 
All cell lines were cultured in RPMI-1640 supplemented with 10% fetal calf senllll. 
Leukemic cell samples: 1\vo leukemic cryopreserved peripheral blood samples from leuke-
mic patients at diagnosis were used to examine the specificity of the BCR-ABL dipstick 
assay. Clinical and laboratory data ofthese patients have been described previously (28, 29): 
one patient suffered from a Ph' CML, with reananged b,a, BCR-ABL genes, the other suf-
fered from a Pit precursor B-ALL, with realTanged Cla2 BCR-ABL genes. 
Antibodies 
All antibodies used were protein G purified and categorized as: 
Catching antibodies: monoclonal antibody (moAb) 7C6 (a generous gift from Dr S Dhut), 
directed towards the brcpitope present in b2a2P210BcR.ABL, bJa2P210BcR-ABL, P160BCR and 
PI30,cR (30); moAb ER-FPI, directed towards the e,a, fusion-point in e,a,PI 90'CR.ABL (28) 
and; moAb Yae (Santa Cruz Biotechn., Santa Cruz, CA, USA) directed towards the amino-
terminus of E2A proteins (31). 
Detecting alllibodies: moAb SE9 (a generous gift from Dr J Wang), directed towards the 
SH2 domain present in c,u1P 190BCR.ABL, b1aZP 190BCR-ABL, b)a2P 190BCR-ADL and P 14SABL (32) 
and; moAb G98-271.1.3 (a generous gift from Dr G Bain) directed towards the carboxyl 
terminus of E2A proteins (33). 
Both moAb SE9 and moAb G98-27 I. 1.3 were biotinylated according to a procedure de-
scribed by Bayer (34). 
Sepho/'Ose-Westel'l/ blotting procedure 
Cells were washed twice with ice-cold phosphate buffered saline (PBS) and lysed in ice-cold 
lysis buffer (I % Triton X-100, 0.05% sodium dodecyl sulfate (SDS), 150 mM NaCI, 5 mM 
EDTA in 10 mM sodium phosphate, pH 7.0), supplemented with 40 III phenyl methyl sulfonyl 
fluoride (PMSF: 100 mM in 2-isopropanol) at a concentration of I x 107 cells/ml for 15 min. 
After the Iysates were centrifuged in an Eppendorf centrifuge to remove insoluble material (5 
min 4 °C), supematants were split into equal volumes, each representing 1 x 107 cells. 
Sepharose-Western blotting was performed by adding either 10 Ilg moAb 7C6 or 21lg moAb 
ER-FPI to the supernatant of lysed cells. Antigen-antibody reaction was allowed for two 
hours on a rotation device at 4°C. Next, 40 Jll of an 80% (v/v) suspension of GanuuaBind G 
sepharose beads (Pharmacia Biotech AB, Uppsala, Sweden) were added. After 30 min, beads 
were collected and washed three times in lysis-buffer without SDS. Beads were boiled for 5 
min in 60 III sample buffer (60 111M TRIS-HCI, pH 6.8, 10% glycerol, 10 mM EDTA, 2% 
SDS, 2% ~-mercaptoethanol aud 0.03% bromophenol blue). Proteins samples (10 Ill/well) were 
subjected to 6% SDS-PAGE and transferred (Mini Protean; Bio Rad, Richmond, CA, USA) 
to nitrocellulose (0.45 llm pore size; Schleicher & Schuell, Dassel, Germany). Nitrocellulose 
sheets were blocked in 5% non-fat dlY milk powder (Protifar, Nutricia, The Netherlands) in 
PBS supplemented with 0.05% Tween-20 (5% MPBS). 
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Next, sheets were incubated for two hours at room temperature in the presence ofbiotillylated 
moAb 8E9 (2 Ilg/ml) in 1% MPBS. Following three washes with PBS supplemented with 
0.05% Tween-20, alkaline phosphatase conjugated to streptavidin (South. Biotechn. Ass., 
Binnillgam, AL, USA) was added to a 1: 1500 dilution and incubation was allowed to pro-
ceed for one hour. The blot was washed twice with PBS supplemented with 0.05% 1\veen-20 
and finally with 0.15 M veronal acetate, pH 9.6. For visualization of antibody-antigen C0111-
plexes we used the alkaline phosphatase substrate nitro blue tetrazoliUlll / 5-bromo-4-
chloroindoxyl phosphate (NBT/BeIP; Sigma, St Louis, MO, USA) as described by Blakeet 
al. (35). 
BCR-ABL dipstick melhod 
Each catching antibody was applied as a single small spot to a (± 2 em x 0.5 em) nitrocellu-
lose (0.45 fun pore size) strip and air dried. Each spot contained either 2 Ilg of moAb 7C6, I 
Ilg moAb ER-FPI or I fIg moAb Yae. Next, these nitrocellulose strips, called 'dipsticks', 
were rinsed in PBS supplemented with 0.05% 1\veen-20 and subsequently blocked in 5% 
MPBS (l h, RT). At tlus point, dipsticks can be air dried and stored in an airtight container at 
4 °c until further use. 
Supematants of cellular lysates (processed as described in the fIrst paragraph of the above sec-
tion), representing I x 10' cells, were added to the dipsticks. Antigen-antibody complex for-
mation was allowed to proceed ovemight at 4 °c on a rotation device. Next, dipsticks were 
rinsed three times in PBS supplemented with 0.05% 1\veen-20 and bound antigens were 
detected by incubating the dipstick with a mixture ofbiotinylated moAb 8E9 (2 ~g/ml) and 
biotinylated moAb G98-27 1. 1.3 (2 ~g/I1lI), diluted in 1% MPBS. From this point on, dip-
sticks were fm1her processed as described in the matellals and method section of the sepharose-
Western blotting procedure. 
Results 
Ryclusive recognition of BCR-ABLproteins ill a sepliarose-lVestem blotting procedure 
To determine whether the tumor-specific BCR-ABL fusion-proteins can be exclu-
sively recognized by immunologic methods, we developed a sepharose-Western blot-
ting procedure. A sepharose-Western blotting procedure is a combination of an 
immunoprecipitation reaction with a catciling antibody, followed by a Westem blot-
ting procedure with delecting antibodies. 
According to this procedure, we examined the combination of moAb 7C6 and moAb 
8E9 as catching and detecting antibody, respectively. MoAb 7C6 specifically recog-
nizes the b,-epitope present in b,a,P2IOHcR.ABL, b,a,P2IOBcR.ABL, P160BCR and Pl30BCR 
proteins (30), while moAb 8E9 recognizes the SH2-domain present in both ABL pro-
teins and BCR-ABL proteins (32). Given the specificity of both moAbs, one would 
expect that BCR-ABL proteins from cellular lysates of either b,a,P210BcR.ABL or 
bJa,P2IOBCR.ABL containing cell lines are recognized by the successive action of moAb 
7C6 and moAb 8E9. To examine the specificity of the combination of moAbs 7C6 
and 8E9, lysates from different cell lines, each harboring a distinctive BCR-ABL 
protein, were employed. 
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Figure 1 Sepharose-Western blotting experiments demonstrating the exclusive recognition of 
BCR-ABL proteins by the antibody combinations: moAbs 7C6/8E9-bio (a) and moAbs ER-FP1I8E9-
bio (b), respectively. MaAhs 7C6 and ER-FPl were used as 'catching' antibodies, precipitating pro-
teins from cellular lysates of LAMA-84 (bJa2P21OBcR-ABL positive celilillc), KCL-22 (bla2P21OBCR-ABL 
positive cell line) or TOM-! (cla2P190BCR-ABL positive ccllline). Cell lines are indicated at the top of the 
blots. Following illUllUlloblotting, precipitated proteins were detected by the successive use of 
biotinylated moAbs 8E9 as 'detecting' antibodies and alkaline-phosphatase conjugated to streptavidin. 
(a) Shows the exclusive recognition of b3azBCR-ABL proteins and bzazBCR-ABL proteins in the 
moAb 7C6 inmllillo-precipitates from cellular lysates of LAMA-84 and KCL-22, respectively. No 
proteins are detected in the 7C6 immuno-precipitate from the lysate of TOM-J cells by biotinyJated 
moAb 8E9. 
(b) Shows the exclusive recognition ofeja2BCR-ABL proteins in theER-FPI immunoprecipitate from 
the TOM-l ceil line. No proteins are detected in the moAb ER-FPl immunoprecipitates from the 
LAlvlA-84 nor from the KCL-22 cell lines by biotinylated moAb 8E9. 
Figure la represents a Western blot of proteins from: (I) LAMA-84 (b3a,P21OBcR.ABL 
positive cell line), (2) KCL-22 (b,a,P2lOBcR.ABL positive cell line) and (3) TOM-I 
(ela,PI90BCR.ABL positive cell line), precipitated by moAb 7C6 and ensuingly detected 
by biotinylated moAb 8E9 and streptavidin-AP. As expected, this procedure leads to 
the detection ofP21OBCR.ABL proteins (Figure la; lanes I and 2). 
Howevel; besides the recognition of P21OBCR.ABL proteins, the moAb 7C6/8E9-bio 
combination also detects proteins with a molecular weight of 190 kDa from cellular 
lysates of LAMA-84 and KCL-22 (Figure la; lanes I and 2). Dlmt et al. and Guo et al. 
both reported on the detection of this abelTant P 190 protein by moAb 7C6 and moAb 
8E9, respectively (30, 32). Given the specificity of both antibodies: I) moAb 7C6, 
exclusively recognizing the b,-epitope present in b,a,P21OBCR.ABL, b3a,P210"CR.ABL, PI60BCR 
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and P130BCR and 2) moAb SE9, recognizing the SH2-domain present in BCR-ABL 
and ABL proteins, we deduce that the aberrant PI90 represents a BCR-ABL protein 
that contains a b,-epitope. Moreover, the aberrant PI90BCR-ABL, detected in Iysates of 
b,a,P21OBCR-ABL or b,a2P210BcR-ABL containing cell lines, is not observed upon a 
sepharose-Western blotting procedure performed with the moAb 7C6/SE9-bio com-
bination inlysates from cells of an ela,PI90BCR-ABL containing cell line, i.e. TOM-I 
(Figure la; lane 3). 
111erefore, we conclude tlmt the moAb 7C6ISE9-bio combination allows fortlleexc/ltsil'e identi-
fication of BCR-ABL proteins from cellulm'lysates ofb,a,P21OBcR-ABL or b,a,P2lOBcR-ABL 
positive cell lines. 
To determine whether the tumor-specific ela2PI90BCR-ABL proteins can be exclusively 
identified, we used moAbs ER-FPI and SE9-bio, as catching antibody and detecting 
antibody, respectively. MoAb ER-FPI specifically recognizes the tumor-specific fu-
sion-point of ela2P 190BCR-ABL proteins. However, this pmticulm' epitope is probably 
also present on other cellular proteins (2S). Therefore, a specific recognition of 
ela,PI90BCR-ABL proteins can only be expected through a combination of the catching 
ER-FPI antibody and the biotin labeled, detecting antibody moAb SE9. We immuno-
precipitated proteins from cellular Iysates of LAMA-S4 ( b,a2P21OBCR-ABL positive), 
KCL-22 (b,a,P2lOBcR-ABL positive) and TOM-I (ela,PI90BCR-ABL positive) by moAb 
ER-FPl. The precipitated proteins were detected by biotinylated moAb SE9 in a West-
ern blotting procedure. 
Figure Ib shows the detection of ela,P190BcR-ABL proteins by the ER-FPI/SE9-bio 
antibody combination of antibodies (lane 3). Neither b,a2P210BCR-ABL (Figure Ib; lane 
I) nor b,a2P21OBCR-ABL (Figure Ib; lane 2) proteins are visible, nor is any other cross-
reactive protein (either immunoprecipitate, Figure I b; lanes I to 3). 
Therefore, the combination of moAbs ER-FPI and SE9-bio allows for the exclusive 
recognition of ela,P 190BCR-ABL proteins. Moreover, the aberrant P 190 protein, detected 
by the moAb 7C6/SE9-bio combination in b,a,P21 O"CR-ABL positive cell lines and 
b,a2P21OBcR-ABL positive cell lines (Figure la; lanes I and 2), is not recognized by the 
moAb ER-FPlISE9-bio combination. This further substantiates our notion that the 
aberrant PI90"CR-ARL protein as detected by the 7C6/SE9-bio combination does not 
represent ela,PI90BCR-ABL. 
In conclusion, our sephm'ose-Western blotting data verify that tumor-specific BCR-
ABL proteins m'e exclusively identified by the appropriate choice of monoclonal an-
tibodies. 
Exclusive recognition of BCR-ABL proteills ill a dipstick assay 
We next investigated whether the sepharose-Westel11 blotting procedure could be sim-
plified. By using the same sets of antibodies as were used in the sepharose-Western 
blotting experiments, we examined the possibilities of an alternative BCR-ABL de-
tection system, termed: the 'BCR-ABL dipstick assay'. 
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The BCR-ABL dipstick assay was designed for the exclusive detection ofBCR-ABL 
proteins, allowing detection and discrimination between b,a,P21ODCR-ABL or b,a2-
P21OBCR-,\BL proteins on the one hand and ela2PI90DCR-ABL proteins on the other. A 
control for proper assay development was also included in case a Ph- sample would be 
investigated. 
The BCR-ABL dipstick is made of nitrocellulose strips on which tln'ee different anti-
bodies are immobilized: I) moAb 7C6 (recognizing the b2 epitope present in 
b,a2P21OBcR-ADL, b,a2P2lOBCR-ABL, PI60DCR and PI30BCR), 2) moAb ER-FPI (recogniz-
ing the ela, fusion-point epitope present in ela2P 190BCR-ABL) and 3) moAb Yae (recog-
nizing the amino-terminus of the ubiquitously expressed transcription factor E2A). 
To investigate whether the BCR-ABL dipstick can be used for the specific detection 
ofBCR-ABL proteins, BCR-ABLdipsticks were either incubated with cellular Iysates 
from: I) LAMA-84 (b,a,P2lODCR-ABL positive cell line), 2) KCL-22 (b,a,P21ODCR-ABL posi-
tive cell line) or 3) TOM-I (ela2PI90BCR-ABL positive cell line). Cellular proteins that 
had been caught by the immobilized antibodies on the BCR-ABL dipstick were de-
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Figure 23 Specificity analysis of the BCR-
ABL dipstick assay. Catching antibodies: moAb 
7C6, moAb ER-FPt and moAb Yae (indicated 
left, from top to bottom, respectively) were used 
to precipitate proteins from different cellular 
lysates. LAMA-84 (bJalP210BCR-ABL positive cell 
line), KCL-22 (b1a1P21 OBCR.ABL positive ceillillc) 
and TOM-! (cla2P190BCR-ABL positive cell line), 
indicated on top of the BCR-ABL dipsticks, were 
used as BCR-ABL protein containing cellular 
lysates. Biotinylated moAb 8E9 was used as de-
tecting antibody, exclusively identifying b3a2_ 
BCR-ABL-, b,a,BCR-ABL- and ela,BCR-ABL 
proteins from LAMA-84, KCL-22 or TOM-I cel-
lular lysates, respectively. The biotinylated de-
tecting antibody 098-271.1.3 was used as a 
positive control, identifying ubiquitously ex-
pressed E2A proteins. 
Figure 2b Schematic representation of the 
BCR-ABL dipstick assay incubation procedure. 
The fIrst step, representing the immobilization of 
catching antibodies to the nitrocellulose strip, is 
indicated left. The second step, representing the 
incubation with the cellular lysate, is indicated in 
the middle. The third step, representing the de-
tecting antibodies, is indicated at the right. BCR-
ABL dipsticks are developed by the successive 
incubation with alkaline-phosphatase conjugated 
to streptavidin, followed by its sub-strate NET/ 
BCIP. 
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tected by subsequent incubation with a mixture of biotinylated moAb SE9 (SE9-bio, 
recognizing the carboxyl terminus of both ABL and BCR-ABL proteins) and 
biotinylated moAb G9S-27 I. 1.3 (G9S-27 I. 1.3, recognizing the carboxyl terminus of 
E2A-proteins) followed by alkaline phosphatase conjugated to streptavidin. 
Incubating a BCR-ABL dipstick with either cellular Iysates from LAMA-S4 or cellu-
Im'lysates from KCL-22, results, upon successive incubation with biotinylated anti-
bodies (i.e. SE9-bio and G9S-271.1.3-bio), streptavidin-AP and its substrate, in visible 
dots located at the moAb 7C6 spot (Figure 2; lanes I and 2, [n'st spot). Considedng the 
sepharose-Western blotting data described above, these dots represent bound 
b,a,P21OBcR-ABL and b,a,P21OBcR-ABL proteins, respectively. Confirmation of the 
specificity of the BCR-ABL dipstick assay is provided by another BCR-ABL dip-
stick, now incubated with a cellulm'lysate from TOM-I cells (e,a,PI90BCR-ABL posi-
tive). Subsequent development of this BCR-ABL dipstick through the successive 
incubation by the aforementioned molecules, does not result in a visible 7C6 spot 
(Figure 2; lane 3, first spot). These results indicate that b,a,P21 OBCR-ABL and b,a,P21OBcR-
ABL proteins present in cellulm'lysates from LAMA-S4 and KCL-22 are recognized by 
the moAb 7C6/SE9-bio combination, but proteins from the cellulm lysate of TOM-I 
cells, especially e,a,PI90BcR-ABL proteins, are not recognized by tltis antibody combi-
nation. 
The tumor-specific e,a,PI90BcR-ABL proteins are recognized by the second spot. This 
spot, representing the ER-FP I/SE9-bio antibody combination is clearly visible (Fig-
ure 2; lane 3, second spot), wltile second spots on the BCR-ABL dipsticks incubated 
with lysates from either LAMA-S4 or KCL-22 (Figure 2,lanes I and 2, second spots) 
remain invisible. These results, together with the sepharose-Western blotting data de-
scribed above, indicate that the ER-FPI/SE9-bio combination exclusively detects 
e,a,PI90BcR-ABL proteins in the BCR-ABL dipstick assay. 
The third spot, represents E2A proteins detected by the combination of moAbs Yael 
G9S-271.l.3-bio. Tltis spot is visible upon subsequent development after incubation 
with either cellulm' lysate (Figure 2, lanes I to 3, third spot). These data demonstrate 
that the Yae/G9S-271.1.3 moAb combination can be used as a positive control, assur-
ing proper assay development in case a Ph negative sample is investigated. 
Together, these data demonstrate that the BCR-ABL dipstick assay can be applied for 
the excillsive detection of the tumor-specific BCR-ABL proteins. 
Sensitivity of the BCR-ABL dipstick assay 
To investigate the sensitivity of the BCR-ABL dipstick assay, we pelformed a series 
of dilution experiments. To this purpose, cells from the b,a,P210BCR-ABL contahting 
KCL-22 cell line and cells from the e,a,PI90BcR-ABL containing TOM-I cell line were 
ntixed at various ratios. BCR-ABL dipsticks, represented by lane 1 to 12 in Figure 3, 
were incubated with the lysates of these various ntixtures and were subsequently de-
veloped. 
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Figure 3 Sensitivity analysis of the BCR-ABL dipstick assay. 1\velve BCR-ABL dipsticks were 
incubated with different mixtures of cellular lysates from KCL-22 (b2a2P210BcR-ABL positive cell line) 
and TOM-l (ela2PI90BCR-ABL positive cell line). Each cellular lysate represents a total of 107 cells per 
dipstick. From left to right, each first spot represents declining amounts of bla2BCR-ABL proteins 
detected by the moAb 7C6/SE9-bio combination. From right to left, each second spot represents de-
clining amounts of ela2BCR-ABL proteins detected by the ER-FPl/SE9-bio combination. The rela-
tions of the number of bla2P21 OBCR-ABL positive cells to the number of elaZP 190BCR-ABL positive cells are 
depicted below. 
The fIrst spot on lane 9, represents the lowest blalP21OBCR-AllL protein concentration that is clearly 
distinguishable from the background staining observed at the fIrst spot on lane 12. Here, ten blar 
P21011CR-ABL positive cells are detected among 90 e]alPI90BCR-AllL negative cells_ 
The second spot on lane 2, represents the lowest e]azPI90BCR-ABL protein concentration that is clearly 
distinguishable from the background staining of the second spot on lane I_ Here, one el alP 190BCR-ABL 
positive cell is detected among 99 blalP21OBcR-ABL negative cells_ 
As shown in Figure 3, the dot representing the 7C6/SE9-bio combination, is still clearly 
visible in lane 9. Here, ten b,a,P21OBcR-ABL positive cells among 90 e1a2_P190BcR-ABL 
negative cells are identified. The negative 7C6/SE9-bio control on lane 12 is hardly 
visible (Figure 3, lane 12). The 7C6/SE9-bio dots on lane 11 and 10 represent detec-
tion of 1 % and 5% b,a2P21OBCR-ABL positive cells, respectively. Unfortunately, staining 
of these dots is less pronounced and barely distinguishable from that of the negative 
7C6/SE9-bio control on lane 12. Yet, when considering the sensitivity of the BCR-
ABL dipstick assay for detecting presence of b,a,P21 OBCR-ABL positive cells, staining 
of the 7C6 spot on lane 9 is indisputably more intense than staining of the 7C6 spot on 
lane 12. Therefore, we conclude that the moAB 7C6/SE9-bio combination is capable to 
detect 10% b,a,P21OBCR-ABL positive tumor cells, at least. 
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The spot in the middle of lane 2, representing one ela,P 190BCR-ABL positive cell among 
99 b,a,P2IOBcR-ABL positive cells detected by the moAb ER-FP1I8E9-bio combination, 
is still visible in lane 2, while the same spot is not visible in lane 1. Thus, the ER-FPII 
8E9-bio combination allows the detection of one ela,PI90BcR-ABL positive cell among 
100 b,a,P2IOBcR-ABL negative cells. 
These results indicate that the BCR-ABL dipstick assay: 1) exclusively detects BCR-
ABL proteins, 2) discriminates ela,BCR-ABL proteins from b,a,BCR-ABL or 
b,a2BCR-ABL proteins and 3) specifically detects 10% BCR-ABL positive cells, at 
least. 
Specific diagllosis ofBCR-ABLpositive leukemias usillg the BCR-ABL dipstick assay 
At this point the BCR-ABL dipstick assay specifically detects BCR-ABL proteins in 
cellular Iysates made from cell lines. Next, we investigated whether the BCR-ABL 
dipstick assay could be applied for specific diagnosis of BCR-ABL positive leuke-
mias. 
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Figure 4a Represents the BCR-ABL dipstick after the analysis of blood samples from two pa-
tients suffering from either CML with rearranged b1az BCR-ABL genes (patient A, lanes I) or ALL 
with rearranged Cjal BCR-ABL genes (patient B, lanes 2). Consistent to the BCR-ABL gene rear-
rangements, dipstick spots are clearly visible: the tirst spot 011 dipstick 1 represents the 7C6/SE9-bio 
combination, \Vhile the second spot on dipstick 2 represents the ER-FPlISE9-bio combination. The 
third spot, representing E2A protein detection by the Yae/G9S-271.1.3-bio combination, is visible on 
both dipsticks. 
Figure 4b Represents the sepharose-\Vestem blotting analysis of the same patients by the SE9! 
8E9-bio antibody combination. Consistent to Figure 4a, b2alP21OBCR-AElL proteins are detected in the 
cellular lysate of blood cells from patient A, while ela2P190RcR-ABL proteins are detected in the cellular 
lysate of blood cells from patient B (lanes I and 2, respectively). 
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Two clyopreserved, Ficoll emiched blood samples from patient A and patient B, re-
spectively, with previously diagnosed BCR-ABL positive leukemias were lysed and 
investigated by both the BCR-ABL dipstick assay as well as a sepharose-Western 
blotting procedure. The blood samples from patient A and patient B represent a Plr 
CML with ctyptic reananged b,a, BCR-ABL genes and a Ph+ ALL with reml'anged 
ela, BCR-ABL genes, respectively. 
Figure 4a, lane I, shows that the first spot representing the 7C6/SE9-bio combination 
on the BCR-ABL dipstick is clearly positive upon incubation with the cellular lysate 
of the blood sample from patient A. The second spot of this BCR-ABL dipstick, 
representing the ER-FP1ISE9-bio combination is negative. These results indicate that 
either b,a,P21OBCR-ABL proteins or b3a,P21OBCR-ABL proteins m'e present in the cellular 
lysate from the blood sample of patient A. This result was verified by a sepharose-
Westet11 blotting procedure, perf0t111ed with moAb SE9 as both catching alld detect-
ing antibody, respectively (Figure 4b, lane 1). The observed P21OBCR-ABL band confirms 
the specificity of the BCR-ABL dipstick; either detecting b,a,P210BCR-ABL or 
b3a,P21OBcR-ABL. 
The BCR-ABL dipstick in Figure 4a, lane 2, shows that the second spot, representing 
the combination ofmoAbs ER-FP1ISE9-bio, is positive upon incubation with the cel-
lular lysate of the blood sample from patient B. Since the first spot, representing the 
combination of moAbs 7C6/SE9-bio, is negative, it is obvious that leukemic cells 
from this patient contain ela,PI90BCR-ABL proteins. The presence of e,a,PI90BcR-ABL 
proteins in the leukemic cells from this patient was confinned by sephm'ose-Westet11 
blotting with the SE9/SE9-bio combination (Figure 4b, lane 2). 
The third spot, representiug E2A proteins detected by the Yae/G9S-271.1.3-bio com-
bination, is positive on both BCR-ABL dipsticks (Figure Sa, lanes 1 and 2). Since the 
ubiquitously expressed E2A proteins are detected in the lysates of leukemic cells 
from both patients, we conclude that E2A protein detection in the BCR-ABL dipstick 
acts as a control for proper assay development. 
Discussion 
The presence of the Philadelphia chromosome in leukemic cells is associated with 
poor prognosis. Especially in ALL, it is inlportant to distinguish Ph+ leukemias from 
Plr leukemias, as the presence of the Ph chromosome identifies a large group of pa-
tients facing an insecure future (19, 20). Yet, this poor therapeutic outcome may be 
improved by an em'ly stmt with more aggressive induction therapies. Therefore, sensi-
tive and reliable diagnostic methods, identifying the Ph cln-omosome or its products at 
an em'ly time-point of the disease, moe extremely impOltant in ALL diagnosis. 
At present, conventional cytogenetic analysis is the method of first choice for identi-
fying various chromosomal abnormalities in ALL. However, the results upon cytoge-
netic analysis moe not always reliable since results Im'gely depend on the number of 
metaphases investigated. Only institutions with special experience in ALL cytogenet-
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ics achieve successful karyotype analysis in almost evelY patient. Even then, some 
cryptic BCR-ABL remmngements escape detection by conventional cytogenetic analy-
sis (36). 
Contrmy to conventional cytogenetic analysis, fluorescent in situ hybridization (FISH) 
techniques are not limited to a laborious analysis of metaphases. By applying probes 
directed against BCR and ABL genes, each labeled with a different fluorochrome, Ph+ 
interphase cells can be identified. Yet, depending on the co-localization of the two 
hybridization signals to one spot, its sensitivity is limited, because artifactual co-locali-
zation in normal lymphocytes may be observed (37,38). 
The polymerase chain reaction (PCR) is at present the most sensitive method for 
detecting genetic abnormalities. In fact, moleculm' analysis frequently detects trans-
locations that are not observed karyotypically (39). However, as breakpoints are scat-
tered over long distances in the tumor-specific BCR-ABL fusion-point introns, the 
PCR procedure is only applicable after reverse transcription of BCR-ABL messenger 
RNA. Being velY sensitive, strict precautions are required to prevent false positive 
(due to cross-contamination) or false negative (due to premature RNA degradation) 
results. 
In tlus paper we describe the development of a new, simple and rapid technique: the 
BCR-ABL dipstick assay. The principle belund the BCR-ABL dipstick assay is based 
on the successive detection of two distinct antigenic sites on the BCR-ABL protein. 
The combined specificity of two different antibodies allows for the exclusive detec-
tion of IUlllor-specific BCR-ABL proteins within 24 hours. Moreover, provided that 
the right combination of antibodies is used, this assay cm1 be applied to discdminate 
b,a, mid b3a,BCR-ABL proteins on the one hand from e,a,BCR-ABL proteins on the 
other. 
Our assumptions concerning exclusive detection of BCR-ABL proteins by the proper 
antibody combinations proved conect as they were first tested in sepharose-Western 
blotting experiments. These experiments demonstrate that b3a,BCR-ABL proteins and 
b,a,BCR-ABL proteins are specifically identified by the moAb 7C6/8E9-bio combi-
nation, while e,a,BCR-ABL proteins are specifically identified by the moAb ER-FPl! 
8E9-bio combination. We next investigated whether the tedious and time consuming 
sepharose-Western blotting procedure could be simplified. The resulting BCR-ABL 
dipstick, a smalliutrocellulose strip on which three different moAbs (i.e. moAb 7C6, 
moAb ER-FPI and moAb Yael are iunllobilized, was examined for both specificity 
and sensitivity by using different Ph+ cell lines. 
The specificity of the BCR-ABL dipstick assay was confirmed by the analysis of Ph 
positive cell lines; each cell line expressing a different type of BCR-ABL protein (i.e. 
the LAMA-84 cell line expresses b3a,P2IOBcR.ABL; the KCL-22 cell line expresses 
b,a,P21 OBCR.ABL and the TOM-l cell line expresses e,a,PI90BCR-ABL). These results m'e 
consistent and were also observed upon testing other Ph positive cell lines such as 
K562 (b3a,P2IOBcR-ABL positive cell line), BY -173 (b,a,P210BcR-ABL positive cell line) 
and MIK/ALL (e,a,PI90BcR-ABLpositive cell line) (results not shown). 
The sensitivity of the BCR-ABL dipstick assay was deternuned to at least 10%. This 
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result indicates that this assay can act as an alternative screening method for detection 
of BCR-ABL positive leukemias at fIrst diagnosis. Dipstick analysis of two leukemic 
cell samples with previously repOlied rearranged BCR-ABL genes (28) showed that 
initial diagnosis of BCR-ABL positive leukemias by the BCR-ABL dipstick assay is 
indeed feasible. Moreover, its sUlplus value considering conventional cytogenetic 
analysis was demonstrated by the analysis of patient A. Even though this patient suf-
fered from a Ph negative CML with ClyptiC rearranged b,a, BCR-ABL genes (29), 
BCR-ABL proteins were readily identifIed upon using the BCR-ABLdipstick method. 
In conclusion, the BCR-ABL dipstick is an easy and fast method that can be per-
formed in any routine hematological laboratory, permitting diagnosis of Ph+ samples 
in only a few steps. So far our results hold promise, although we are aware that larger 
studies are required to validate the use of this new assay for future diagnosis of Ph+ 
leukemias. 
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Characteristic genetic abnonnalities are strongly conelated with the prognosis of a 
patient suffering from cancer and, as a consequence, fonn a basis on which therapeu-
tic decisions are made. 
In this respect, it has been suggested that the poor prognostic features of BCR-ABL 
positive leukemias can be improved through the em'ly identification of tlus chm'acter-
istic genetic aberration. An aggressive kind of therapy, that is certainly not applicable 
to treat all leukemia sUbtypes and is only defensible by the otherwise poor prognosis 
of BCR-ABL positive leukemias, might, when given at an em'ly time point of the 
disease, eradicate the tumor completely before it relapses during, or shortly after, the 
fU'st rounds of therapy (1-3). 
This was exemplified by E2A-PBXl positive leukemias, of which the prognosis mark-
edly improved in the early 1990s tln'ough the use of more intensive chemo-therapeutic 
protocols (4, 5). Probably the best example that demonstrates the clilucal importance 
of an accurate diagnosis is provided by the t(15;17)(q21 ;qll-22). Tlus translocation is 
pmiicularly observed in acute promyelocytic leukenua (APL). In tlus translocation, 
the critical ligand- and DNA-binding domains of the retinoid acid receptor-a (RARa) 
gene from chromosome 17 are fused to sequences of the PML gene on chromosome 
15 (6-8). By administering pharmacological doses of all-trans retinoid acid (i.e. the 
ligand for the RARo: protein) to patients with t(15;17) positive APL,leukenuc cells 
respond by differentiating into mature granulocytes, leading to morphological renlis-
sions (9-11). 
The concept that tumor-cells are different from nonnal cells has prompted many in-
vestigators for many yem's to search for (tumor-specific) markers that are exclusively 
expressed by tumor-cells. At present, various tumor-specific markers, such as abnor-
mal chromosomes, abnormal genes, and abenant proteins, have been identified in 
characteristic tumor-types. The diagnostic value of current chromosomal and molecu-
lar genetic teclnuques in tumor diagnosis is well acknowledged: each diagnostic tech-
nique is c11m'acterized by its own specific, diagnostic applications and linlitations. 
When considering an immunological tumor diagnosis, it is realized that immunologic, 
tumor-specific diagnostic techniques are stilllinuted in their use. Yet, it is anticipated 
that the im/llunologic identification of tumor-specific proteins, or antigens, would not 
only contribute to an accurate, nucroscopic diagnosis of certain tumor types, but may 
also prove invaluable to develop new therapeutic strategies, such as immunotherapy 
(12, 13). In this chapter we discuss some of the considerations that emerged during 
our research aimed at generating antibodies specifically recogIuzing tumor-cells. 
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Thlllor diagnosis and antigens 
It is obvious that not every antigen which is expressed by tumor cells, is suitable for a 
tumor-specific diagnosis. Although many tumor-antigens have been discovered by 
monoclonal antibodies on characteristic tumor types, they are often not tumor-spe-
cific. In fact, most antigens are alternatively classified as 'tumor-related' or, 'shared' 
antigens because they are detected on both tumor-cells as well as on normal cells. 
This overlap, however, does not necessarily preclude the use of antibodies as diagnos-
tic tools to recognize cancer cells, although their precise diagnostic applicability ap-
pears to depend on the methods through which these antibodies have been derived. 
Typical examples are discussed below. 
ThIllOl' cells as antigens: 
Many tumor-antigens known today, have been discovered by evaluating the innnune 
response oflaboratory animals towards injected (tumor-)cells. Especially in leukemia 
research it was recognized that most tumor-related antigens reflect characteristic dif-
ferentiation stages that typify the ongoing development from stem cells towards ma-
ture, differentiated blood cells. Even though these antigens are not exclusively expressed 
by tumor-cells and are also expressed by normal cells, they have become extremely 
important as differentiation markers. According to international agreements different 
antibodies have been categorized into antibody clusters, provided that identical anti-
gens are recognized within each cluster. Antibody clusters are discriminated from one 
another by different CD (cluster of differentiation) codes (e.g. CD 1, CD2, etc.). Ow-
ing to the clonal proliferation of malignant cells, it is nowadays custommy to classify 
leukemic cells according to their degree of differentiation (14-16). While most 'CD 
antigens' were relatively easily discovered by evaluating antibody responses from 
laboratory animals (most often mice) towards injected (tumor)-cells, it has appeared 
that none of these CD-antigens is tumor-specific and that tumor-specific antigens are 
difficult to reveal (12-16). 
Tumor-cells resemble normal cells to a large extent. Immunization strategies that are 
based on the injection of complete tumor-cells m'e, as a result of the antigenic resem-
blance between tumor-cells and normal cells, likely to result in the identification of 
antigens that are also expressed by the normal counterpmt of the involved tumor-cell. 
Exceptions to tlus nIle m'e two recently described monoclonal antibodies, both de-
rived by injecting laboratOlY animals with (tumor-)cells. Since the reactivity of each 
of these antibodies exemplify some of the problems that m'e connllon to an immuno-
logical based tumor-specific diagnosis, they m'e briefly discussed below: 
a. MoAb KOR-SA3544: identifies ALLs with the t(9;22)(q34;q II) (17). This mono-
clonal antibody was discovered through immunizing mice with a human, 
t(9;22)(q34;qll) positive, ALL derived leukenuc cell line. The antibody was se-
lected through its reactivity with 68 human cell lines, from which it appem'ed to 
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identify t(9;22)(q34;q I I) positive lymphoid cell lines. Unfortunately, MoAb KOR-
SA3544 cross-reacts with normal granulocytes, as well as with some leukemic 
cell lines with a I I q23 translocation. 
b. MoAb 7.1: identifies childhood ALLs with the t(4;II)(q21;q23) and t(II;19) 
(q23;pI3) as well as AMLs with abnormalities of chromosome band IIq23 (18, 
19). This antibody was derived after the immunization of mice with a stromal cell 
line that descends from human bone mmmw. The antibody was selected on the 
basis of its reactivity with various human cell lines, normal blood cells and bone 
marrow cells. It was found that this antibody specifically reacted with the human 
homologue of the rat chondroitin sulfate proteoglycan, N02. TillS antigen is ex-
pressed on the cell smface of both AML and ALL blasts with abnormalities in 
chromosome band IIq23. Since the N02 antigen is not expressed on normal 
hematopoietic tissue, it seems likely that the moAb 7. I can be used as a tool to 
specifically identify leukenllc cells with an abnDll11ality in cIu'omosome band IIq23. 
The 'master-gene' model introduced by Rabbitts (20), essentially states that protein 
products of abell'antly expressed master-genes are, either directly or indirectly (by 
affecting the expression of 'responder genes'), involved in the malignant transforma-
tion of previously normally functioning cells. According to this model, one may ex-
pect that the antigeillc profile of malignant cells is essentially changed by the aberrant 
expression of master-genes and differs from that of their normal counterparts. 
When considering the reactivity of moAb KOR-SA3544 and moAb 7.1, it would 
appem' that both antibodies recognize antigens that are encoded by so-called 'responder' 
genes. It is recognized that the 90 kDa antigen detected by moAb KOR-SA3544 is 
different from the tumor-specific PI 90BeR.ABL 'master' protein (17), while the N02 
molecule that is detected by moAb 7. I, differs from the MLL proteins (18, 19). MLL 
proteins are encoded by MLL, the 'master' gene that is located on chromosome band 
I Iq23 (21, 22). 
As exemplified by the 90 kDa antigen of moAb KOR-SA5344, it is probable that an 
imnuullzation strategy that is based on the immunization with tumor cells, results in 
antibodies detecting tumor-related antigens of which both its function as well as its 
derivation are unknown (17). As a consequence further elaborate studies are required 
to exanllne the nature of the 90 kDa antigen and if possible, discover the encoding 
gene(s) (17-19). 
TIms, an immunization approach intended foJ' generating antibodies that exclusively 
recognize tumor cells, which depends on the injection oftumer cells, is likely to result 
in elaborate studies to deduce whether the detected antigens are exclusively expressed 
by tumor cells. Most of these studies are inclined to end with antibodies that recognize 
so called 'shared' antigens that m'e also expressed on normal cells. 
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Tnmor (specific) proteins as antigens: 
When considering generating antibodies that exclusively identify tumor-cells, it is 
obvious that an immunization approach should aim at directing the immune response, 
thereby diminishing the chance of generating antibodies that are reactive towards 
lIOn-tumor-specific antigens. Recent molecular genetic findings in cancer research 
have identified new genes that are, as 'master' genes, directly involved in the malig-
nant transformation of certain cells. 
From the moment that the nucleotide sequence of such tumor genes has been re-
vealed, it is easy to predict the complete amino acid sequence and, based on its se-
quence homology with other genes, predict the cellular function of the tumor-gene. A 
tumor gene's cDNA can be cloned, inserted in a suitable expression vector and used to 
express (recombinant) tumor-proteins (23). As immunogens, these recombinant tu-
mor-proteins provide a new means to produce antibodies. Two sets of antibodies that 
have been generated by injecting recombinant proteins are depicted below. 
a. TALl proteins: are potentially useful as tumor-antigens for diagnosing T-cell ALLs 
in which the TALl gene is involved, such as in del(1)(p32), t(1;17)(p32;q35) and 
t(1;14)(p32;qll) positive T-cell ALLs. Four monoclonal antibodies (i.e. moAbs 
BTL73, 2TL75, 2TLl70 and 2TL242) were derived after immunizing mice with 
recombinant TALI proteins (24). Antibodies were tested for their reactivity to-
wards these recombinant proteins in appropriate assays, such as ELISA and West-
em blotting. Inununocytochemical studies indicate that these antibodies specifically 
react with cell lines expressing nuclear TALI proteins, including T-cell lines cany-
ing tumor-specific TALI gene abel1'ations. Although the TALl gene is expressed 
in a variety of tissues, it is normally not expressed in T-cells (25, 26). Therefore, 
these antibodies are of pm1icular interest to specifically diagnose T-cell ALLs in 
which TALI proteins m'e expressed. 
b. PML-RARaproteins: are specifically expressed in t(15;17)(q2l;qll-q22) posi-
tive APL. These proteins are truly tumor-specific since these chimeric proteins 
are not expressed in cells without the t(15; 17) (q21;q ll-q22).Immunohistochemi-
cal examination of APL cells reveals a unique abnormal distribution of anti-PML 
and anti-RARa antibody labeling. The PML pattem observed in normal cells 
consists of 5 to 10 discrete spherical nuclear bodies called PODs (for 'PML onco-
genic domains'), whereas that of APL cells consists of smaller and fm' more nu-
merous speckled patterns (27, 28). This abnormal PML staining pattern was 
demonstrated in cells from patients with t(15;17)-associated leukemias but not in 
patients with other neoplastic disorders (29). Moreover, reorganization of the speck-
led PML labeling pattern into PODs is observed in APL cells from patients re-
ceiving all-trans retinoid acid therapy (29, 30). 
Ectopically expressed proteins, such as TALI, m'enot exclusively expressed by tumor 
cells. Even though one estimates that the transition from a n0I111al T-cell to a malig-
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nant T-ALL cell is caused by the aberrant expression of TALl proteins in (TALI 
positive) T-cells, TALI proteins are themselves not tumor-specific. Since TALl pro-
teins are also expressed by other cell types (e.g. erythroid, megakaryocytic, and epi-
thelial cells), it is impOltant when using the TALI antigen as a tumor marker, to 
distinguish T-cells from other hematopoietic cell lineages by using multiple marker 
analysis. 
Chimeric fusion-proteins, such as PML-RARa, BCR-ABL and E2A-PBXl are, as 
tumor-specific proteins, exclusively expressed by tumor cells. When considering 
microscopy or flow-cytometry as diagnostic read-out, it is impOltant to recognize that 
not evelY antibody that reacts with a pmticular chimeric protein is suited for tumor-
specific diagnostic purposes. A lnicroscopic, tumor-specific diagnosis with antibod-
ies recognizing chimeric and wild type proteins (e.g. normal PML or RARa proteins) 
might be feasible in some instances (e.g. PML speckles in t(15; 17) positive cells ver-
sus PODs in normal cells upon anti-PML staining). However, one should anticipate 
that not every tumor cell that expresses chimeric proteins can be discriminated from 
nOlIDal cells by a chm'actedstic (intra-)cellulm' localization of the chimeric protein, 
Immunolabeling procedures that recognize bOlh chimeric proteins as well as wild 
type proteins m'e often not tumor-specific. 
Thus, an immunization strategy aimed at generating antibodies that exclusively iden-
tify tumor-cells, which depends on the immunization with a complete (recombinant) 
tumor protein, is likely to result in antibodies that also recognize normal, wild type 
proteins expressed by nOlIDal cells, 
Thmor specific epitopes as antigens: 
Molecular genetic studies have c1em'ly demonstrated that pm·ticular genetic abelTa-
tions, such as point mutations and gene rearrangements, generally result in the exclu-
sive expression of Ilewly generated, hence, tumor-specific proteins, Yet, sequence 
homology studies indicate that most of the predicted amino acid sequence of tumor-
specific proteins is identical to (parts of the) amino acid sequence of the wild type 
protein counterpmt(s), When considering tumor-specific proteins as antigenic targets 
to diagnose tumor cells specifically, it is evident that only certain regions of the pro-
tein m'e applicable as so called 'tumor-specific' epitopes. 
According to the definition, tumor-specific epitopes m'e, as continuous and/or discon-
tinuous epitopes, exclusively expressed on tumor-specific proteins. In this respect, 
continuous epitopes are defined as a stretch of contiguous amino acid residues in 
direct peptide linkage, while discontinuous epitopes consist of a unique group of 
residues that are brought together by folding of the polypeptide chain or by juxtaposi-
tion of two separate peptide chains (31). 
It is difficult to predict the composition of discontinuous tumor-specific epitopes, but 
it is relatively simple to estimate the location and amino acid sequence of continuous 
tumor-specific epitopes upon comparing the predicted amino acid sequence of the 
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tumor protein with that of the wild type protein(s). Such tumor-specific continuous 
epitopes can be reproduced upon synthesizing peptides. Synthesized peptides with an 
amino acid sequence identical to that of a tumor-specific epitope me excellent tools to 
specifically direct the immune response, thereby diminishing the chance of generat-
ing antibodies that cross-react with normal proteins. 
It is easily demonstrated that a cel1ain region of the chimeric BCR-ABL fusion-pro-
tein, i.e. the protein region that includes the junction between BCR detived amino 
acids and ABL derived amino acids, forms a contiguous amino acid sequence that is 
not present in normal BCR or in normal ABL proteins. Depending on the localization 
of the fusion-site between BCR and ABL genes in Ph-chromosome positive leuke-
mias, different BCR-ABL fusion-proteins are transcribed and translated: each BCR-
ABL protein characterized by a specific amino acid sequence surrounding the 
fusion-point (i.e. e,a,PI9()BcR.ABL, b,a,P21OBcR-ABL or b,a,P21OBCR-ABL). 
Van Denderen ef al. (32-34) have shown that each of these BCR-ABL tumor-specific 
amino acid sequences is, as a fusion-point-peptide catTier-protein conjugate, suitable 
for i1l1llmnization procedures. Accordingly, different (polyclonal) antibodies have been 
generated, each of them exclusively recognizing one of the chimeric BCR-ABL fu-
sion-proteins. 
From these initial studies it was concluded that fumor-specific BCR-ABL fusion-
point sequences are al/figel/ica/ly exposed and can serve as a I/ell' means for tumor-
specific diagnostic purposes (32-34). 
To investigate whether a 'fusion-point peptide' based immunization strategy is a use-
ful instrument to develop antibodies tlu'ough which other characteristic tumor types 
can be specifically diagnosed, we immunized mice with an E2A-PBXI fusion-point 
peptide (35). The E2A-PBXI fusion-protein is exclusively found in t(1;19) positive 
leukemias in which E2A and PBX] genes are real1'anged and fused (36). 
Instead of using a fusion-point-peptide carrier-protein conjugate to enhance the pep-
tide's immunogenicity, we inullunized mice with a multiple antigenic E2A-PBXI pep-
tide, or MAP antigen. By using the MAP antigen as an inullunogen, we minimized the 
chance to develop antibodies that would cross-react with the protein-catTier (37). The 
antisel1lm that was generated, termed BP 1119, specifically recognizes the fusion-
point ofE2A-PBXI proteins and, wlule a tumor-specific microscopic detection of Ph-
chromosome positive tumor-cells had not been realized upon immuno-staining 
expetiments with polyclonal anti-BCR-ABL fusion-point specific antisera, the results 
of BP 1119 immunostaliung experiments indicate that our anti-E2A-PBXl fusion-
point antisel1lm is pat1iculat'ly useful to distinguish, at the cellular level, t(1 ;19)posi-
tive leukemias from t(I;19) negative leukemias or normal cells (35, 38). 
Regarding the limitations of polyclonal antibodies (e.g. !inuted supplies, variable 
specificity upon subsequent inllllllluzation and background problems in il1llllul1o-
assays), monoclonal anti-fusion-polilt specific antibodies are clearly favored. Essen-
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tially by using conventional hybddoma teclmologies, we were able to generate two of 
such anti-fusion-point specific monoclonal antibodies (termed: ER-G04 and ER-FP 1, 
respectively) (39, 40). The results of different innnuno analytical assays, such as pep-
tide inhibition studies, (sepharose-) Western blotting experiments and protein tyro-
sine kinase assays, verified the specificity of our antibodies: i.e. ER-G04 moAb 
specifically reacts with an E2A-PBXl fusion-point epitope and, ER-FPl moAb spe-
cifically reacts with the e 1 a2 junction in eIa,P 190BCR.ABL proteins. Additionally, 
inllnunostaining experiments have demonstrated that moAb ER-G04 specifically iden-
tifies COS cells transfected with cDNA encoding E2A-PBXl proteins but does not 
detect E2A transfected COS cells nor does moAb ER-G04 detect PBX1 transfected 
COS cells. Likewise, COS cells transfected with cDNA encoding eIa,P190BCR.ABL pro-
teins are specifically identified by using moAb ER-FPl, willie COS cells transfected 
with cDNA encoding b,a,P21OBcR.ABL or b3a,P210"cR.ABL proteins are not recognized 
by ER-FPl antibodies. These immunofluorescence studies prove that tumor-specific 
fusion-point epitopes are a11ligellically exposed at the cellular level, on both E2A-
PBXl as well as eIa, BCR-ABL proteins (39, 40). 
The results from our experiments with both polyclonal and monoclonal antibodies 
indicate that, when fusion-point epitopes from chimeric proteins are antigenically 
exposed within a cell, they can: (1) act as tumor-specific targets, and (2) allow a 
tumor-specific, microscopic identification of leukemic cells. Unfortunately, both of 
our monoclonal antibodies do not, when used in immunofluorescence microscopy, 
discriminate between leukemic cells and normal cells. Regarding the perfonnance of 
ER-G04 moAbs and ER-FP1 moAbs in inmlUnofluorescence experiments, we sug-
gest that the level of expression of either E2A-PBX1 or eIa,P190BcR.ABL proteins is 
probably too low for specific recognition of sillgle t( 1; 19)E'A.PBxI or eIa,-t(9;22)BCR~ABL 
positive leukemic cells by our monoclonal antibodies (39, 40). 
Various inllnunological methodologies have been developed tlll'ough which the pres-
ence of particular tumor-cells in a patient's sample are specifically demonstrated at 
first diagnosis (e.g. protein tyrosine kinase assay, Western-blotting and the BCR-ABL 
dipstick assay (41 )). Unf0l1tmately, most of these techniques are often less valuable to 
detect residual tumor-cells during therapy. One of the exceptions that enables the 
detection of small numbers of leukemic cells, is immunofluorescence microscopy. 
Depending on the immunophenotype of the leukemia, immunological, microscopic 
teclmiques are extremely sensitive; able to detect one abenant cell among 10,000 
normal cells (14). However, present microscopic techniques still rely on the recogni-
tion of lIoll-tumor-specific differentiation-antigens and are, as a result, not capable to 
identify tumor cells specifically. It is evident that an ilmnunological, Illmor-specific 
microscopic diagnosis is favored. 
Exemplified by the tumor-specific recognition of single t( 1; 19)E2A~PBxI tumor-cells by 
our BP 1/19 antiserum: an antibody-based, tumor-specific microscopic identification 
of leukemic cells is feasible. Yet, both of our anti-fusion-point specific monoclonal 
antibodies are not suitable for leukemia diagnosis. The tumor-specific, immunologi-
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cal recognition seems hampered by particular problems that concern: (l) the intra-
cellular concentration of the tumor-specific chimeric protein, (2) the affinity of the 
monoclonal antibodies and/or, (3) the peptide-based inununization strategy that is 
used to generate such antibodies. 
New problems to be solved: 
The relatively low intra-cellular concentration ofbothE2A-PBXI as well as ela, BCR-
ABL proteins limits the intended use of our monoclonal antibodies, i.e. the specific 
microscopic identification of either t(I;19)E'A.PBxl or ela, t(9;22)BCR-ABL positive leuke-
mic cells by moAb ER-G04 or moAb ER-FPI, respectively. Unless the intracellular 
concentration of either chimeric protein is sufficiently (and specifically) increased 
(e.g. by activating the promotor or enhancer regions of the chimeric gene in question), 
both antibodies are not suitable for microscopic diagnostic procedures. Besides the 
fact that the promotor and enhancer regions of these genes are not yet known, it would 
be impractical, given the low frequencies with which the t(I;19) and the t(9;22) occur 
in childhood ALL (6% and 5%, respectively), to submit all new leukemic samples to 
such hypothetical diagnostic procedures. 
More realistic solutions to our cUlTent, antibody based, diagnostic microscopic prob-
lems are to be found when one attempts to: (1) increase the antibody's affinity and/or 
the antibody's avidity towards the tumor-specific epitope or, (II) change the procedure 
through which such antibodies are generated. In this paragraph we propose several 
solutions that would benefit a tumor-specific, microscopic diagnosis by immunologi-
cal means: 
I. Increasing the antibody's affinity and/or avidity: 
a. mOlloclonal antibodies: it is important to realize that a continuous epitope of a 
chimeric fusion-protein is tumor-specific when it: I) exclusively occurs on tumor-
specific proteins, and 2) contains both pruts of the chimeric protein flanking the 
fusion-point. Given the observation that the smallest patt of a protein fragment 
l'umor-spedfic fusioll-PO;,l1 D D D D D D D l1lil1lil1lil1lil1lil1lil1li 
tumor-spedficepitope I 000000. 
tumor-specific cpitope 2 000001111 
tumor-specific epitope 3 DODD IIIIB 
tumor-specificepitope 4 00011111111 
tumor-specific epitope 5 001111111111 
tumor-specific epitope 6 0111111111111 
Figure 1 Schematic representation of the tumor-specific fusion-point of a hypothetical chimeric 
fusion-protein. Different continuous tumor-specific epitopes are available for antibody recognition. 
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which is able to bind to an immunoglobulin molecule, is estimated at 5-7 amino 
acids (31), it is obvious that at least 4-6 different tumor-specific epitopes are avail-
able for antibody recognition (see Figure I). Since paratope-epitope interactions 
not only depend on the epitope's composition of the contiguous stretch of amino 
acid residues, but also depend on the epitope's conformation, it is imaginable that, 
within a pmticular tumor-specific protein, different tumor-specific fusion-point-
epitopes m'e at hand to be specifically recognized by monoclonal antibodies. 
Thus, although both moAb ER-FPI as well as moAb ER-G04 are limited in their 
diagnostic use, it might be possible to discriminate at the cellular level, tumor-
cells from normal cells, by generating new monoclonal antibodies towards these 
different tumor-specific epitopes. 
b. oligoclollal antibodies: when considering the polyvalent nature of our polyclonal 
antisenlln BP 1119, it can be concluded that the microscopic, tumor-specific rec-
ognition of t( I; 19)E2A-PBx, tumor-cells by BP 1119 antiselUm is caused by a combi-
nation of differently reactive anti-fusion-point specific antibodies, Although it is 
well known that the concomitant presence of /10/1 specific immunoglobulins in 
antisera generally increases the background of various immunoanalytical assays, 
it is expected that when different anti-fusion-point specific (monoclonal) antibod-
ies m'e properly mixed, they enhance the avidity of the oligoclonal antibody mix-
ture towm'ds the fusion-point epitope (42). As exemplified in Figure 2, it is estimated 
that background problems can be held to a minimum by using oligoclonal anti-
body mixtures, despite cross-reaction of celtain anti-fusion-point antibodies with 
/10/1 tumor-specific cellular proteins, 
tumor-specific fusion-points Icross-reactivel antigens specificity of ollgoc!onal 
on chimeric protein A & anlibody specificity antibody mixture 
C 
I I A 1 00000l1lil1li ----.. A D 
E 
I I 
c 
I 
DOD l1lil1lil1lil1li ----.. A D 
F E 
G 
I I 
F 
I 
o l1lil1lil1lil1lil1lil1li ----.. A G 
H H 
Figure 2 Schematic representation of the specificity of an oligoclonal antibody mixture directed 
towards the tumor-specific fusion-points of a hypothetical chimeric protein. 
A single anti-fusion-point antibody may bind to a tumor-specific epitope that is not only specific for 
chimeric protein A but also for other antigens (C and D or, E and F or, G and H). The avidity of oligo-
clonal anti-fllsion-point antibody mixture would be high towards the fusion-point epitope of the chi-
meric protein but low to any other antigen. 
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Thus, by generating an oligoclonal pool of different monoclonal antibodies, it should 
be possible to differentiate, by immunological means, between tumor-cells and nor-
mal cells, at the microscopic level. 
Even though either of both of the suggestions depicted above, could result in the 
development of a new ilrununological tumor-specific, microscopic identification of 
charactelistic leukemic cells, both of them involve the generation of new monoclonal 
antibodies. When considering to generate new anti-fusion-point specific antibodies 
by usillg conventional hybridoma procedures, one should anticipate to a vast amount 
of work and a small chance of success in finding a suitable antibody (e.g. moAb ER-
G04 is the only anti-E2A-PBXI reacting antibody that resulted from ten different cell 
fusion experiments or, approximately 8,000 different hybridomas tested). Moreover, 
especially during our attempts to generate anti-BCR-ABL antibodies, we noted a dis-
crepancy between the reactivity of so-called anti-peptide and anti-pmteil1 antibodies. 
While anti-BCR-ABL peptide antibodies were frequently detected during initial 
hybridoma screening procedures regarding theil' reactivity towards coated BCR-ABL 
peptides (ELISA), we found that most of the anti-BCR-ABL peptide antibodies did 
not recognize the cognate BCR-ABL proteins (Western blotting or protein tyrosine 
kinase assay; unpublished results). Tlus discrepancy in reactivity between anti-pep-
tide antibodies and anti-protein antibodies is well acknowledged and is largely attrib-
uted to the conformational differences between the peptides and their cognate proteins 
(31). 
However, considering the need to direct the immune response towards the tumor-
specific epitope ill order to diminish the chance of raising antibodies towards 11011 
tumor-specific epitopes (see paragraph: 'tumor-specific proteins as antigens'), it seems 
unavoidable to use a peptide based strategy. Peptide innllllluzation procedures apperu' 
to be, despite theil' llinitations, the only suitable option when deciding to generate 
anti-fusion-point specific antibodies by using conventional hybridoma technologies. 
II. Alternative (phage) antibodies: 
Recent molecular genetic engineering of (human) antibodies seems to have bypassed 
both the hybridoma technology as well as the need to immunize laboratOly mumals 
(43). Lru'ge repetloires of antibody V (vruiable) genes, either harvested from lymphocyte 
populations or assembled ill vitm, have been cloned for display on the smface of 
filamentous bacteriophages. 
From libraries containing large numbers (107 - 1012) of phages expressing single chain 
fragments that are encoded by variable regions from IG genes (scFv), rare antibody 
phages can be selected upon binding to an antigen that has been coated on a solid 
surface. Once specific phages have bound to the coated antigen, 11011 binding phages 
are simply washed away. Specific antibody phages that have bound to the antigenru'e 
subsequently eluted from the solid smface by usillg conventional methods (43). As 
these phage particles are infectious they can be fmlher grown in bactelial culture 
before subjecting these phages to fmlher rounds of selection. Accordingly, phages can 
General disclission 141 
be enriched to a 107-fold by four rounds of selection within two weeks at most (44). 
When considering the 'clonal' outgrowth of selected phages it can be stated that the 
phage display technology mimics the antigen-driven proliferation of B cells ill vi/IV. 
The ill vi/IV selection of antibody phages circumvents the immunization of laboratOlY 
animals according to time-consuming immunization schedules and, likewise, evades 
the need to test the antibody responses of these animals towm'ds the injected inununo-
gen. Exemplified by the poor antibody responses of mice injected with the multiple 
antigenic E2A-PBXl peptides, i.e. approximately only one in ten immunized mice 
develops a sufficiently specific antibody response that allows the exclusive detection 
of t(l; 19)E2MBXl positive cells (unpublished results), it is obvious that the phage tech-
nology limits the time and the number of laboratory animals otherwise needed to 
immunize and screen for proper antibodies. Moreover, when one realizes that gener-
ally only one in 10' splenocytes can be immortalized by using the conventional 
hybridoma technology (45), it is not difficult to imagine that, when deciding to itn-
mortalize the splenocytes from an inulllmized animal using conventional cell fusion 
techniques, one risks to lose the anti-fusion-poillt specific, antibody producing cell. 
CalE1 ad M13ari 
Figure 3 Phagemid pHEN I (top) and a phage-antibody (bottom). PIO, JacZ promotor/operator; 
L, pelB leader; VII + VL. scFv encoding gene; M, Myc-tag~ A, amber codon~ g3, gene3; colEl ori, 
B.coli origin of replication; AMpR, ampicillin resistance gene; M13 ori, phage intergcnic region; g3p, 
coat protein 3 
Thus, when consideritlg the conventional hybridoma technology; its low efficiency 
and the vast amount of work that involves testing the vadous supel1latants of the 
hybridoma cell lines, it is obvious that the phage technology is prefel1'ed. There m'e 
various formats for antibody phage display. The format used in the followitlg para-
graphs is based on the phagemid vector pHEN 1. The scFv fragments that m'e dis-
played on the suttace of the phage pat1icle are encoded by VII gene and V L gene 
fragments, inserted in litle in pHENl (Figure 3) (46). The phage display technology is 
evolving fast and already has potential to generate GlllijllSioll-PlVleill specific anti-
bodies by a vatiety of means. 
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a. nelV monoe/onal 'phage antibodies': our preliminary, unpublished studies indi-
cate that it is possible to select phages that specifically recognize the multiple 
antigenic E2A-PBXl peptide. These anti-peptide phages have been selected after 
pre-absorbing cross-reactive phages on a 11011 tumor-specific mixture of multiple 
antigenic E2A peptides and multiple antigenic PBXl pep tides. The remaining 
antibody-phage repertoire (i.e. the phage library without cross-reactive anti-E2A 
and anti-PBX I antibody phages) was used for binding to the multiple antigenic, 
tUlllor-specific E2A-PBXI peptide. By repeating the pre-absOlption and selection 
procedure 4-5 times, we were able to emich single antibody phages. These phages 
are specifically reactive with the mUltiple antigenic E2A-PBXl peptide and do 
not recognize multiple antigenic E2A or PBXl peptides (unpublished results). 
Unfortunately, these phage antibodies did not bind to (ill vitro translated) E2A-
PBX I proteins and their specificity seems restricted to conformational epitopes 
that are specifically exposed on the multiple antigenic E2A-PBXI peptide. 
It is likely that a peptide based selection procedure of antibody phages suffers 
from the same problems that were also found during screening procedures follow-
ing conventional hybridoma techniques. The discrepancy of antibodies reacting 
with the peptide, but not with the cognate protein, makes a peptide based selection 
strategy less preferable to generate anti-fusion-protein phages. 
Yet, the phage display technology does not necessarily depend on peptide based 
selection procedures: pre-absorbing antibody-phages from the complete reper-
toire on wild type, recombinant proteins, such as E2A and PBX I proteins, dimin-
ishes the chance of rendering phage antibodies that are directed towards non 
tumor-specific epitopes. A subsequent selection from the remaining library of 
phages towards the recombinant tumor-specific protein (e.g. E2A-PBXI) should 
then be performed to select those phages that are reactive with tumor-specific 
epitopes. 
The phage technology offers the 0pP0l1unity to select antibodies that specifically 
recognize bothcOlltillllOus tumor-specific fusion-point epitopes as well asdiscoll-
tilllIOUS tumor-specific epitopes. In contrast to the conventional hybridoma tech-
nology, the phage display technology has the potential of eliminating cross-reactive 
antibodies by pre-absorbing procedures. Such procedures may prove useful to 
identify any discontinuous tumor-specific epitope and provide an alternative for 
generating antibodies recognizing continuous tumor-specific epitopes. 
b. lIIu/a/ed monoe/onal 'phage antibodies': theoretical studies suggest that the greater 
the variability of the phage display librmy, the greater the chance of finding anti-
bodies reactive to a given epitope and, likewise, the greater the possibility of 
selecting phage-antibodies with a high affinity towards the antigen (47). Yet, it is 
imaginable that high affinity anti-fusion-point specific antibody-phages are sim-
ply not present in the librmy used. Both ill vitro (e.g. elmr prone polymerase 
reaction (48)) as well as ill vivo (e.g. by using mutator strains of bacteria (49)) 
antibody V -gene mutations offer an opportunity to increase the low affinity of 
General discuss;OIl 143 
selected antibody phages. Accordingly, new phages can be generated and selected 
for higher affinity towards a particular tumor-specific epitope. 
Such antibody V -gene mutations are not only suited for increasing the specificity 
of low affinity antibody phages, but are also useful for increasing the affinity of 
existing monoclonal antibodies that have been generated by conventional 
hybddoma technologies. The V -genes from hybridoma cell lines, such as those 
producing ER-FPl moAbs or ER-G04 moAbs, are relatively easy cloned, mu-
tated and inselted for display on ftIamentous bacteriophages. This newly gener-
ated library is liable to contain anti-fusion-point specific antibody-phages and it is 
expected that subsequent selections towards respective chimeric proteins, Le. ela, 
BCR-ABL or E2A-PBXl, result in high affinity antibody-phages. 
Thus, by mimicking the affinity maturation of B-cells ill vitro, it should be possi-
ble to select new antibody phages with high affinity towards the fusion-point epitope 
of a chimeric protein. Such anti-fusion-point specific antibody-phages are par'-
ticularly useful in microscopic and/or flow cytometric diagnostic assays. Given 
the fact that the specificity of an antibody largely depends on the analytical assay 
used (Le. pelformance testing) (50), we propose that new antibody phages are 
initially selected on the basis of the antibody's staining pattern on fixed and 
permeabilized cells (e.g. COS cells transfected with cDNAs encoding ela, BCR-
ABL proteins or E2A-PBXl proteins). We expect that antibodies that have been 
selected according to these proposed procedures are more liable to be of practieal 
use in future, tumor-specific diagnostic procedures. 
c. bivalellt alld bispecific 1Jllage alltibodies ': molecular' genetic engineering tech-
niques ar'e not only useful to enhance the affinity of a par·tieular antibody(-phage) 
by mutating the antibody V-genes, but can also be used to mimic the bivalent, 'Y-
shaped' structure of immunoglobulin molecules. 
Protein interaction domains, derived from leucine zipper transcription factor en-
coding genes such as FOS or JUN, can be used to form/lOlIlodillleric complexes. 
Once the cDNA of a leucine zipper domain is cloned it can be fused, together with 
cDNA that encodes the hinge region of an immunoglobulin molecule, to previ-
ously isolated scFv DNAs. The flexibility of the hinge area permits the two anti-
gen binding sites to operate independently. It has been demonstrated that the 
subsequent transcription and translation of 'scFv-hillge-FOS' genes, result in spon-
taneous formation of bivalent antibody fragments: Le. (scFv-hinge-FOS:FOS-
hinge-scFv) homodimers or, in short, (scFv), (51). When considering to generate 
anti-fusion-point specific bivalent (scFv), antibody fragments, a greater affinity 
and specificity towards the fusion-point is expected from bivalent (scFv), anti-
bodies, than that of single chain scFv fragments. 
Peptide fragments from FOS or JUN transcription factors can also be used to form 
heterodillleric complexes. By reducing, reshuffling and reoxidizing homodimeric 
(scFv-hinge-FOS), and (scFv-hinge-JUN), fragments, it is possible to generate 
bispecijic antibody fragments such as (scFv-hinge-FOS:JUN-hinge-scFv) (51). 
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These antibody fragments contain two differently reactive scFv molecules, 
dimerized as one single, bispecijic antibody fragment. Given the observation that 
chimeric BCR-ABL proteins are specifically recognized by the combinatorial use 
of two differently reactive antibodies in the 'BCR-ABL dipstick assay', it is im-
aginable that, as long as the two separate scFv fragments of a bispecific antibody 
recognize distinctive epitopes flanking the BCR-ABL protein fusion-point and do 
not hamper each other's binding, anti-BCR-ABL bispecific antibody fragments 
can be generated. In this respect, anti-BCR-ABL bispecific antibodies are rela-
tively easy made from existing antibody V -genes present in hyblidoma cell lines 
such as ER-FPl and 8E9. When considering to generate anti-BCR-ABL bispecific 
antibody fragments by combining the reactivity ofER-FPl antibodies (i.e. recog-
nizing e,a, P190BCR.ABL proteins and possibly other proteins) with that of8E9 anti-
bodies (i.e. recognizing the carboxyl terminus of both ABL and BCR-ABL 
proteins), it is estimated that these bispecific antibody fragments have a greater 
affinity and specificity towards the e,a, BCR-ABL fusion-protein than that of the 
monoclonal antibodies, ER-FPl and 8E9, respectively. It should be realized, how-
ever, that much of the specificity of such bispecific antibodies depends on the 
flexibility of the hinge-region that is located between the scFv and FOS or JUN 
peptide fragments. 
Conclusion: 
Antibodies that specifIcally recognize cancer cells facilitate the microscopic diagno-
sis of characteristic tumor-types. Among the many different antigens that are usually 
identified in or on tumor-cells, chimeric proteins are one of the few cellular proteins 
that are /lot expressed by normal cell types. Chimeric proteins are the main repercus-
sion of gene-fusion and it should be realized that fusion-genes are prominent features 
found in both hematological as well as 1101l-hematological tumors (52). 
It is evident that chimeric proteins are excellent tumor-specific markers, distinguish-
able fi'Om non-tumor-specific proteins by their presence of characteristic tumor-spe-
cific fusion-point epitopes. We have demonstrated that tumor-specific fusion-point 
epitopes of chimeric e,a, BCR-ABL and E2A-PBXl proteins are antigenically ex-
posed, both at the peptide, the protein as well as at the cellular level. Our microscopic 
studies have verified that these tumor-specific epitopes are useful for tumor-specific 
diagnostic pUlposes by microscopic means. BP 1119 antiserum is the first immuno-
logical reagent through which chimeric E2A-PBXl proteins are specifically identi-
fied at the microscopic level in t( I; 19) positive leukemic cells. 
There are various techniques available, all capable of a tumor-specific diagnosis. Yet, 
it is evident that immunological, tumor-specific microscopic techniques are preferred: 
they are simple, quick, cheap and very sensitive. There is a clear future for the tumor-
specific recognition of chimeric proteins. Tedious procedures that involve the 'old 
fashioned' hybridoma-techniques are no longer necessary. Phage display technolo-
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gies offer many opportunities to detect both continuous as well as discontinuous tu-
mor-specific epitopes. It is expected that new mOl/oclonal or oligoclol/al anti-tumor-
specific (phage-)antibodies can be developed through which chimeric proteins, such 
as BCR-ABL and E2A-PBX1, are exclusively detected. 
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Summary 
Cancer is a heterogeneous disease regarding both its biology as well as its prognosis. 
A simple, universal treatment is, because of the heterogeneity of the disease, not pos-
sible. The kind of therapy chosen does not only depend on the organ affected by the 
primary tumor, but also depends on the outcome of so-called prognostic 'risk factors'. 
Risk factors predict the malignant potential of a certain type of tumor and some of 
these risk factors, e.g. the size and the metastatic spread of the tumor, are highly 
associated with the patient's chance of surviving cancer. 
Only recently, researchers clearly demonstrated that most cancers have a genetic ba-
sis. Various genetic aberrations have been categorized already and nowadays, it is 
possible to distinguish between different cancer types more accurately. 
Tlus thesis describes our experimental work aimed at the development of new immu-
nological diagnostic techniques. Accurate, but also simple diagnostic tecluuques are 
necessmy to asses the prognosis of an individual patient more properly and to select 
(or develop) the most appropriate therapy. 
To place our experimental work in perspective, this thesis stmis with a general review 
of the concepts about cancer. 
In Chapter 1, the classification of cancer is described. Traditionally, cancer diagnosis 
is based on both the cell type and tissue type from wluch a cancer originates. Its 
heterogeneity and its clonal character are mentioned briefly and the basic treatment 
protocols m'e sununmized. Before ending this chapter, we emphasize that the effec-
tiveness of anti-cancer treatment depends on a COlTect tumor-diagnosis. 
Chapter 2 covers the theoretical basis of cancer. Malignant cells are characterized by 
uncontrolled cellular proliferation. To understand their malignant behaviour, regula-
tion of non-neoplastic, normal cell proliferation is discussed first. The malignant be-
haviour of previously normal, healthy cells is then explained upon introducing typical 
chromosomal, molecular genetic and protein abel1'ations found in cancer cells. 
In Chapter 3, the heterogeneity of cancer is exemplified by presenting the sub-classi-
fication of cancer. Leukemia is a life-threatening disease that is characterized by un-
controlled proliferation of blood-forming cells located in the bone marrow. Different 
types of leukemia are distinguishable and, depending on the expected duration of the 
(untreated) disease, they are traditionally classified as acute or chronic. A fmiher 
diagnostic sub-classification is usually made according to morphological and (cyto-) 
chenlical features of the cell type involved. 
Yet, even within each morphological distinguishable subgroup, not allleukenuas re-
spond equally well to treatment. Apparently, the malignant behaviour of leukenuc 
cells is only pmily reflected by a morphological sub-classification of leukenua. A 
more refined treatment becomes feasible when the morphological classification is 
combined with data gathered upon analyzing the chromosomal and/or molecular ge-
netic aberrations often found in leukenuc cells. 
ISO Summary 
Chromosomal and molecular genetic abel1'ations are at the basis of leukemogenesis. 
They are divided into those leading to abel1'ant expression of nOl1nal genes (e.g. TALl) 
and those leading to the expression of aberrant chimeric genes, such as BCR -ABL and 
E2A-PBXl. Chimeric means: composed of patts with a different genetic background. 
The BCR-ABL gene results from the reciprocal exchange of chromosome fragments 
between chromosomes 9 and 22. This chromosomal translocation; the t(9;22)(q34;qll), 
fuses part of the ABL gene to patt of the BCR gene on chromosome 22. Likewise, the 
t(l;19)(q23;pI3) results in a chimeric E2A-PBXI gene, in which part of the PBXl 
gene is fused to patt of the E2A gene on chromosome 19. Both chimeric fusion-genes 
encode unique fusion-proteins that, as far as protein function is considered, do not 
resemble nonnal BCR, ABL, E2A or PBX I proteins. In this respect, abnonnal chi-
meric fusion-proteins are, in contrast to aberrantly expressed nOimal proteins such as 
TALI, prototypes of a new kind of leukemogenesis. Both BCR-ABL as well as E2A-
PBX1 genes at'e involved in the oncogenic conversion of previously nonnal cells and 
both genes have typical prognostic and therapeutic implications for an individualleuke-
mia patient. 
As such, the chimeric BCR-ABL and E2A-PBX1 genes are tumor-specific; both genes 
do not occur in normal healthy cells and both genes at'e only found in malignant cells 
with previously mentioned chromosomal translocations. Moreover, these chimeric 
genes provide excellent tumor-markers: e.g. the BCR-ABL gene is specifically de-
tected by the fluorescent in situ hybridization technique (FISH) and, after reverse 
transcription of mRNA into cDNA, the chimeric BCR-ABL or E2A-PBXlmRNA is 
specifically detected by the polymerase chain reaction (RT-PCR) technique. 
During the past few years we have attempted to develop diagnostic reagents through 
which it should be possible to specifically identify chimeric fusion-proteins by using 
immunological methods. 
In Chapter 4 we describe the generation of a polyclonal antiserum, telmed BP 1119. 
This antiserum reacts specifically with E2A-PBXl proteins and does not recognize 
E2A nor does it recognize PBXI proteins. E2A-PBXl proteins resemble the normal 
wild-type E2A and PBXI proteins to a great deal. The only part of the protein which 
is present in E2A-PBXI proteins but not in normal E2A or PBXl proteins, is located 
at the fusion-point of the E2A-PBXI protein. By immunizing mice with a multiple 
antigenic peptide with an amino acid sequence identical to that of the E2A-PBXI 
fusion-point we were able to generate an antiserum that specifically identifies E2A-
PBXI proteins. We show that this antiserum distinguishes t( I; 19)E2,\-P8xl positive cell 
lines from t(I;19) negative cell lines, not only at the protein but also at the micro-
scopic level. Incubating t(l; 19)E2A-PBxl positive cells with diluted BP 1119 antiserum 
results in a characteristic, granular nuclear fluorescence. These results verify that the 
fusion-point of E2A-PBXl proteins is antigenic ally exposed and is, as such, suitable 
for tumor-specific diagnosis by im1l1unologicalmethods. 
The diagnostic applicability, i.e. the specific diagnosis of t(l; 19)E2MBXI positive pre-B 
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acute lymphoblastic leukemia (pre-B ALL), is demonstrated in Chapter 5. Here, we 
evaluated the specificity of BP 1119 immunostainmg on different cell lines in more 
detail. To this purpose, an extended anay of cell lines was used. This array represents 
various hematopoietic cell types normally found in both peripheral blood as well as 
bonemanow samples. TI,e specificity of the BP1/19 immunostaining technique proved 
conect as BP 1119 only stained the nuclei of t(1;19) positive cell lines but not the 
nuclei of t(1;19) negative cell lines. The sensitivity of the BP 1119 innnunostaining 
teclmique was determined to one malignant t(1; 19)"lA-P8X' positive cell among 10,000 
normal cells through artificial mixing experiments. Its diagnostic value was ascer-
tained when BP 1119 specifically stained the leukemic cells isolatcd from patients 
suffering from t(l; 19) positive pre-BALL. Nuclear staining was not observed in t( 1; 19) 
negative pre-B ALL or common ALL patients, nor was it observed in the leukemic 
cells from a patient with a t(1; 19) negative, t(9;22) positive chronic myeloid leukemia 
(CML) in blast crisis. 
Yet, in tumor-diagnosis, monoclonal antibodies are clearly favored over polyclonal 
antibodies. In Chapter 6 we describe a monoclonal antibody, termed ER-G04. The 
ER-G04 hybridoma cell line is the only 'anti-E2A-PBXl fusion-point specific anti-
body' producing cell line that resulted from ten different conventional cell fusion 
experiments performed (or, approximately 8,000 hybridoma cell lines tested). Its 
specificity towards the E2A-PBXl fusion-point was conflrmed at both the peptide as 
well as the protein level. Unfortunately, in contrast to the BP 1/19 antisenllll described 
above, ER-G04 antibodies do not distinguish between t(l; 19)E'A-PBx, positive cell lines 
and t( 1; 19) negative cell lines when they are used in cell-staining expetiments. How-
ever, ERG04 antibodies do recognize intracellular E2A-PBXI proteins expressed in 
COS cells transfected with cDNA encoding E2A-PBXI proteins. It is likely that the 
limited applicability of ER-G04 antibodies in tumor-diagnosis is a matter of a rela-
tively low E2A-PBXl protein concentration in single t(1; 19)E2A-PBX' positive cells. 
Another fusion-point specific monoclonal antibody, termed ER-FPl, is described in 
Chapter 8. The ER-FPl antibody is directed towards e,a,PI90"cR-ABL proteins. The 
e,a,PI90BcR-ABL proteins belong to the BCR-ABL proteins which are exclusively ex-
pressed in t(9;22)(q34;q II) positive leukemic cells. The specificity ofER-FP I mono-
clonal antibodies was confilllled at both the peptide as well as the protein level: ER-FPl 
specifically recognizes e,a,PI90BcR-ABL but does not recognize the resembling b,a,-
P2IOBCR-ABL or b3a,P210BcR-ABL proteins. However, like ER-G04, ER-FPl does not 
discriminate between leukemic and normal healthy cells at the microscopic level. To 
investigate whether the ela2 fusion-point of e,a, PI90BCR-ABL proteins is antigenically 
exposed in intact, albeit fixed cells, we performed immunostaining experiments with 
ER-FPl antibodies on transfected COS cells. These COS cells were transfected with 
cDNA either encoding e,a,PI90BcR-ABL, b,a,P210BcR-ABL, or b3a,P2IOBCR-ABL proteins. 
Since ER-FPl specifically detects ela2 BCR-ABL transfected COS cells and not the 
b2a2 BCR-ABL nor the b3a2 BCR ABL transfected COS cells, we could vetify that 
the fusion-point epitope of e,a, P 190BCR-ABL proteins remains intact after cell fixation. 
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Our expedmental results clearly demonstrate that the el a2 fusion-point is antigenically 
exposed and is as such, suitable for tumor-specific diagnosis by immunological means. 
The need to develop new kinds of diagnostic techniques is exemplified by the poor 
prognosis of BCR-ABL positive acute lymphoblastic leukemias. Unlike other ALLs, 
BCR-ABL positive ALLs frequently relapse during or shortly after their first round of 
(induction) therapy. Obviously, it is impOltant to specifically diagnose BCR-ABL 
positive leukemias before starting 'conventional' induction therapy. New (experimental) 
therapies such as more aggressive induction chemotherapy with or without bone mar-
row transplantation are expected to improve the otherwise insecure future of patients 
suffedng from BCR-ABL positive ALLs. 
In Chapter 8 we describe the development of a new simple and rapid diagnostic tech-
tuque: the 'BCR-ABL dipstick assay'. This assay is based on the successive detection 
of distinctly different antigenic detenninants present on BCR-ABL proteins. The com-
bination of differently reactive antibodies in the BCR-ABL dipstick assay allows for 
the detection of BCR-ABL proteins in a relatively easy, yet, specific fasluon. Early 
therapy adjustment becomes feasible, as the BCR-ABL dipstick assay allows for a 
specific diagnosis of BCR-ABL positive leukemias within 24 hours. 
The final chapter of this thesis, Chapter 9, summarizes the different categories of 
antibodies used in tumor-diagnosis. Most antibodies available recognize antigens that 
are also expressed by normal healthy cells (e.g. differentiation antigens). The diag-
nostic value of single antibodies is linuted, although some of these antibodies are 
extremely helpful in tumordiagnosis when they are combined with other antibodies 
(e.g. 'multi-parameter' analysis). In contrast to differentiation antigens, clumeric anti-
gens, such as the BCR-ABL and E2A-PBXI proteins, are truly tumor-specific. Even 
though chimeric proteins strongly resemble proteins also present in normal, healthy 
cells, they can be discriminated from other proteins by one (or more) tumor-specific 
antigenic determinant(s). We have demonstrated that t(I;19)E2A-PBXI positive tumor-
cells are, at the nucroscopic level, specifically identified by BP 1/19. The tumor-
specific epitope of E2A-PBXI proteins is, like the tumor-specific epitope of 
ela,PI90BcR-ABL proteins, antigenic ally exposed. It is expected that tumor-specific 
epitopes from different chimeric tumor-proteins can be recogtuzed by using a similar 
strategy. In this respect, it is estimated that the phage display technology offers new 
opportunities to develop tumor-specific phage antibodies in a relatively easy fashion, 
realizing accurate diagnosis of malignant cells. 
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Samenvatting 
Kanker is, vanuit een biologisch en prognostisch standpunt bezien, een heterogene 
ziekte. Ben eenvoudige, algemeen geldende behandeling is door de heterogeruteit van 
de ziekte, ruet mogelijk. De gekozen behandelingswijze hangt niet aileen af van het 
orgaan dat door de primaire tumor is aangedaan, maar hangt ook af van de uitkomst 
van zogenaamde prognostische 'risicofactoren'. Risicofactoren voorspellen het kwaad-
am'dig karakter van een bepaald type tumor en sommige risicofactoren, bijv. de grootte 
en de uitzaaiing van de tumor, zijn in belangrijke mate gekoppeld aan de kans dat een 
patient de kanker overleeft. 
Onlangs werd door onderzoekers duidelijk aangetoond dat de meeste kankers een 
genetische achtergrond hebben. Verschillende genetische afwijkingen zijn reeds in 
kaart zijn gebracht en het is tegenwoordig mogelijk om een betel' onderscheid te ma-
ken tussen de verschillende sootten kanker. 
Dit proefsclnift beschrijft ons experimentele werk dat is gericht op de ontwikkeling 
van nieuwe inllllunologische, diagnostische technieken. Accurate, mam' tevens een-
voudige diagnostische teclmieken zijn noodzakelijk om de prognose van een indivi-
due1e kankerpatient betel' in te schatten en om de meest geschikte therapie te kiezen 
(of te ontwikkelen). 
Om ons experimentele werk in een breder perspectief te plaatsen, begint elit proef-
schrift met een algemene beschouwing van de denkbeelden omtrent kanker. 
In hooJdsfuk 1 wordt de indeling van kanker beschreven. De diagnose kanker is van 
oudsher gebaseerd op zowel het celtype als het weefseJtype van waaruit kaaker ont-
staat. De heterogeniteit en het klonale karakter van kanker worden in het kort bespro-
ken en de algemeen geldende therapieen worden samengevat. Aan het einde van dit 
hoofdstuk, benadl1lkken we dat de effectiviteit van kankerbehandeling afhangt van 
een correcte tumordiagnose. 
HooJdsfllk 2 gaat over de theoretische achtergrond van kanker. Maligne cellen worden 
gekelllllerkt door ongecontroleerde celproliferatie. Om het kwaadam'dige gedrag van 
kankercellen te begrijpen wordt eerst de regulering van niet-neoplastische, nOl1nale 
celproliferatie besproken. Het kwaadam'dig karakter van voorheennoJ'lnale, gezonde 
cellen wordt vervolgens verklaard na een eerste introductie van, voor kankercellen, 
typische cln'omosomale, moleculair genetische en eiwit afwijkingen. 
In hooJdsfllk 3 wordt de heterogeniteit van kaaker verduidelijkt door de onderverde-
ling van leukemie nam' voren te brengen. Leukemie is een levensbedreigende ziekte 
welke wordt gekemnerkt door ongecontroleerde deling van bloedvormende cellen die 
zich in het beenmerg bevinden. Verschillende typen leukemie zijn te onderscheiden 
en zij worden vanouds, afhaakelijk van de te verwachten ziekteduur van de (niet be-
handelde) ziekte, onderverdeeld in acute en chronische leukemieen. Ben verdere dia-
gnostische onderverdeling wordt doorgaans gemaakt volgens motfologische en (cyto-) 
chemische kenmerken van het betrokken eel type. 
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Eehter, zelfs binnen iedere mOlfologiseh te onderseheiden subgroep, reageert niet 
iedere leukemie evengoed op de behandeling. Blijkbaar wordt het kwaadaardige ge-
drag vanleukemieeellen sleehts ten dele weergegeven door de morfologisehe onder-
verdeling van leukemie. Een beter afgestemde behandeling is te verwezenlijken indien 
de morfologisehe onderverdeling wordt geeombineerd met gegevens verkregen na 
analyse van de, in leukemiecellen vank aangetroffen, ehromosomale en/of moleculair 
genetisehe afwijkingen. 
Chromosomale en moleeulair genetische afwijkingen liggen ten grondslag aan het 
ontstaan van leukemie. Zij worden onderverdeeld in afwijkingen die leiden tot abnor-
male expressie van nonllale genen (bijv. TALl) en afwijkingen die leiden tot de ex-
pressie van abnonnale ehimere genen zoalsBCR -ABL enE2A-PBXl. Chimeer betekent: 
samengesteld uit delen van verschillend genetisehe herkomst. HetBCR -ABL gen komt 
voort uit de reciproque verwisseling van chromosoomfragmenten tussen de chromo-
somen 9 en 22. Deze chromosoom translocatie; de t(9;22)(q34;qll), koppelt een deel 
van hetABL gen aan een deel van hetBCR gen op chromosoom22. Op een vergelijk-
bare wijze resulteert de t(I;19)(q23;pI3) in een ehimeer E2A-PBXl gen, walliin een 
deel van hetPBXl gen is gekoppeld aan een deel van hetE2A gen op chromosoom 19. 
Beide ehimere genen eoderen voor unieke fusie eiwitten die, voor wat betreft eiwit-
functie, niet lijken opnormale BCR, ABL, E2A of PBX I eiwitten. In dit opzieht zijn 
abnormale ehimere fusie eiwitten, in tegenstelling tot abnormaal geproduceerde nor-
male eiwitten zoals TALI, het voorbeeld van een nieuwe ontstaanswijze van leuke-
mie. Zowel BCR-ABLals E2A-PBXI genen zijn betrokken bij de oncogene conversie 
van voorheennonnale cellen en beide worden gekelmlerkt door typische prognostische 
en therapeutische gevolgen voor een individuele leukemie patient. 
De ehimere BCR-ABL en E2A-PBXl genen zijn als zodanig tumor specifiek: beide 
genen komen niet in normale, gezonde cellen voor en beide genen worden aileen 
gevonden in kwaadaardige cellen met eerder genoemde chromosomale translocaties. 
Bovendien, chimere genenleveren uitzonderlijk goede tumormarkers op: het BCR-
ABL gen wordt bijvoorbeeld specifiek gedeteeteerd door de fluorescentie in situ 
hybridisatie techniek (FISH) en, na omzetting vanmRNA in cDNA, wordt het chimere 
BCR-ABL of E2A-PBXI mRNA specifiek door de polymerase ketting reactie (RT-
PCR) aangetoond. 
Gedurende de afgelopen jaren hebben we geprobeerd diagnostische reagentia te ont-
wikkelen waardoor het mogelijk moest worden om, m.b.v. immunologisehe 
detectiemethoden, chimere fusie-eiwitten specifiek aan te tonen. 
In /lOofdsllIk 4 besclnijven we de ontwikkeling van een polyklonaal antisenlln, ge-
naamd BP 1119. Oit antiserum herkent specifiek E2A-PBXI eiwitten en reageert niet 
met E2A noch met PBXI eiwitten. E2A-PBXI eiwitten lijken in sterke mate op de 
nm'male wildtype E2A en PBX I eiwitten. Het enige deel van het eiwit dat aanwezig is 
in E2A-PBXlmaar niet in normale E2A eiwitten of PBXl eiwitten, bevindt zieh op 
het fusiepunt van het E2A-PBXl eiwit. Door mllizen te il11mllnisere1ll11et een meer-
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voudig antigeen peptide waarvan de aminozuur volgorde overeenkomt met dat van 
het E2A-PBXl fusiepunt waren wij in staat om het BP 1/19 antiserum te genereren 
dat specifiek E2A-PBXl eiwitten herkent. We laten zien dat dit antisenun t(1;19)ElA'PBXI 
positieve cellen onderscheidt van t(1;19) negatieve cellijnen, niet alleen op eiwit-
niveau mam' ook op cellulair niveau. Het incuberen van t(l; 19)E2A,PBXI positieve cellen 
met verdund BP 1119 resulteert in een kmakteristieke, granulaire kernfluorescentie. 
Deze resultaten bevestigen dat het fusiepunt van E2A-PBXl eiwitten op een antigene 
wijze tot expressie komt en als zodanig geschikt is voor specifieke tumordiagnostiek 
d.m. v. inmlUnologische detectiemethoden. 
De diagnostische toepassing van het BP 1/19 antiserum, d. w.z. de specifieke diagnose 
van t(1;19)E2A'PBxl positieve pre-B acute Iynrfatische leukemie (pre-B ALL), komt in 
Iwofdstuk 5 ter sprake. In dit hoofdstuk, wordt de specificiteit van de BP 1/19 innnu-
nologische celkleuring op verschillende cellijnen nader beschouwd. Een uitgebreide 
verzameling cellijnen werd hiervoor gebruikt. Deze verzameling is representatief voor 
de verscheidenheid aan hematopoetische celtypen welke nonnaal in zowel perilere 
bloed- als beenmergmonsters voorkomen. De BP 1/19 inmlUnologische celkleuring is 
specifiek, omdat BP 1119 alleen de kemen van t(1;19) positieve cellijnen aankleUlt 
maar niet de kernen van t(1;19) negatieve cellijnen. De sensitiviteit van de BP 1119 
aankleuringstechniek, zoals vastgesteld werd d.m.v. artificiele mengexperimenten, is 
cen kwaadaardige t( I ; 19)E2A,PBXI positieve cel op 10.000 nonnale cell en. 
De diagnostische waarde van BP 1119 voor tumordiagnostiek werd duidelijk op het 
moment dat dit antiserum specifiek de leukemische cellen van patienten Iijdend aan 
t(1; 19) positieve pre-B ALL aankleurde. De typische kernkleuring van BP 1/19 anti-
lichamen werd niet wamgenomen in cellen afkomstig van t(1;19) negatieve pre-B 
ALL of common ALL patienten, noch werd de typische kernkleuring wam'genomen 
in leukemiecellen van een patient lijdend aan een t(1;19) negatieve, t(9;22) positieve 
c1n'onische myeloide leukemie (CML) in blastencrisis. 
Echter, voor wat betreft tumordiagnostiek geldt dat monoklonale antilichamen duide-
Iijk de voorkeur genieten boven polyklonale antilichamen. In Iwofds/llk 6 beschrij-
ven we een monoklonaal antilichaam, genaamd ER-G04. De ER-G04 hybridoma 
cellijn is de enige 'anti-E2A-PBXl fusiepunt specifieke antilichaam' producerende 
cellijn die voortkwam uit tien verschillende conventioneel uitgevoerde celfusie expe-
rimenten (m.a.w. ongeveer 8000 geteste hybridoma cellijnen). De specificiteit voor 
het E2A-PBXI fusiepunt werd bevestigd op zowel het peptide als op het eiwitniveau. 
In tegenstelling tot het BP 1119 antiserum maken ER-G04 antilichamen, indien zij 
gebruikt worden in celk1euring experimenten, helaas geen onderscheid tussen 
t(l ; 19)E2A-PBXI positieve en t(1 ; 19) negatieve cellijnen. Echter, ERG04 antilichamen 
herkelmen wei de intracellulaire E2A-PBXl eiwitten in COS cellen getransfecteerd 
met cDNA coderend voor E2A-PBX I eiwitten. Het is aannemelijk dat de gelimiteerde 
toepassing van ER -G04 antilichamen in de tumordiagnostiek een kwestie is van een 
relatieflage E2A-PBXI eiwitconcentratie binnen afzonderlijket(1 ; 19)E2A,PBXI positieve 
leukemiecellen. 
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Een ander fusiepunt specifiek monoklonaal antilichaam, genaamd ER-FPI, wordt 
besproken in /wofds/uk 7, Het ER-FPl monoklonaal is gericht tegen e,a,PI90llCR-ABL 
eiwitten. De e,a,PI90BcR-AllL eiwitten behoren tot de BCR-ABL eiwitten die exclusief 
tot expressie komen in t(9;22)(q34;qll) positieve leukemie cellen. De specificiteit 
van ER-FPl werd op zowel het peptide- als op het eiwitniveau bevestigd: ER-FPI 
herkent specifiek e,a2P 190BCR-ABL, maar herkent niet de sterk gelijkende b,a,P21OBCR-ABL 
of b,a,P21OBcR-AllL eiwitten. Echter, evenals ER-G04, maakt ER-FPI op microsco-
pisch niveau geen onderscheid tussen leukemie cellen en normale gezonde cellen. am 
te onderzaeken of het ela2 fusiepunt van e,a,PI90BCR-ABL eiwitten op een antigene 
wijze tot expressie komt in intacte, doch gefixeerde cellen, hebben we ilmmmologi-
sche celkleuring experimenten met ER-FPl antilichamen op getransfecteerde COS 
cellen uitgevoerd. Deze COS cellen waren getransfecteerd met cDNA coderend voor 
Of e,a,PI90BCR-ABL, b2a,P21OBcR-AllL Of b3a,P2lOBCR-ABI. eiwitten. Omdat ER-FPI speci-
fiek ela2 BCR-ABL getransfecteerde COS cellen herkent en niet de b2a2 BCR-ABL 
of de b3a2 BCR-ABL getransfecteerde COS cellen, konden we bevestigen dat het 
fusiepunt van e,a,P 190BCR-ABL intact blijft na celfixatie. Onze exper1mentele resultaten 
laten duidelijk zien dat het ela2 fusiepunt op een antigene wijze tot expressie komt en 
als zodanig geschikt is voor specifieke tumordiagnostiek d.m.v. immunologische me-
thoden. 
Het belang om nieuwe diagnostische technieken te ontwikkelen wordt verduidelijkt 
door de slechte prognose van BCR-ABL positieve acute lymfatische leukemieen. In 
tegenstelling tot andere acute Iymfatische lellkemieen, recidiveren BCR-ABL posi-
tieve leukemieen vaak al tijdells ofkOlt na de eel"Ste (inductie) therapieronde. KClme-
lijkis het belangrijk om BCR-ABL positieve leukemieen te herkennen voordat gestart 
wordt met de 'conventionele' inductie therapie. Van nieuwe (experimentele) thera-
pieen zaals een veel agressievere inductie chemotherapie eventueel aangevuld met 
beenmergtransplantatie wordt verwacht dat deze de anders onzekere toekomst van 
patienten lijdend aan BCR-ABL positieve ALLs verbeteren. 
In hoofds/uk 8 beschrijven we de ontwikkeling van een nieuwe, eenvoudige en snelle 
diagnostische techniek: de 'BCR-ABL dipstick analyse'. Deze methode is gebaseerd 
op de achtereenvolgende detectie van duidelijk verschillende anti gene detenninanten 
op BCR-ABL eiwitten. De combinatie van verschillend reagerende antilichamen in 
de BCR-ABL dipstick analyse maakt het mogelijk om BCR-ABL eiwitten op een 
relatief eenvoudige, doch specifieke wijze aan te tonen. Een vroege therapiebijstelling 
wordt mogelijk doordat de BCR-ABL dipstick analyse een specifieke diagnose van 
BCR-ABL positieve leukemieen binnen 24 UUl' mogelijk maakt. 
Het laatste hoofdstuk van dit proefschrift, /wofds/uk 9, vat de verschillende groepen 
antilichamen die gebruikt worden in de irmnunologische tumordiagnostiek samen. De 
meeste antilichamen herkennen antigenen die ook bij nonnale, gezonde cellen tot 
expressie komen (bijv. differentiatie antigenen). De diagnostische waarde van derge-
lijke antilichamen is beperkt, of schoon enkele antilichamen bijzonder geschikt zijn in 
de tumordiagnostiek indien zij in combirlatie met andere antilichamen gebruikt wor-
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den (i.e. 'multi-parameter' analyse). In tegenstelling tot differentiatie antigenen zijn 
chimere antigenen, zoals de BCR-ABL en E2A-PBXl eiwitten, werkelijk tumor-spe-
cifiek. Of schoon chimere eiwitten sterk lijken op eiwitten die ook in normale cellen 
voorkomen, kunnen zij van andere eiwitten onderscheiden worden door een (of meerdere) 
tumor-specifieke antigene determinant( en). We hebben aangetoond dat t( 1; 19)E2A.PBxl 
positieve tumorcellen specifiek herkend worden door BP 1/19. De tumor-specifieke 
epitoop van E2A-PBXl eiwitten komt, evenals de tumor-specifieke epitoop van 
ela,P 190BCR.ABL eiwitten, op een antigene wijze tot expressie. Het is te verwachten dat 
tumor-specifieke epitopen van andere chimere tumor eiwitten op eenzelfde wijze spe-
cifiek zijn aan te tonen. In dit opzicht wordt verwacht dat de 'phage display' techniek 
nieuwe kansen biedt om tumor-specifieke 'faag' antilichamen op een relatief eenvou-
dige manier te ontwikkelen en zodoende accurate detectie van kwaadaardige cellen 
mogelijk maakt. 

A 
ABL 
ALL 
AML 
AMLl 
ANLL 
APL 
ATP 
B-ALL 
BamHI 
B-eells 
BCL 
BCR 
(b-) HLH 
BM 
BP-l 
BPlfl9 
BP-2 
BP-ALL 
BSA 
C 
cALL 
CD 
eDNA 
CML 
CLL 
Cy 
del' 
DNA 
E2A 
EcoRI 
ER-FPl 
ER-G04 
FAB 
FCS 
FITC 
FISH 
G 
GRB2 
ETO 
GATA 
Hil/dlll 
HOX 
Ig 
List of abbreviations 
adenosine 
gene homologous to the Abelson murine leukemia virus 
acute lymphoblastic leukemia 
acute myeloid leukemia 
acute myeloid leukemia gene 1 
acute non-lymphoblastic leukemia 
acute promyelocytic leukemia 
adenosine triphosphate 
B-eell aCllte lymphoblastic leukemia 
restriction endonuclease isolated from Bacillus amyloliquefaciens H 
bone lllarrow derived lymphocytes 
B-eellieukemia-lymphoma gene 
breakpoint cluster region gene 
(basic) helix-loop-helix DNA binding motif 
bonemanuw 
anti b2a2 P21 OBCR-ABL fusion-point specific antiscmITI 
anti E2A-PBXl fusion-point specific antiserum 
anti bJu2 P210BCR-ARL fusion-point specific antiserum 
anti c1a2 P 190BCR-ABL fusion-point specific antiserum 
bovine serum albumin 
cytosine 
common ALL 
cluster of differentiation (or, designation) 
complementary desoxyribonucleic acid 
chronic myeloid leukemia 
chronic lymphocytic leukemia 
cytoplasmic 
derivative 
deoxyribonucleic acid 
gene encoding E2-box binding proteins 
restriction endonuclease isolated from Escherichia coli 
anti e1a2 P 190BCR-ABL fusion-point specific monoclonal antibody 
anti E2A-PBXI fusion-point specific monoclonal antibody 
French American British 
fetal calf serum 
fluorescein isothyocyanate 
fluorescent ill situ hybridization 
guanosine 
gene encoding growth factor receptor binding protein 2 
eighty-twenty-one gene 
gene encoding proteins that specifically bind to (A/f)GATA(A/G) 
restriction endonuclease isolated from Haemophilus influenza Rd 
homeobox gene 
immunoglobulin 
159 
160 
IGH 
IGL 
IL3 
kb 
kDa 
KLH 
LCK 
LYL 
MAP 
m-BCR 
M-BCR 
moAb 
mRNA 
Mw 
MYC 
PAGE 
PBS 
PBXI 
PCR 
Ph 
PML 
pre-B ALL 
RARo. 
RAS 
RBTN 
RT 
RT-PCR 
Sm 
SP 
SV40 
T 
TANI 
TALl 
TEL 
T-cells 
TCR 
TRITC 
U 
WTI 
inunul1ogiobulin heavy-chain gene 
immunoglobulin light-chain gene 
interleukin 3 gene 
kilo base 
kilo Dalton 
keyhole Limpet Hemocyanin 
lymphocyte specific kinase gene 
lymphoid leukemia gene 
mUltiple antigenic peptide 
minor breakpoint cluster region 
major breakpoint cluster region 
monoclonal antibody 
messenger ribonucleic acid 
molecular weight or molecular mass 
gene homologous to the avian myelocytomatosis vinIS 
polyacrylamide gel electrophoresis 
phosphate buffered saline 
pre-B cell leukemia gene 
polymerase chain reaction 
Philadelphia 
promyelocytic leukemia gene 
acute lymphoblastic leukemia of pre-B cell origin 
gene encoding retinoid acid receptor ex 
ROllS Avian sarcoma gene 
rhombotin-like gene 
room temperature 
reverse transcriptase polymerase chain reaction 
smface membrane 
synthetic peptide 
simian sarcoma virus 40 
thymidine 
translocation associated Notch homologous gene 
T-cell acute leukemia gene I 
translocation ETS leukemia gene 
thymus derived lymphocytes 
T-cell receptor gene 
te11ramethyl rhodamine isothyocyanate 
uridine 
Wilms' tumor gene 1 
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Dankwoord 
Het dankwoord is missehien nog wei het moeilijkst te sehrijven gedeelte van een 
proefsehrift. 
Zeker tijdens wetensehappelijk onderzoek geldt dat er gezien de vaak teleurstellende 
resultaten van experimenteei werk, veel voor nodig is om gemotiveerd naar het werk 
te blijven gaan. Vele mensen zijn een belangrijke bran van steun geweest en het liefst 
zou ik de namen van al deze mensen in dit dankwoord willen velmelden. 
Helaas, tussen willen en kUlmen gaapt een grate kloof en dit moment van scln'ijven 
leert simpelweg dat u met teveel bent om allemaal persoonlijk te worden genoemd. 
De mimte in het boekje, maar meer nog de vrees dat ik enkele namen niet zou noe-
men, noodzaken mij om de meeste van u op deze wijze hmtelijk te bedanken. 
Eehter, uitzondelingen bevestigen de regel en eakele mensen zijn voor de totstandko-
ming van dit proefsehrift van zodanige invloed geweest dat ik hen in dit dankwoord 
niet onvermeld willaten: 
Mijn promotor, Prof. dr Willem van Ewijk wil ik op deze wijze bijzonder bedanken 
voor de welhaast onoveltrefbare fijne werkplek op de afdeling Immunologie. Beste 
Willem, al ben je dan misschien geen politieagent, toeh weet je jouw mensen op een 
fantastisehe wijze te stimuleren. Je bent voor mij het voorbeeld van de wetensehapper 
die de essentie van een onderwerp weet te vatten en deze weet te veltalen op een voor 
je omgeving begrijpelijke wijze. Mede dankzij jouw raadgevingen is het mij hopelijk 
gelukt om een praefsehrift te sehrijven dat naast wetensehappelijk, vooral ook lees-
bam' is gebleven. 
AIs basis van dit praefschrift geldt het keuze-onderzoek dat ik als geneeskunde stu-
dent destijds bij dr Janneke van Denderen heb gevolgd. Lieve Jmmeke (let weI, dit 
geenliefdesverkiming, zie stelling 10 vanjouw proefsclnift), aIs toemnalig onderzoeks-
begeleidster heb je mij op een voortreffelijke wijze geleerd om proeven goed op te 
zetten en uit te werken. Jouw gave om zelfs bij de meest teleurstellende onderzoeks-
resultaten toch nog wat 'motiverende' studentenhaver uit de pap te hal en, heb ik he-
laas nooit kunnen evenm·en. Opmerkingen als: 'In ieder geval wordt het substraat 
ZOllder enzym niet omgezet', kionken uit mijn mond immel's andel's. 
Gezien de bijzonder goede motivatie van mijll studenten, was mijn kretologie geluk-
kig niet nodig. Sterkel' nog, zowel Shu Shimizu als Janine Veenman hebben een uiter-
mate belangrijke bijdrage geleverd aan dit proefsehrift, waarvoor ik hen veel dank 
versehuldigd ben. 
Of schoon de onderzoeksprojeeten op lab 853 zeer divers zijn, de mensen van lab 853 
zijn in elkaars werk ge'jnteresseerd en zijn bereidwil1ig om elkaar met raad en daad bij 
te staan. Voor wat betreft het laatste, wil ik dan ook in het bijzonder dr Pieter Leenen 
en dr Mamten Egeler bedanken voor hun inzet om het 'breukpuntenwerk' een duw in 
de goede richting te geven. 
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Oat de onderlinge betrokkenheid soms te vel' kan gaan, blijkt uit een vreemd SOOlt 
familiegevoel dat zich aileen bij sommigen van ons heef! ontwikkeld. In dit opzicht is 
het reuze jarruner dat ik, in tegenstelling tot dr Walen tina Slieker, geen nieuwe zusje 
heb ontdekt op lab 853. Wei ben ik, in de vorm van Peter Paul Platenburg en dr Michel 
de Weers, twee (para-)neven rijker. Mede dankzij Peter Paul en Michel was het oer-
gezellig op het lab en ik ben ervan overtuigd dat zij beiden een zeer belangrijke rol 
zullen hebben tijdens de verdediging van dit proefschrift. De centrale spil van ons lab, 
Jane Voennan, verdient een speciaal woord van dank. Ais rook- en koffiemaatje, als 
gewillig 001', maar zeker ook omdat Jane een nieuwe functie (de zoveelste) gaat ver-
vullen. Met Jane als 'kern-paranimf' vel1rauw ik erap dat eventuele festiviteiten na de 
promo tie vooral netjes zullen verlopen. 
Ommij niet teveel in superlatieven te hoeven uitdrukken wil ik aile mensen van lab 
853, ook diegenen die reeds vertrokken zijn, bijzonder hm1elijk dmlken voor de fijne, 
gezellige, mam' vooral ook leerzame afgelopenjaren! 
'Het geloof in eigen kunnen' krijgt gedurende het onderzoek van tijd tot tijd een 
behoorlijke knauw. Ik heb het bijzonder stimulerend gevonden dat zelfs wetenschap-
pel'S buiten het lab, ruimte, tijd en appm'atuur hebben vrij gemaakt om mij tel' wille te 
zijn. 
Dr Andre Hoogeveen geldt hierin als de man van het eerste uur. AI verliep de eerste 
kemllsmaking wat moeizaam ('dam' heb je er weer zo een'), renden Andre en Nicolle 
al spoedig het vuur uit de sloffen omilleuwe peptiden te synthetiseren. Beste Andre, 
je bent een gouwe kerel en ik heb de afgelopen jaren echt veel steml aan je gehad. 
Minstens zo belangrijk voor het onderzoek was de inbreng van dr Marc van Oijk. Ais 
'E2A-PBX1-wetenschapper' was jij mijn hofleverancier van de verschillende 
plasmiden en van ill vitro getransleerd E2A-PBXI. Bovendien bleek ookjij niet te 
beraerd om nieuwe testmaterialen te ontwikkelen. Zo is bijvoorbeeld het 'wildtype 
E2A-PBXl eiwit' van grate wam'de is gebleken voor de selectie van de ER-G04 
hybddoma cellijn. 
Op het lab van dr Ton Logtenberg werden mijn eerste schreden gezet op de 'phage-
display' technologie. Niet aileen het fagen-werk, doch ook de muzikale werkomgeving 
zorgden voor nieuwe impulsen welke snel hun navolging hebben gekregen in Rotter-
dam. Of schoon de eerste proeven niet direct tot het gewenste resultaat hebben geleid 
(de tijd om het ccht goed uit te zoeken ontbrak gewoonweg), ben ik ervan oveltuigd 
dat anti-fusiepunt specifieke fagen zekcr een toekomst hebben in de tumordiagnostiek. 
Een andere wetenschappelijke doorbraak werd uit Lelystad verwacht waar kippen 
werden ge'immuniseerd met breukpunt peptiden. Helaas geldt ook bij kippen dat anti-
peptide antilichamen echt andel'S zijn dan anti-eiwit antilichamen. Toch ben ik dr 
Suzmme Jeurissen en Prof. dr Eric Claassen veel dmlk verschuldigd voor de tijd en 
moeite die zij genomen hebben om het destijds behoorlijk vastgelopen breukpunten 
onderzoek van nieuwe impulsen te voorzien. 
Paul Berendes. 
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